

# PROGRAMME ECC & RICAI, 2004

Wednesday mercredi	1 December décembre	18:00 19:30	Salle Bordeaux	SYMPORIUM Symposium	1s
-----------------------	------------------------	----------------	----------------	------------------------	----

## HISTORIC SYMPOSIA ON BETA LACTAM ANTIBIOTICS SYMPOSIUM HISTORIQUE SUR LES BETA LACTAMINES

Présidents/Chairpersons : J. Acar, G. Daikos, Y. Chabbert

- |       |   |
|-------|---|
| 1/1S  | <b>The birth of penicillin</b><br><u>A.M. Geddes</u><br><i>School of Medicine, University of Birmingham, Birmingham, United Kingdom</i>   |
| 18:00 |   |
| 2/1S  | <b>The first patients treated with penicillin extracts in Oxford</b><br><u>M. Wilkinson</u><br><i>London, United Kingdom</i>  |
| 18:10 |   |
| 3/1S  | <b>The Greek connection</b><br><u>G.L. Daikos</u><br><i>1st Department of Propedeutic Medicine, Laikon General Hospital, Goudi Athens, Greece</i>                                       |
| 18:17 |   |
| 4/1S  | <b>The French connection</b><br><u>J. Acar</u><br><i>Paris, France</i>  |
| 18:24 |   |
| 5/1S  | <b>The development of beta-lactams</b><br><b>The day we isolated 6-amino penicillanic acid</b><br><u>G.N. Rolinson</u><br><i>London, United Kingdom</i>                                 |
| 18:31 |   |
| 6/1S  | <b>Life with Abrahams and Heatly; the purification of 7-amino-cephalosporanic acid</b><br><u>J. Hamilton-Miller</u><br><i>Royal Free and University College, London, United Kingdom</i> |
| 18:46 |   |

Thursday jeudi	2 December décembre	09:00 10:30	Salle Bordeaux	SYMPORIUM Symposium	2s
-------------------	------------------------	----------------	----------------	------------------------	----

## ADVANCES IN THE MANAGEMENT OF VIRAL HEPATITIS IN HIV CO-INFECTED PATIENTS

PRISE EN CHARGE THÉRAPEUTIQUE DES HÉPATOPATHIES VIRALES SÉVÈRES CHEZ LES PATIENTS COINFECTÉS PAR LE VIH ET LES VIRUS DES HÉPATITES

Présidents/Chairpersons : D. Salmon, J.E. Rockstroh

- |       |  |
|-------|--|
| 7/2S  | <b>Management of the cirrhosis complications in HIV patients co-infected with viral hepatitis</b><br><u>P. Sogni</u><br><i>Hôpital Cochin - Saint Vincent de Paul, Paris, France</i> |
| 09:00 |  |
| 8/2S  | <b>Should HIV-HCV co-infected patients with severe hepatitis be treated for hepatitis C?</b><br><u>J.E. Rockstroh</u><br><i>University of Bonn, Bonn, Germany</i>                    |
| 09:20 |  |
| 9/2S  | <b>Should HIV-HBV co-infected patients with severe hepatitis be treated for hepatitis B?</b><br><u>M. Nelson</u><br><i>Chelsea and Westminster Hospital, London, United Kingdom</i>  |
| 09:40 |  |
| 10/2S | <b>Use of antiretroviral agents in patients with cirrhosis</b><br><u>D. Salmon-Ceron</u><br><i>Hôpital Cochin - Saint Vincent de Paul, Paris, France</i>                             |
| 10:00 |  |

**GROUP A STREPTOCOCCAL INFECTIONS IN EUROPE: WHERE ARE WE NOW?**  
**INFECTIONS À STREPTOCOQUES DU GROUPE A EN EUROPE : OÙ EN SOMMES-NOUS MAINTENANT ?**  
Organized by the Strep Euro

Présidents/Chairpersons : N. Legakis, A. Efstratiou

- 11/3S Severe *Streptococcus pyogenes* infections in Europe: Strep-Euro two years on**  
09:00 A. Jasir, C. Schalén, on behalf of Strep-EURO  
*Lund University Hospital, Lund, Sweden*

- 12/3S Nosocomial streptococcus pyogenes infections**  
09:15 G. Carret<sup>1</sup>, L. Mihaila-Amrouche<sup>2</sup>, C. Chirouze<sup>2</sup>, J. Loubinoux<sup>2</sup>, A. Bouvet<sup>2</sup>  
<sup>1</sup>Hospices Civils de Lyon, Faculté de Médecine, Lyon Sud<sup>2</sup>Centre National de Référence des Streptocoques, Hôtel Dieu, Université Paris 5, France

- 13/3S Emerging trends in the epidemiology of invasive Group A streptococcal infections in England and Wales**  
09:30 T. Lamagni<sup>1</sup>, S. Neal<sup>2</sup>, A. Efstratiou<sup>2</sup>  
<sup>1</sup>Communicable Disease Surveillance Centre<sup>2</sup>Specialist and Reference Microbiology Division, Health Protection Agency, London, United Kingdom

- 14/3S Invasive Group A streptococcal (GAS) infections amongst children**  
09:45 L. Zachariadou<sup>1</sup>, A. Stathi<sup>2</sup>, J. Papaparaskevas<sup>2</sup>, A. Efstratiou<sup>4</sup>, T. Lamagni<sup>3</sup>, A. Pangalis<sup>1</sup>  
<sup>1</sup>Medical Microbiology, Aghia Sophia Children's Hospital<sup>2</sup>Medical Microbiology, University of Athens, Medical School, Athens, Greece<sup>3</sup>Communicable Disease Surveillance Centre<sup>4</sup>Specialist and Reference Microbiology Division, Health Protection Agency, London, United Kingdom

- 15/3S MLST and PFGE characterisation of Czech Group A streptococcal invasive disease isolates**  
10:00 L. Strakova<sup>1</sup>, A. Tanna<sup>2</sup>, A. Efstratiou<sup>2</sup>, P. Kriz<sup>1</sup>  
<sup>1</sup>National Institute of Public Health, Prague, Czech Republic<sup>2</sup>, United Kingdom

- 16/3S Role of HLA and superantigens in the pathogenesis of severe Group A streptococcal infections**  
10:15 A. Norrby-Teglund  
*Karolinska Institute, Stockholm, Sweden*

**EXPERIMENTAL INFECTIONS MODELS AND CURRENT GUIDELINES**  
**MODÈLES INFECTIEUX EXPÉRIMENTAUX ET RECOMMANDATIONS ACTUELLES**

Présidents/Chairpersons : P. Chavanet, E. Giamarellos-Bourboulis

- 17/4SOTA Optimal anti infective therapy in *Legionella pneumonia*: lessons from experimental models and current guidelines**  
9:00 C. Chidiac  
*Hôpital de la Croix Rousse, Lyon, France*

- 18/4O Design of a murine model for *Coxiella burnetii* infection by aerosol route**  
09:30 F. Ricci<sup>3</sup>, A. Stein<sup>2</sup>, C. Louveau<sup>4</sup>, H. Lepidi<sup>2</sup>, P. Baylac<sup>4</sup>, B. Davoust<sup>1</sup>, D. Raoult<sup>2</sup>  
<sup>1</sup>Direction du Service de Santé en Région Terre Sud-Est, Lyon<sup>2</sup>Unité des Rickettsies, Faculté de Médecine, Marseille<sup>3</sup>Secteur Vétérinaire Interarmées de Lyon, Rillieux-La-Pape<sup>4</sup>Centre d'Etudes du Bouchet, Vert-Le-Petit, France

- 19/4O In vivo impact of efflux on the efficacy of ceftazidime (CAZ), ticarcillin (TIC) and piperacillin-tazobactam (PTC) in a *Pseudomonas aeruginosa* (PA) experimental endocarditis model: intermittent dosing versus continuous infusion?**  
09:45 J. Caillon<sup>2</sup>, C. Jacqueline<sup>2</sup>, V. Le Mabecque<sup>2</sup>, D. Bugnon<sup>2</sup>, P. Plesiat<sup>1</sup>, G. Potel<sup>2</sup>  
<sup>1</sup>Laboratoire de Bactériologie, Hôpital Minjoz, Besançon<sup>2</sup>Laboratoire d'Antibiologie, UPRES EA 1156, Nantes, France

- 20/4O Emergence of resistant mutants in the digestive tract of gnotobiotic mice mono-associated with *Enterococcus faecalis* and treated with various regimens of linezolid.**  
10:00 N. Bourgeois-Nicolaos<sup>2,3</sup>, F. Doucet-populaire<sup>1,3</sup>, B. Couson<sup>1</sup>, A. Andremont<sup>2</sup>  
<sup>1</sup>Microbiologie, CH Versailles, Le Chesnay<sup>2</sup>Laboratoire de Bactériologie, Hôpital Bichat Claude Bernard<sup>3</sup>Laboratoire de Microbiologie, UFR des Sciences Biologiques et Pharmaceutiques, Université Paris V, Paris, France

- 21/4O In vivo impact of MexXY efflux system on aminoglycoside efficacy in an experimental *Pseudomonas aeruginosa* pneumonia human-like model treated with tobramycin**  
10:15 B. Martha<sup>2</sup>, D. Croisier<sup>2</sup>, D. Durand<sup>2</sup>, D. Hocquet<sup>1</sup>, P. Plesiat<sup>1</sup>, L. Piroth<sup>2</sup>, H. Portier<sup>2</sup>, P. Chavanet<sup>2</sup>  
<sup>1</sup>Bactériologie, CHU Besançon, Besançon<sup>2</sup>Laboratoire des Maladies Infectieuses, EA 562, Dijon, France

<b>22/4O</b>	<b>Synergy of colistin and rifadin in experimental sepsis by multidrug-resistant (MDR) <i>Acinetobacter baumannii</i></b>
10:30	A. Pantopoulou <sup>2</sup> , M. Raftogiannis <sup>1</sup> , P. Koutoukas <sup>1</sup> , V. Koussoulas <sup>1</sup> , I. Dontas <sup>2</sup> , D. Perrea <sup>2</sup> , E.J. Giamarellos-Bourboulis <sup>1</sup> <sup>1</sup> 4th Department of Internal Medicine <sup>2</sup> Laboratory for Experimental Surgery, Athens Medical School, Athens, Greece

Thursday jeudi	<b>2</b>	December décembre	09:00 10:30	ROOM Salle	<b>352B</b>	SYMPORIUM Symposium	<b>5s</b>
-------------------	----------	----------------------	----------------	---------------	-------------	------------------------	-----------

**NEW DEVELOPMENTS IN MRSA**  
**NOUVEAUX DÉVELOPPEMENTS DANS LE MRSA**  
Organized by the Scottish Microbiology Society

Présidents/Chairpersons : I.M. Gould, H. Richet

<b>23/5S</b>	<b>MRSA in Europe- ARPAC data</b>
09:00	<u>F. MacKenzie</u> Department of Microbiology, Aberdeen Royal Infirmary, Aberdeen, United Kingdom
<b>24/5S</b>	<b>The clinical significance of MRSA</b>
09:15	<u>S. Dancer</u> , A. Leonard Scottish Centre for Infection and Environmental Health, Glasgow, United Kingdom
<b>25/5S</b>	<b>Admission screening for MRSA - the missing link in control efforts?</b>
09:30	<u>G. Edwards</u> Department of Microbiology, Glasgow Royal Infirmary, Glasgow, United Kingdom
<b>26/5S</b>	<b>Is antibiotic use a risk factor for MRSA?</b>
09:45	<u>D. Monnet</u> Statens Serum Institute, Copenhagen, Denmark
<b>27/5S</b>	<b>Decolonization and prophylaxis options</b>
10:00	<u>A. Seaton</u> Gartnavel General Hospital, Glasgow, United Kingdom
<b>28/5S</b>	<b>Treatment of MRSA infection</b>
10:15	<u>D. Nathwani</u> Kings Cross Hospital, Dundee, United Kingdom

Thursday jeudi	<b>2</b>	December décembre	09:00 10:30	ROOM Salle	<b>341</b>	SYMPORIUM Symposium	<b>6s</b>
-------------------	----------	----------------------	----------------	---------------	------------	------------------------	-----------

**REVERSAL OF RESISTANCE**  
**INVERSION DE LA RÉSISTANCE AUX ANTIBIOTIQUES**  
Organized by the EU Cost B16 programme

Présidents/Chairpersons : L. Amaral, J.M. Pages

<b>29/6S</b>	<b>Efflux pumps in <i>Enterobacter aerogenes</i>, regulation, activity and inhibition</b>
09:00	<u>J.M. Pages</u> Faculté de Médecine Timone, Marseille, France
<b>30/6S</b>	<b>Antibiotic induced reversible resistance of <i>E.coli</i>: the role of the ACRAB and ACREF operons</b>
09:15	<u>L. Amaral</u> University of Lisbon, Lisbon, Portugal
<b>31/6S</b>	<b>Molecular basis of antifungal resistance in yeast and moulds</b>
09:30	<u>K. Kuchler</u> Max F. Perutz University Laboratories, Vienna, Austria
<b>32/6S</b>	<b>Efflux pumps of antimalarial resistant <i>Plasmodium falciparum</i></b>
09:45	<u>F. Nogueira</u> Institute of Hygiene and Tropical Medicine, Lisbon, Portugal

<b>33/6S</b>	<b>Reversal of resistance of cancer cells by inhibition of efflux pumps</b>
10:00	J. Molnar <sup>2</sup> , N. Gyémánt <sup>2</sup> , M. Tanaka <sup>2</sup> , Z.S. Schelz <sup>2</sup> , J. Hohmann <sup>3</sup> , M.J. Umbelino Ferreira <sup>5</sup> , P. Molnar <sup>1</sup> , R. Didziapetris <sup>4</sup>
	<sup>1</sup> Department of Biochemistry and Medical Chemistry, University of Pecs, Faculty of Medicine, Pecs <sup>2</sup> Department of Medical Microbiology and Immunobiology <sup>3</sup> Department of Pharmacognosy, University of Szeged, Faculty of Medicine, Szeged, Hungary <sup>4</sup> Pharma Algorythms Inc, Vilnius, Lithuania <sup>5</sup> Department of Chemistry, University of Lisbon, Faculty of Pharmaceutical Sciences, Lisbon, Portugal

Thursday jeudi	<b>2</b>	December décembre	09:00 10:30	ROOM Salle	<b>342B</b>	SYMPOSIUM Symposium	<b>7s</b>
-------------------	----------	----------------------	----------------	---------------	-------------	------------------------	-----------

***HELICOBACTER PYLORI: UPDATE 2004***  
***HELICOBACTER PYLORI : ACTUALITÉS 2004***  
Organized by the European and French Helicobacter Study Groups

Présidents/Chairpersons : F. Megraud, A. Hirschl

<b>34/7S</b>	<b>Is there a role for serology in the management of <i>H. pylori</i> infection?</b>
09:00	<u>A. Hirschl</u> <i>Department of Clinical Microbiology, Institute of Hygiene and Medical Microbiology, Vienna, Austria</i>
<b>35/7S</b>	<b>Is it necessary to eradicate <i>H. pylori</i> before prescribing long term aspirin?</b>
09:20	<u>J.C. Delchier</u> <i>Hôpital Henri Mondor, Créteil, France</i>
<b>36/7S</b>	<b>Is <i>H. pylori</i> infection really involved in extra digestive diseases?</b>
09:40	<u>J.D. de Korvin</u> <i>CHU de Nancy, Nancy, France</i>
<b>37/7S</b>	<b>Highlights from the EHSG workshop in Vienna</b>
10:00	<u>S. Suerbaum</u> <i>Institute of Medical Microbiology and Hospital Epidemiology, Hannover Medical School, Hannover, Germany</i>

Thursday jeudi	<b>2</b>	December décembre	09:00 10:30	ROOM Salle	<b>343</b>	SYMPOSIUM Symposium	<b>8s</b>
-------------------	----------	----------------------	----------------	---------------	------------	------------------------	-----------

**VIRAL THREAT IN MEDICALLY ASSISTED PROCREATION**  
**RISQUE VIRAL EN PROCRÉATION MÉDICALE ASSISTÉE**

Présidents/Chairpersons : C. Rouzioux, R. Lévy

<b>38/8S</b>	<b>Management of couples with viral risk in MAP</b>
09:00	<u>R. Tubiana</u> <i>Hôpital Pitié Salpêtrière, Paris, France</i>
<b>39/8S</b>	<b>Viral Threat linked to HIV</b>
09:15	<u>C. Pasquier</u> <i>Hôpital Purpan, Toulouse, France</i>
<b>40/8S</b>	<b>Viral Threat linked to HCV</b>
09:30	<u>T. Bourlet</u> <i>CHU Saint Etienne, Hôpital Nord, Saint Etienne, France</i>
<b>41/8S</b>	<b>Viral safety in laboratory of reproductive biology</b>
09:45	<u>P. Jouannet</u> <i>Hôpital Cochin, Paris, France</i>
<b>42/8S</b>	<b>Management of viral threat in medically assisted procreation: Brussels experiment</b>
10:00	<u>Y. Englert</u> <i>Erasme Hospital, Brussels, Belgium</i>

**INVASIVE FUNGAL INFECTIONS: FROM PHYSIOPATHOLOGY TO TREATMENT**  
**MYCOSES INVASIVES : DE LA PHYSIOPATHOLOGIE À LA PRISE EN CHARGE**

Présidents/Chairpersons : A.M. Tortorano, J.P. Brion

**43/9O The toxin verruculogen of *Aspergillus fumigatus* responsible for electrophysiological modification of human nasal epithelial cells, in vitro**

9:00

K. Khoufache<sup>2</sup>, F. Botterel<sup>2</sup>, O. Puel<sup>3</sup>, D. Rivollet<sup>2</sup>, A. Coste<sup>1</sup>, E. Escudier<sup>1</sup>, S. Bretagne<sup>2</sup><sup>1</sup>Physiopathologie et thérapeutiques respiratoires, INSERM U492 <sup>2</sup>Parasitologie, UMR 956 BIPAR <sup>3</sup>Pharmacologie-Toxicologie, UR 66 INRA, Créteil, France**44/9O Chronic necrotizing pulmonary aspergillosis. Report of 26 cases.**

9:15

G. David<sup>2</sup>, M.A. Piens<sup>1</sup>, J.F. Cordier<sup>4</sup>, J.C. Guerin<sup>3</sup>, P.J. Souquet<sup>5</sup>, D. Peyramond<sup>2</sup><sup>1</sup>Parasitologie, mycologie médicale et maladies tropicales, Faculté Rockefeller <sup>2</sup>Maladies infectieuses <sup>3</sup>Pneumologie, Hôpital de la Croix-Rousse <sup>4</sup>Pneumologie, Hôpital Louis Pradel, Lyon <sup>5</sup>Pneumologie, Centre hospitalier Lyon sud, Pierre Bénite, France**45/9O False positive *Aspergillus* antigenemia related to semisynthetic penicillin therapy is more complex than expected: new facts and new hypothesis.**

9:30

E. Bart-Delabesse, D. Souville, M. Danis, A. Datry

Laboratoire de Parasitologie-Mycologie, G.H. Pitié-Salpêtrière, Paris, France

**46/9O Biological consequences of small mutations in *Candida glabrata***

09:45

S. Brun<sup>1</sup>, F. Dalle<sup>4</sup>, P. Saulnier<sup>3</sup>, G. Renier<sup>2</sup>, A. Bonnin<sup>4</sup>, D. Chabasse<sup>1</sup>, J.P. Bouchara<sup>1</sup><sup>1</sup>Groupe d'Etudes des Interactions Hôte-parasite, UPRES-EA 3142 <sup>2</sup>Laboratoire d'Immunologie, Centre Hospitalier Universitaire <sup>3</sup>Ingénierie de la Vectorisation Particulaire, INSERM U 646, Angers <sup>4</sup>Laboratoire de Parasitologie-Mycologie, Hôpital du Bocage, Dijon, France**47/9O Survey of azole-resistant candida species after implementation of pre-emptive antifungal strategy in a surgical intensive care unit**

10:00

F. Grenouillet<sup>2</sup>, K. Boisson<sup>1</sup>, I. Biot<sup>2</sup>, G. Blasco<sup>3</sup>, L. Millon<sup>2</sup>, P. Balvay<sup>3</sup>, A. Boillot<sup>3</sup>, R. Piarroux<sup>2</sup><sup>1</sup>Bactériologie <sup>2</sup>Mycologie <sup>3</sup>Soins intensifs en Chirurgie, Hôpital Universitaire, Besançon, France**48/9O Posaconazole treatment in rhino-cerebro-ocular zygomycosis**

10:15

T. Bregenzer<sup>2</sup>, P. Schöneborn<sup>1</sup>, M. Podvinec<sup>3</sup><sup>1</sup>Augenklinik <sup>2</sup>Division of Infectious Diseases <sup>3</sup>HNO-Klinik, Kantonsspital Aarau, Aarau, Switzerland

Président/Chairperson : J.P. Stahl

**49/10EL Obesity, diabetes and infections of the respiratory and urinary tracts**

09:45

A. Hoepelman

University Medical Center, Utrecht, The Netherlands

**HIV THERAPY: CHALLENGES OF TODAY AND TOMORROW**  
**TRAITEMENT DU VIH : LES ENJEUX D'AUJOURD'HUI ET DE DEMAIN**

Présidents/Chairpersons : R. Cauda, F. Raffi

**50/11S First-line and rescue: the situation today**

11:00

J.M. Molina

Hôpital Saint Louis, Paris, France

**51/11S Facing the challenges problems and solutions of tuberculosis and HIV**

11:20

S. de Wit

CHU Saint Pierre, Brussels, Belgium

**52/11S Cardiovascular complications and HIV: myths and reality (HAART, sweet HAART)**

11:40 J. Lundgren  
*Hvidovre University Hospital, Copenhagen, Denmark*

**53/11S Novel strategies for tomorrow's challenges**

12:00 J. Reynes  
*Hôpital Gui de Chauliac, Montpellier, France*

Thursday  
jeudi 2 December  
décembre

11:00  
11:45

**Salle Havane**

EXPERT LECTURE  
Conférence

12E

Président/Chairperson : A. Andremont

**54/12EL Epidemiology of streptococcal disease in Europe- An update on incidence of *S. pneumoniae* and *S. pyogenes* and new data on resistance mechanisms**

11:00 R. Reinert  
*Aachen University Hospital, Aachen, Germany*

Thursday  
jeudi 2 December  
décembre

11:00  
12:30

ROOM  
Salle 342A

SYMPOSIUM  
Symposium

13s

**ALERT TO THE EPIDEMICS: FROM THE BENCH TO THE BELL**  
**ALERTE AUX ÉPIDÉMIES : DE LA PAILLASSE À LA SONNETTE D'ALARME**

Présidents/Chairpersons : V. Jarlier, G. Cornaglia

**55/13S Influenza and related viruses**

11:00 B. Lina  
*Laboratory of Virology, Domaine Rockefeller, Lyon, France*

**56/13S Legionellosis, waters and towers**

11:20 J. Etienne  
*Hôpital Edouard Herriot, Lyon, France*

**57/13S Old and new MRSA in hospital**

11:40 V. Jarlier  
*Hôpital Pitié Salpêtrière, Paris, France*

**58/13S MBL producing *Pseudomonas aeruginosa* and *Acinetobacter* outbreaks**

12:00 G. Cornaglia  
*University of Verona, Verona, Italy*

Thursday  
jeudi 2 December  
décembre

11:00  
12:30

ROOM  
Salle 351

STATE OF THE ART  
State of the art

14SOTA

**RESISTANT GRAM POSITIVE COCCI**  
**COCCI À GRAM-POSITIFS RÉSISTANTS**

Présidents/Chairpersons : S. Tyski, J. Soussy

**59/14SOTA Sensitive to surveillance**

11:00 M. Heginbothom  
*National Public Health Service for Wales, Cardiff, United Kingdom*

**60/14O Methicillin-resistant *staphylococcus aureus* (MRSA) in long-term care facilities: what is the best strategy?**

11:30 D. Talon<sup>1</sup>, A. Wollner<sup>2</sup>, S. Bonin<sup>2</sup>, X. Bertrand<sup>1</sup>  
<sup>1</sup>*Hygiène Hospitalière, CHU<sup>2</sup> CLS Bellevaux, Besançon, France*

<b>61/14O</b>	<b>Methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) in acute care units: value of screening cultures and risk factors for acquisition.</b>
11:20	J.C. Lucet, L. Armand-Lefevre, C. Rioux, W. Merabet, B. Régnier, A. Andremont <i>Hôpital Bichat - Claude Bernard, Paris, France</i>
<b>62/14O</b>	<b>Epidemiology and antimicrobial resistance of pneumococci in Greece: A preliminary report of the Hellenic Study for the susceptibility of <i>Streptococcus Pneumoniae</i> Group 2004 (HSSP-2004).</b>
11:50	G. Poulikou, I. Katsarolis, I. Matthaiopoulou, And The Hellenic Study Group For The Susceptibility Of Streptococcus Pneumoniae 2004 <i>4th Department of Internal Medicine, Attikon University General Hospital, Athens University Medical School, Athens, Greece</i>
<b>63/14O</b>	<b>Persistence of animal and human glycopeptide resistant enterococci on Norwegian poultry farms formerly exposed to avoparcin is associated with a widespread plasmid-mediated vanA-element</b>
12:00	P. Johnsen <sup>2</sup> , M. Sørum <sup>1</sup> , H. Sletvold <sup>2</sup> , T. Rosvoll <sup>2</sup> , J.I. Østerhus <sup>2</sup> , H. Kruse <sup>1</sup> , K. Nielsen <sup>2</sup> , G.S. Simonsen <sup>2</sup> , A. Sundsfjord <sup>2</sup> <sup>1</sup> Norwegian Zoonosis Center, National Veterinary Institute, Oslo <sup>2</sup> Microbiology and Virology, University of Tromsø, Tromsø, Norway
<b>64/14O</b>	<b>Methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) in French cystic fibrosis patients : an epidemiologic approach.</b>
12:10	C. Segonds <sup>3</sup> , P. Clavel-Batut <sup>3</sup> , K. Eydieux-Laporte <sup>3</sup> , I. Le Thomas-Bories <sup>3</sup> , E. Bingen <sup>1</sup> , P. Mariani <sup>1</sup> , N. Brahimi <sup>1</sup> , S. Ravilly <sup>2</sup> , G. Chabanon <sup>3</sup> <sup>1</sup> Service de Microbiologie, Hôpital Robert Debré <sup>2</sup> Vaincre la Mucoviscidose, Paris <sup>3</sup> Laboratoire de Bactériologie-Hygiène, Hôpital Rangueil, Toulouse, France

Thursday jeudi	2	December décembre	11:00 12:30	ROOM Salle	352B	SYMPORIUM Symposium	15s
-------------------	---	----------------------	----------------	---------------	------	------------------------	-----

**INFECTIONS IN THE INTENSIVE CARE UNIT**  
**INFECTIONS EN UNITÉ DE SOINS INTENSIFS**  
Organized by the Hellenic Society for Chemotherapy

Présidents/Chairpersons : H. Giamarellou, J. Carlet

<b>65/15S</b>	<b>Resistance surveillance in european ICU's</b>
11:00	J. Carlet <i>Hôpital Saint Joseph, Paris, France</i>
<b>66/15S</b>	<b>Current diagnosis of ventilator acquired pneumonia</b>
11:20	J. Chastre <i>Hôpital Pitié Salpêtrière, Paris, France</i>
<b>67/15S</b>	<b>Management of central vascular line infections in the ICU</b>
11:40	A. Antoniadou <i>Attikon University General Hospital, Athens, Greece</i>
<b>68/15S</b>	<b>Therapeutic approach of multiresistant infections in ICU</b>
12:00	H. Giamarellou <i>Medical School University of Athens, Athens, Greece</i>

Thursday jeudi	2	December décembre	11:00 12:30	ROOM Salle	341	SYMPORIUM Symposium	16s
-------------------	---	----------------------	----------------	---------------	-----	------------------------	-----

**VACCINATION FAILURES IN 2004**  
**ECHECS DE VACCINATION EN 2004**  
Organized by the Pediatric Infectious Disease Group of the French Pediatric Society

Présidents/Chairpersons : C. Perronne, E. Grimpel

<b>69/16S</b>	<b>Vaccinal failures related to immune response: examples of conjugated polysaccharide vaccines</b>
11:00	P. Reinert <i>Hôpital Intercommunal de Créteil, Créteil, France</i>
<b>70/16S</b>	<b>Vaccinal failures related to background: example of hepatitis B vaccine</b>
11:25	F. Denis <i>CHU Dupuytren, Limoges, France</i>

<b>71/16S</b>	<b>Vaccinal failures related to vaccinal strategies: examples of measles mumps rubella (MMR) and <i>H. influenzae</i> (HIB)</b>
11:50	P. Bégué Hôpital Trousseau, Paris, France

Thursday jeudi	<b>2</b>	December décembre	11:00 12:30	ROOM Salle	<b>342B</b>	SYMPORIUM Symposium	<b>17s</b>
-------------------	----------	----------------------	----------------	---------------	-------------	------------------------	------------

**MALARIA AND CHIMIORESISTANCE: TOWARDS A BETTER USE OF ANTIMALARIALS**  
**PALUDISME ET CHIMIRESISTANCE : VERS UN MEILLEUR USAGE DES ANTIPALUDIQUES**  
Organized by the French Society of Parasitology

Présidents/Chairpersons : P. Brasseur, F. Peyron

<b>72/17S</b>	<b>Update on imported malaria in France and epidemiology of resistance</b>
11:00	M. Danis CNR pour les Maladies d'Importation, Paris, France

<b>73/17S</b>	<b>Molecular mechanisms of <i>P. falciparum</i> resistance to antimalarics</b>
11:20	J. Lebras CNR pour la Chimiosensibilité du paludisme, Paris, France

<b>74/17S</b>	<b>Consequences on the prophylactic and therapeutic strategies</b>
11:40	O. Bouchaud Hôpital d'Avicenne, Bobigny, France

<b>75/17S</b>	<b>Therapeutic in future: new antimalarial agents</b>
12:00	F. Nosten <sup>2</sup> , P. Brasseur <sup>1</sup> <sup>1</sup> IRD Dakar, Senegal <sup>2</sup> Shlolo Malaria Research Unit, Bangkok, Thailand

Thursday jeudi	<b>2</b>	December décembre	11:00 12:30	ROOM Salle	<b>343</b>	ORAL SESSION Session Orale	<b>18o</b>
-------------------	----------	----------------------	----------------	---------------	------------	-------------------------------	------------

**VIRAL DIAGNOSTIC**  
**DIAGNOSTIC VIROLOGIQUE**

Présidents/Chairpersons : M. Nelson, F. Stoll-Keller

<b>76/18O</b>	<b>Comparative evaluation of the VIUDAS HIV DUO ultra assay for the combined detection of HIV-1 antigen and antibodies to HIV</b>
11:00	T. Bourlet <sup>2</sup> , C. Pretis <sup>1</sup> , S. Pillet <sup>2</sup> , M. Lesénéchal <sup>1</sup> , J. Piche <sup>1</sup> , B. Pozzetto <sup>2</sup> <sup>1</sup> BioMérieux, Lyon <sup>2</sup> Department of Microbiology, Hôpital Nord, CHU de Saint-Etienne, Saint-Etienne, France

<b>77/18O</b>	<b>Trak-c is a new diagnostic tool in the management of therapeutic follow-up of HIV/HCV co-infected patients treated for chronic hepatitis C.</b>
11:15	A. Pivert <sup>1</sup> , C. Payan <sup>1</sup> , F. Lunel Fabiani <sup>1</sup> , P. Morand <sup>2</sup> <sup>1</sup> Laboratoire de Virologie, CHU Angers, Angers <sup>2</sup> Laboratoire de Virologie, CHU Grenoble, Grenoble, France

<b>78/18O</b>	<b>HBV viral load assessment using sensitive technique and definition of HBV Pre C-C mutant chronic infection clinical entity</b>
11:30	C. Lebarbier <sup>1</sup> , V. Williams <sup>3</sup> , C. Garandeau <sup>1</sup> , G. Bellaliche <sup>2</sup> , P. Dény <sup>3</sup> , L. Maisonneuve <sup>1</sup> , E. Gordien <sup>2</sup> <sup>1</sup> Biologie Médicale <sup>2</sup> Gastro-entérologie, Hôpital Robert Ballanger, Aulnay-Sous-Bois <sup>3</sup> Bactériologie, Virologie et Hygiène, Hôpital Avicenne, Bobigny, France

<b>79/18O</b>	<b>Quantification of Hepatitis Delta Virus RNA in serum by real-time PCR improves patients' monitoring for all HDV types</b>
11:45	E. Gault <sup>1,2</sup> , F. Le Gal <sup>1,2</sup> , E. Gordien <sup>1,2</sup> , D. Affolabi <sup>1,2</sup> , T. Hanslik <sup>3,4</sup> , C. Alloui <sup>1,2</sup> , P. Dény <sup>1,2</sup> <sup>1</sup> Laboratoire de Bactériologie-Virologie-Hygiène, Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris <sup>2</sup> EA3604, Université Paris 13, Bobigny <sup>3</sup> Unité de Médecine Interne, Hôpital Ambroise Paré, Assistance Publique-Hôpitaux de Paris, Boulogne Billancourt <sup>4</sup> Université de Versailles -St-Quentin-en-Yvelines, Versailles, France

<b>80/18O</b>	<b>Development of a real-time PCR assay to differentiate Human herpesvirus -6 variants A and B</b>
12:00	C. Duros <sup>3</sup> , D. Boutolleau <sup>1,3</sup> , D. Caïola <sup>3</sup> , H. Agut <sup>3</sup> , A. Gautheret Dejean <sup>2,3</sup> <sup>1</sup> Laboratoire de Bactériologie-Virologie-Parasitologie-Hygiène, Faculté de Médecine Paris Sud, CHU de Bicêtre, Le Kremlin-Bicêtre <sup>2</sup> Laboratoire de Microbiologie, Faculté des Sciences Pharmaceutiques et Biologiques <sup>3</sup> Laboratoire de Virologie, UPRES EA 2387, GH Pitié-Salpêtrière, Paris, France

<b>81/18O</b>	<b>Herpes viruses and enteroviruses in central nervous system infections:laboratory diagnosis by PCR Consensus methodology.</b>
12:15	G. Vrioni, C. Gartzonika, T. Priavali, C. Christaki, S. Levidiotou <i>Department of Microbiology, Medical School, University of Ioannina, Ioannina, Greece</i>

Thursday jeudi	<b>2</b> December décembre	11:00 12:30	ROOM Salle	<b>352A</b>	ORAL SESSION Session Orale	<b>19o</b>
-------------------	-------------------------------	----------------	---------------	-------------	-------------------------------	------------

**MISCELLANEOUS INFECTIONS 1**  
*INFECTIONS DIVERSES 1*

Présidents/Chairpersons : R. Cohen, A.M. Geddes

<b>82/19O</b>	<b>Role of the mutator phenotype in experimental osteomyelitis due to <i>Staphylococcus aureus</i> and in antibiotic resistance</b>
11:00	C. Daure <sup>1,2</sup> , A.L. Prunier <sup>1</sup> , L. Garry <sup>3</sup> , F. Chau <sup>2</sup> , R. Leclercq <sup>1</sup> , B. Fantin <sup>2</sup> <sup>1</sup> <i>Microbiologie, Centre Hospitalier Universitaire, Caen</i> <sup>2</sup> <i>E9933, Faculté Médecine Xavier Bichat</i> <sup>3</sup> <i>0339, INSERM, Paris, France</i>
<b>83/19O</b>	<b>Spontaneous bacterial peritonitis caused by viridans group streptococci in cirrhotic patients with ascites</b>
11:15	F. Ben <sup>2</sup> , L. Noussair <sup>2</sup> , N. Lambert <sup>2</sup> , D. Valla <sup>1</sup> <sup>1</sup> <i>Hépatologie</i> <sup>2</sup> <i>Microbiologie, Hopital Beaujon, Clichy, France</i>
<b>84/19O</b>	<b>Outbreak of glycopeptid-resistant <i>Enterococcus faecium</i> in a French tertiary care hospital: the end of the “French paradox”?</b>
11:30	F. Robin <sup>5,4</sup> , C. Aumeran <sup>5</sup> , F. Thiollière <sup>5</sup> , B. Villemagne <sup>3</sup> , C. Chaleteix <sup>3</sup> , L. Amrouche <sup>7</sup> , J.P. Romaszko <sup>4</sup> , F. Gourdon <sup>5</sup> , J.M. Constantin <sup>6</sup> , O. Baud <sup>1</sup> , B. Souweine <sup>2</sup> , J. Beytout <sup>5</sup> , H. Laurichesse <sup>5</sup> , O. Lesens <sup>5</sup> <sup>1</sup> <i>Hygiène hospitalière, CHU</i> <sup>2</sup> <i>Réanimation polyvalente, Hôpital Gabriel Montpied</i> <sup>3</sup> <i>Hématologie clinique</i> <sup>4</sup> <i>Laboratoire de bactériologie</i> <sup>5</sup> <i>Maladies infectieuses</i> <sup>6</sup> <i>Réanimation adulte, Hôtel Dieu, Clermont-Fd</i> <sup>7</sup> <i>Bactériologie-Virologie, Hôtel Dieu (AP-HP), Paris, France</i>
<b>85/19O</b>	<b>Evaluation of a strategy of multiple -site screening of methicillin-resistant <i>Staphylococcus aureus</i> at admission to a teaching hospital.</b>
11:45	M. Eveillard, E. Lancien, M.L. Joly-guillou <i>Microbiologie-hygiène, CHU Louis Mourier, Colombes, France</i>
<b>86/19O</b>	<b>French National Survey of Nasopharyngeal (NP) Carriage of <i>Streptococcus pneumoniae</i> (Sp) among infants and toddlers suffering from Acute Otitis Media (AOM): third year after 7-Valent pneumococcal conjugated vaccine (7-VPnC) launch</b>
12:00	R. Cohen <sup>2</sup> , C. Levy <sup>1</sup> , F. De La Rocque <sup>1</sup> , B. Fritzell <sup>3</sup> , M. Cottard <sup>3</sup> , R. Tetelbaum <sup>3</sup> , P. Reinert <sup>2</sup> , M. Boucherat <sup>1</sup> , E. Varon <sup>4</sup> <sup>1</sup> <i>ACTIV</i> <sup>2</sup> <i>CHI Crétell</i> <sup>3</sup> <i>Wyeth, France</i> <sup>4</sup> <i>HEGP, Paris, France</i>
<b>87/19O</b>	<b>Antibiotic prescribing for adults hospitalized patients referred from the emergency room (ER)</b>
12:15	E. Papy, V. Beaumesnil, M. Wolff, J.C. Lucet, A. Andremont, E. Bouvet, A. Certain, R. Farinotti, A. Fischelle, C. Leport, The Antibiotic Study Group <i>Hôpital Bichat Claude Bernard, Université Paris VII, Paris, France</i>

Thursday jeudi	<b>2</b> December décembre	11:45 12:30	<b>Salle Havane</b>	EXPERT LECTURE Conférence	<b>20EL</b>
-------------------	-------------------------------	----------------	---------------------	------------------------------	-------------

Président/Chairperson : H. Portier

<b>88/20EL</b>	<b>Severe pneumococcal pneumonia: monotherapy or combination therapy?</b>
11:45	J. Garau <i>Hospital Mutua de Terrassa, Barcelona, Spain</i>

**PRATICAL CONSEQUENCES OF EXTENDED SPECTRUM BETA-LACTAMASES (ESBLs)**

CONSEQUENCES PRATIQUES DES BÉTA-LACTAMASES À SPECTRE ÉTENDU  
Organized by the Antibiogram Committee of the French Microbiological Society and EUCAST

Présidents/Chairpersons : P. Nordmann, J. Mouton

**89/21S Evolution of ESBLs**

14:00 A. Philippon  
*Hôpital Cochin, Paris, France*

**90/21S Technical procedures for detection of ESBLs**

14:20 M.H. Nicolas-Chanoine  
*Hôpital Ambroise Paré, Paris, France*

**91/21S Impact of PK/PD on breakpoints of third generation cephalosporins**

14:40 J.W. Mouton  
*Casinius - Wilhelmina Hospital, Nijmegen, The Netherlands*

**92/21S International comparison of breakpoints of third generation cephalosporins**

15:00 G. Kahlmeter  
*Central Hospital, Växjö, Sweden*

Président/Chairperson : L. Stratchouski

**93/22EL *Acinetobacter baumanii*: emergence of resistance**

14:00 P. Nordmann  
*Hôpital Bicêtre, Le Kremlin Bicêtre, France*

**CURRENT SITUATION WITH HIV INFECTION**  
SITUATION ACTUELLE DE L'INFECTION DU VIH

Présidents/Chairpersons : M. Egger, T. May

**94/23S Epidemiology of AIDS in France**

14:00 D. Costagliola  
*INSERM EMI 0214, Paris, France*

**95/23S Factors of clinical progression**

14:20 M. Egger  
*University of Bristol, Bristol, United Kingdom*

**96/23S Side effects of HAART**

14:40 X. Duval  
*CHU Bichat Claude Bernard, Paris, France*

**97/23S Morbidity and causes of death**

15:00 G. Chêne  
*INSERM U593, Bordeaux, France*

**CURRENT ANTIBIOTIC RESISTANCE PROBLEMS**  
**PROBLÈMES RENCONTRÉS DANS LA RÉSISTANCE AUX ANTIBIOTIQUES**

Présidents/Chairpersons : L. Dubreuil, O. Ang

**98/24SOTA Antibiotic resistance among *Bacteroides preotella* and *Clostridia* - present and future**14:00 L. Dubreuil

Faculté des Sciences Pharmaceutiques et Biologiques, Lille, France

**99/24O A nosocomial outbreak of *Acinetobacter baumannii* isolates expressing the carbapenem-hydrolyzing oxacillinase oxa-58**

14:30

C. Héritier<sup>1</sup>, A. Dubouix<sup>2</sup>, L. Poirel<sup>1</sup>, N. Marty<sup>2</sup>, P. Nordmann<sup>1</sup><sup>1</sup>Hôpital de Bicêtre, Assistance Publique/Hôpitaux de Paris, Service de Bactériologie-Virologie, Le Kremlin-Bicêtre <sup>2</sup>CHU Rangueil, Laboratoire de Bactériologie-Hygiène, Toulouse, France**100/24O Retrospective analysis of multi-resistant *Acinetobacter baumannii* strains isolated in a university hospital**

14:40

J. Filliaux<sup>1</sup>, A. Dubouix<sup>1</sup>, S. Daude<sup>1</sup>, M. Archambaud<sup>1</sup>, C. Segonds<sup>1</sup>, C. Conil<sup>3</sup>, J. Laguerre<sup>2</sup>, N. Marty<sup>1</sup><sup>1</sup>Bactériologie-Hygiène <sup>2</sup>Brûlés <sup>3</sup>Réanimation, CHU Rangueil, Toulouse, France**101/24O Investigation of the new QNR-based mechanism of quinolone resistance and first description in *Enterobacter cloacae***

14:50

S. Honoré<sup>1</sup>, C. Lascols<sup>1</sup>, P. Legrand<sup>1</sup>, C.J. Soussy<sup>1</sup>, E. Cambau<sup>1,2</sup><sup>1</sup>Bactériologie-Virologie-Hygiène, CHU Henri Mondor APHP, Créteil <sup>2</sup>Bactériologie-Hygiène, CHU Pitié Salpêtrière APHP, Université De Paris, France**102/24O Emergence of plasmid-mediated quinolone resistance in *Escherichia coli* in Europe**

15:00

H. Mammeri<sup>1</sup>, M. Van De Loo<sup>1</sup>, L. Poirel<sup>1</sup>, L. Martinez-martinez<sup>2</sup>, P. Nordmann<sup>1</sup><sup>1</sup>Service de Bactériologie-Virologie, Hôpital de Bicêtre, Le Kremlin-Bicêtre, France <sup>2</sup>Department of Microbiology, University Hospital Marquès de Valdecilla, Santander, Spain**103/24O Type II topoisomerase genotype of quinolone-resistant clinical isolates of *Escherichia coli* isolated in France.**

15:10

C. Lascols<sup>1</sup>, L. Attalah<sup>1</sup>, C.J. Soussy<sup>1</sup>, E. Cambau<sup>1,2</sup><sup>1</sup>Bactériologie-Virologie-Hygiène, CHU Henri Mondor APHP, Créteil <sup>2</sup>Bactériologie-Hygiène, CHU Pitié Salpêtrière APHP, Université De Paris, France**NOSOCOMIAL PNEUMONIA - EVIDENCE BASED GUIDELINES**PNEUMONIE NOSOCOMIALE - DIRECTIVES BASÉES SUR DES PREUVES  
Organized by the British Society of Antimicrobial Chemotherapy

Présidents/Chairpersons : J.Y. Fagon, R. Masterton

**104/25S Nosocomial pneumonia due to resistant bacteria: risk factors and management**14:00 J.Y. Fagon

Hôpital Européen Georges Pompidou, Paris, France

**105/25S Prevention of infection**14:20 A. Galloway

Royal Victoria Infirmary, Newcastle, United Kingdom

**106/25S Diagnosis of pneumonia**14:40 G. French

St Thomas Hospital, London, United Kingdom

**107/25S Treatment update**15:00 M. Street

Royal Sussex County Hospital, Brighton, United Kingdom

**ANTIMICROBIAL PRACTICES AND RESISTANCE IN DEVELOPING COUNTRIES**  
**PRATIQUES ANTIMICROBIENNES ET RÉSISTANCE DANS LES PAYS EN DÉVELOPPEMENT**  
Organized by the Slovak Society of Chemotherapy

Présidents/Chairpersons : V. Krcmery, A. Andremont

**108/26S Antibiotic practices and resistance among HIV positive Cambodian children**

14:00 A. Docze<sup>1</sup>, G. Benca<sup>1</sup>, P. Beno<sup>2</sup>, V. Krcmery<sup>2</sup>

<sup>1</sup>St. Elisabeth Medical University, Phnom Penh, Cambodia <sup>2</sup>School of Public Health, University of Trnava, Trnava, Slovakia

**109/26S Antibiotic practices and consumption of Antibiotics in malaria and non-malaria season in South Sudan**

14:20 A. Augustin<sup>1</sup>, M. Taziar<sup>2</sup>

<sup>1</sup>School of Health and Social Work, University of Trnava, Trnava, Slovakia <sup>2</sup>2nd Mary Immaculate and DOR Hospital, Mapuordit, Sudan

**110/26S Infections and resistance of pathogens in malnourished children from slums in Nairobi**

14:40 Z. Kniezo<sup>1</sup>, A. Ondrus<sup>2</sup>

<sup>1</sup>1st Mary Immaculate Clinic, Nairobi, Kenya <sup>2</sup>DOR Hospital 2nd Mary Immaculate Clinic, Mapuordit, Sudan

**111/26S Antibiotic consumption and resistance among indian population in rural Bolivia**

15:00 F. Paradisi

Institute of Infectious Diseases, University of Florence, Florence, Italy

**DISEASES DIAGNOSED IN TRAVELLERS AFTER RETURN**

**MALADIES DIAGNOSTIQUÉES AU RETOUR D'UN VOYAGE**

Organized by the Society for Travel Medicine

Présidents/Chairpersons : E. Caumes, T. Loescher

**112/27S Spectrum of illness diagnosed in travellers returning from the tropics**

14:00 E. Caumes

Hôpital Pitié Salpêtrière, Paris, France

**113/27S Respiratory tract infections in travellers**

14:20 M. Mutsch

Institute of Social and Preventive Medecine, Zurich, Switzerland

**114/27S Imported malaria in Europe**

14:40 T. Loescher

Department of Infectious Diseases and Tropical Medicine, University of Munich, Munich, Germany

**115/27S Malaria drug resistance imported in France, 1993-2004**

15:00 J. Le Bras, B. Pradines, G. Cottrell, R. Durand, D. Parzy, & Members of Corresponding Group  
CNR Chimiosensibilité du Paludisme, Paris & Marseille, France

**116/27S Atovaquone-proguanil therapeutic failures in France in 2003-2004.**

15:10 L. Musset, L. Massias, S. Matheron, O. Bouchaud, J. Le Bras and Corresponding Group

Hôpital Bichat-Claude Bernard, CNR Chimiosensibilité du Paludisme, Laboratoire de Parasitologie, Paris, France

**117/27S Illnesses in travellers returning from the tropics: a prospective study of 622 patients**

15:20 S. Ansart<sup>1</sup>, L. Perez<sup>2</sup>, O. Vergely<sup>2</sup>, M. Danis<sup>2</sup>, F. Bricaire<sup>2</sup>, E. Caumes<sup>2</sup>

<sup>1</sup>Maladies infectieuses et tropicales, Hopital de la Cavale Blanche, Brest <sup>2</sup>Maladies infectieuses et tropicales, Parasitologie-Mycologie, Hopital Pitié-Salpêtrière, Paris, France

**ROTAVIRUS AND OTHER VIRAL DIARRHOEAS**  
*ROTAVIRUS ET AUTRES DIARRHÉES VIRALES*

Présidents/Chairpersons : D. Gendrel, P. Pothier

**118/28S Physiology of viral diarrhoeas**

14:00 M. Lorrot

Hôpital Saint Vincent de Paul, Paris, France

**119/28S Calicivirus and related viruses**

14:20 P. Pothier

Hôpital du Bocage, Dijon, France

**120/28S Viral diarrhoeas in adults**

14:40 E. Nicand

HIA Val de Grâce, Paris, France

**121/28S Prospects for anti-rotavirus vaccines**

15:00 D. Gendrel

Hôpital Saint Vincent de Paul, Paris, France

**PHARMACOKINETICS, SAFETY AND PHARMACOECONOMY OF ANTIINFECTIVE DRUGS**  
*PHARMACOCINÉTIQUE, TOLÉRANCE ET PHARMACOÉCONOMIE DES ANTIINFECTIEUX*

Présidents/Chairpersons : J.M. Scherrmann, P. Tulkens

**122/29O A post-marketing study (PMS) to confirm the cardiac safety profile of IZILOX®**14:00 P. Veyssier<sup>2</sup>, P. Voiriot<sup>3</sup>, B. Bégaud<sup>1</sup>, C.F. Brentano<sup>4</sup><sup>1</sup>Unité de Pharmaco-Epidémiologie, Université Victor Segalen, Bordeaux <sup>2</sup>Service de Médecine Interne, Centre Hospitalier, Compiègne <sup>3</sup>Unité de Pharmaco-Epidémiologie, Vandoeuvre Les Nancy, Nancy <sup>4</sup>Service de Pharmacologie Clinique, Hôpital Saint Antoine, Paris, France**123/29O The influence of educational and restrictive interventions on outpatient antibiotic consumption in Slovenia.**14:15 M. Cizman<sup>2</sup>, T. Srovin<sup>2</sup>, M. Pokorn<sup>2</sup>, S. Cad Pecar<sup>1</sup><sup>1</sup>Institute of Public Health of the Republic of Slovenia <sup>2</sup>Department of Infectious Diseases, University Medical Centre, Ljubljana, Slovenia**124/29O Targeted surveillance of antibiotic prescription - a clinical governance design**14:30 P.B. Nielsen<sup>1,2</sup>, L. Nielsen<sup>2</sup>, N. Phillimore<sup>2</sup>, V. Shaw<sup>2</sup><sup>1</sup>Microbiology, Northwick Park Hospital, Harrow, Middlesex <sup>2</sup>Pharmacy & Microbiology, Peterborough District Hospital, Peterborough, United Kingdom**125/29O Therapeutic drug monitoring (TDM) of nelfinavir (NFV) can be improved using a model integrating diurnal and food-effects:PEKAVIR study.**14:45 J.M. Besnier<sup>5</sup>, P. Rodon<sup>1</sup>, F. Bastides<sup>5</sup>, T. Prazuck<sup>2</sup>, W. De Jong<sup>5</sup>, C. Michelet<sup>4</sup>, F. Raffi<sup>3</sup>, E. Autret-leca<sup>5</sup>, G. Paintaud<sup>5</sup>, P. Choutet<sup>5</sup>, C. Le Guellec<sup>5</sup><sup>1</sup>Hôpital, Blois <sup>2</sup>Hôpital Universitaire, Nantes <sup>3</sup>Hôpital, Orléans <sup>4</sup>Rennes <sup>5</sup>Hôpital Universitaire, Tours, France**126/29O Single intravenous application of 500 mg levofloxacin results in high liver tissue concentrations**15:00 M. Weinrich<sup>1</sup>, S. Scheingraber<sup>1</sup>, T. Stremovskaja<sup>2</sup>, M.K. Schilling<sup>1</sup>, F. Kees<sup>3</sup>, G.A. Pistorius<sup>1</sup><sup>1</sup>Department of General, Visceral and Vascular Surgery <sup>2</sup>Institute of General and Special Pathology, University Hospital of the Saarland, Homburg/Saar <sup>3</sup>Institute of Pharmacology, University of Regensburg, Regensburg, Germany**127/29O Microdialysis study of imipenem distribution in non-infected rats skeletal muscle and lung extracellular fluids**15:15 S. Marchand<sup>3,2</sup>, C. Dahyot<sup>1</sup>, I. Lamarche<sup>3</sup>, O. Mimoz<sup>1,3</sup>, W. Couet<sup>2,3</sup><sup>1</sup>Département d'Anesthésie et de Réanimation Chirurgicale <sup>2</sup>Laboratoire de Pharmacocinétique, CHU <sup>3</sup>EA 3809, Pôle Biologie Santé, Poitiers, France

**MICROBIOLOGICAL METHODS**  
**MÉTHODES MICROBIOLOGIQUES**

Présidents/Chairpersons : N. Legakis, G. Chabanon

**128/30O A novel E-test method to evaluate drug interactions on *Pseudomonas aeruginosa***14:00 K. Boisson, D. Hocquet, I. Patry, P. Plesiat, GESPA Group  
*Bacteriologie, CHU, Besançon, France***129/30O Change of susceptibility rates with time or location: how does it impact on predictive values of disk diffusion susceptibility testing reports?**14:15 B. Lamy<sup>2,3</sup>, G. Carret<sup>2,3</sup>, J.P. Flandrois<sup>2,3</sup>, M.L. Delignette<sup>1</sup>  
<sup>1</sup>Unité de microbiologie alimentaire et prévisionnelle, Ecole Nationale Vétérinaire de Lyon, Marcy L'étoile<sup>2</sup>Dynamique des populations bactériennes, UMR CNRS 5558, Oullins<sup>3</sup>Laboratoire de bactériologie, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre Benite, France**130/30O Evaluation of a disk diffusion method with cefoxitin (30µg) for detection of methicillin-resistant coagulase negative staphylococci (CNS).Preliminary results.**14:30 E. Giannitsioti, R. Vorou, I. Galani, V. German, E. Koratzanis, M. Souli, K. Orlandou, G. Greka, H. Giamarellou  
*University General Hospital "ATTIKON", 4th Department of Internal Medicine, University of Athens, Athens, Greece***131/30O Evaluation of a PCR assay for detection of *Nocardia* DNA in human clinical specimens**14:45 A. Couble<sup>1</sup>, V. Rodriguez-nava<sup>1</sup>, M. De Montclos<sup>2</sup>, P. Boiron<sup>1</sup>, F. Laurent<sup>1</sup>  
<sup>1</sup>UMR CNRS 5557 - Center for Microbial Ecology - Opportunistic Pathogens and Environment Research Group - Observatoire Français des Nocardioides (OFN), Université Claude Bernard Lyon 1 - Faculté de Pharmacie de Lyon, Lyon<sup>2</sup>Laboratoire de Bactériologie, Centre Hospitalier Lyon Sud, Pierre Bénite, France**132/30O Contribution of the technique of hybridization protected ARNr in the diagnosis of the STD with *C. trachomatis* and *N. gonorrhoeae***15:00 B.K. Mansour, S. Abdeddayem, M. Zribi, A. Soudani, A. Masmoudi, C. Fendri  
*Laboratory of Microbiology, UHC of Rabta, Tunis, Tunisia***133/30O Usefulness of a triplex real time (RT) PCR for initiation of appropriate antibiotic treatment in patients with positive blood cultures with Gram positive cocci (GPC) on direct smear examination**15:15 R. Ruimy<sup>3</sup>, M. Dos-santos<sup>3</sup>, L. Raskine<sup>4</sup>, F. Bert<sup>2</sup>, M. Hornstein<sup>1</sup>, R. Masson<sup>3</sup>, A. Andremont<sup>3</sup>  
<sup>1</sup>Laboratoire de bactériologie, Hôpital Avicenne, Bobigny<sup>2</sup>Laboratoire de Bactériologie, Hôpital Beaujon, Clichy<sup>3</sup>Laboratoire de Bactériologie, Groupe Hospitalier Bichat - Claude-Bernard<sup>4</sup>Laboratoire de Bactériologie, Hôpital Lariboisière, Paris, France

Président/Chairperson : P. Plésiat

**134/31EL Inhibitors of antibiotic efflux pumps**14:45 O. Lomovskaya  
*Mpx Pharmaceuticals, San Diego, United States***UPDATE ON MULTIDRUG RESISTANT BACTERIA: FROM SURVEILLANCE TO GENETICS**  
**ACTUALITÉS DES BACTÉRIES MULTIRÉSISTANTES : DE LA SURVEILLANCE À LA GÉNÉTIQUE**  
Organized by the ONERBA

Présidents/Chairpersons : L. Gutmann, D. Monnet

**135/32S Panton-Valentine leukocidin-producing methicillin-resistant *Staphylococcus aureus* (PVL MRSA) in France: ONERBA survey (2001-2004)**16:00 J. Robert  
*Faculté de Médecine Pitié Salpêtrière, Paris, France*

<b>136/32S</b>	<b>PVL MRSA in Europe: physiopathology and molecular epidemiology</b>
16:20	<u>J. Etienne</u> <i>Centre National de Référence des Staphylocoques, Lyon, France</i>
<b>137/32S</b>	<b>ESBL-producing Enterobacteria: a new start? results from ONERBA's networks 1997-2004</b>
16:40	<u>F. Grobst</u> <i>LABM Darrasse et Dufau, Biarritz, France</i>
<b>138/32S</b>	<b>ESBL-producing Enterobacteria: inter-species spread of old beta-lactamases or new enzymes?</b>
17:00	<u>L. Poirel</u> <i>Hôpital de Bicêtre, Paris, France</i>

Thursday 2 December 2004 16:00 - 17:30 ROOM Salle 342A SYMPOSIUM Symposium 33s

### ANTIVIRAL CHEMOTHERAPY IN IMMUNO-COMPROMISED HOSTS CHIMIOTHÉRAPIES ANTIVIRALES ET DÉFICIT IMMUNITAIRE LORS DES INFECTIONS VIRALES

Présidents/Chairpersons : G. Herbein, P. Meylan

<b>139/33S</b>	<b>Immunosuppressor treatments and hepatitis C</b>
16:00	<u>F. Stoll-Keller</u> <i>INSERM 74, Strasbourg, France</i>
<b>140/33S</b>	<b>CMV in immunosuppressed patients: is serological follow-up needed?</b>
16:20	<u>A. Coaqueute</u> <i>CHU de Besançon, Besançon, France</i>
<b>141/33S</b>	<b>Opportunistic infections with Polyomavirus type BK and JC in renal transplantation</b>
16:40	<u>L. Andreoletti</u> <i>CHU Robert Debré, Reims, France</i>
<b>142/33S</b>	<b>Monitoring EBV in immunocompromised patients: where virology borders oncology</b>
17:00	<u>P. Meylan</u> <i>Lausanne University, Lausanne, Switzerland</i>

Thursday 2 December 2004 16:00 - 17:30 ROOM Salle 351 SYMPOSIUM Symposium 34s

### UPDATE ON INFECTIONS IN THE ELDERLY ACTUALITÉS SUR LES INFECTIONS DU SUJET Âgé

Organized by the Spanish Society of Chemotherapy and the French geriatrics Society

Présidents/Chairpersons : P. Veyssier, E. Perea

<b>143/34S</b>	<b>Infectious risk and the aged</b>
16:00	<u>C. Trivalle</u> <i>Hôpital Paul Brousse, Paris, France</i>
<b>144/34S</b>	<b>Epidemiology in infectious diseases in community and nursing home residents</b>
16:15	<u>J. Belmin, M. Rothan-Tondeur</u> <i>Hôpital Charles Foix, Ivry sur Seine, France</i>
<b>145/34S</b>	<b>Fluoroquinolones in the elderly</b>
16:30	<u>J. Honarato</u> <i>University of Navarra, Pamplona, Spain</i>
<b>146/34S</b>	<b>Respiratory tract infections in the elderly</b>
16:45	<u>J. Gaillat</u> <i>Hôpital d'Annecy, Annecy, France</i>

**147/34S Current therapeutic strategy**17:00 J.J. Picazo*San Carlos University Hospital, Madrid, Spain*Thursday  
jeudi**2**December  
décembre16:00  
17:30ROOM  
Salle**352B**SYMPOSIUM  
Symposium**35s****PROPHYLAXIS AND MANAGEMENT OF INFECTIVE ENDOCARDITIS***PROPHYLAXIE ET PRISE EN CHARGE DE L'ENDOCARDITE INFECTIEUSE*

Organized by the Endocarditis Group of the Paul Ehrlich Society

**Présidents/Chairpersons :** B. Hoen, C. Naber**148/35S What can we learn from the International Collaboration on Endocarditis (ICE)?**16:00 B. Hoen*Hôpital Saint Jacques, Besançon, France***149/35S Resistance problems and new antibiotics in patients with endocarditis**16:20 H. Giamarellou*Medical School University of Athens, Athens, Greece***150/35S Should surgery be performed more often in the treatment of infective endocarditis?**16:40 C. Naber*Department of Cardiology, Essen University Hospital, Essen, Germany***151/35S Antibiotic prophylaxis of endocarditis today**17:00 C. Lepot*CHU Bichat Claude Bernard, Paris, France*Thursday  
jeudi**2**December  
décembre16:00  
17:30ROOM  
Salle**341**SYMPOSIUM  
Symposium**36s****CLINICAL SIGNIFICANCE OF PK/PD CORRELATION IN ICU PATIENTS***SIGNIFICATION CLINIQUE DE LA CORRÉLATION PK/PD POUR LES PATIENTS EN USI*

Organized by the Italian Society of Chemotherapy

**Présidents/Chairpersons :** A. Novelli, B. Rouveix**152/36S Introduction**16:00 A. Novelli*University of Florence, Florence, Italy***153/36S PK/PD Correlation: state of the art and parameters predictive of clinical outcome**16:20 F. Scaglione*Pharmacology, University of Milan, Milan, Italy***154/36S Pharmacokinetics in critically ill patients**16:40 T. Mazzei*University of Florence, Florence, Italy***155/36S Evidence based results in critical care infections**17:00 J.P. Sollet*Service de Réanimation Médicale, CH Argenteuil, Argenteuil, France*

**RISK FACTORS FOR MRSA**  
**FACTEURS DE RISQUES POUR MRSA**

Présidents/Chairpersons : P. Charbonneau, A. Seaton

- 156/37O Fluoroquinolone use and subsequent multidrug-resistant bacteria emergence in the intensive care unit**  
16:00 S. Nseir<sup>2</sup>, C. Di Pompeo<sup>3</sup>, P. Delour<sup>2</sup>, S. Soubrier<sup>2</sup>, H. Lenc<sup>2</sup>, M. Roussel-Delvallez<sup>1</sup>, T. Onimus<sup>2</sup>, F. Saulnier<sup>2</sup>, D. Mathieu<sup>2</sup>, A. Durocher<sup>2</sup>  
<sup>1</sup>Laboratoire de Bactériologie<sup>2</sup>Unité de Soins Intensifs, Hôpital Calmette<sup>3</sup>Laboratoire d'Analyses Médicales, Université de Lille II, Lille, France
- 157/37O Risk factors for *Staphylococcus aureus* infection in liver transplant recipients**  
16:15 F. Bert<sup>4</sup>, C. Bellier<sup>3</sup>, L. Lassel<sup>5</sup>, V. Lefranc<sup>3</sup>, F. Durand<sup>2</sup>, J. Belghiti<sup>1</sup>, F. Mentré<sup>5</sup>, B. Fantin<sup>3</sup>  
<sup>1</sup>Chirurgie digestive<sup>2</sup>Hépatologie<sup>3</sup>Médecine interne<sup>4</sup>Microbiologie, Hopital Beaujon, Clichy<sup>5</sup>Biostatistique, Hopital Bichat, Paris, France
- 158/37O MRSA at an English children's hospital from 1998 - 2003**  
16:30 A. Adedeffi, J.W. Gray  
Department of Microbiology, Birmingham Children's Hospital (BCH), Birmingham, United Kingdom
- 159/37O Emergence of a new highly epidemic methicillin-resistant *Staphylococcus aureus* clone producing the toxic shock syndrome toxin, responsible either for hospital-acquired and community-acquired infections in France**  
16:45 G. Durand, M. Bes, H. Meugnier, F. Forey, G. Lina, F. Vandenesch, J. Etienne  
Faculté de Médecine, Laennec Centre National de Référence des Staphylocoques, INSERM E0230, Lyon, France
- 160/37O Incidence and risk factors for endemic respiratory tract infection in an adult intensive care unit: a prospective longitudinal study**  
17:00 M.H. Halwani, R.S. Slack, H.G. Grundmann  
Division of Microbiology & Infectious Diseases, University Hospital of Nottingham, Nottingham, United Kingdom
- 161/37O MRSA colonisation in patients with cystic fibrosis: Antimicrobial susceptibility pattern.**  
17:15 D. Monclús, B. Buendía, R.M. Girón, A. Pérez de Ayala, E. García-Peña, M. López-Brea  
Microbiology, H.U. de la Princesa, Madrid, Spain

**PEDIATRIC VIROLOGY**  
**VIROLOGIE PÉDIATRIQUE**

Présidents/Chairpersons : E. Grimpel, M. Marguet

- 162/38O The epidemiological burden of influenza in infants and young children in East London, UK**  
16:00 E.K. Ajayi-obe, R. Handa, PG. Coen, K. Hawrami, C. Aitken, J. Breuer, EDG. McIntosh, R. Booy  
Centre of Child Health, Queen Mary University School of Medicine and Dentistry, Barts and the London NHS Trust, London, United Kingdom
- 163/38O Use of Respiratory Syncytial Virus Rapid Diagnostic Test (RSV-RDT) to Predict the Occurrence of Bronchiolitis in Children Under 3 Months of Age Suffering from Acute Viral Rhinitis**  
16:15 O. Romain<sup>1</sup>, C. Levy<sup>2</sup>, Benani<sup>2</sup>, F. Corrado<sup>2</sup>, Deberdt<sup>2</sup>, A. Elbez<sup>2</sup>, M. Koskas<sup>2</sup>, La Rocca<sup>2</sup>, Lastmann-lahmi<sup>2</sup>, C. Romain<sup>2</sup>, C. Schlemmer<sup>2</sup>, A. Wollner<sup>2</sup>, C. Wollner<sup>2</sup>, Zalusky<sup>2</sup>, M. Boucherat<sup>2</sup>, F. De La Rocque<sup>2</sup>, R. Cohen<sup>1</sup>  
<sup>1</sup>Groupe Français des Infections Pédiatriques, Société Française de Pédiatrie<sup>2</sup>ACTIV, St Maur, France
- 164/38O Replicative and immune response to primary human metapneumovirus infection in BALB/c mice**  
16:30 M. Darniot<sup>2</sup>, S.L. Aho<sup>3</sup>, T. Petrella<sup>1</sup>, P. Pothier<sup>2</sup>, C. Manoha<sup>2</sup>  
<sup>1</sup>Service de Pathologie, Centre de Pathologie CHU du Bocage<sup>2</sup>Laboratoire de Virologie<sup>3</sup>Service d'Epidémiologie et d'Hygiène hospitalière, CHU du Bocage, Dijon, France
- 165/38O HHV-6 as a causative agent of fulminant hepatic failure in young children**  
16:45 D. Boutolleau<sup>1-5</sup>, L. Chevret<sup>3</sup>, D. Debray<sup>2</sup>, N. Idrì<sup>1</sup>, C. Pallier<sup>1</sup>, P. Nordmann<sup>1</sup>, D. Devictor<sup>3</sup>, O. Bernard<sup>2</sup>, H. Agut<sup>5</sup>, A. Gautheret Dejean<sup>4-5</sup>  
<sup>1</sup>Laboratoire de Bactériologie-Virologie-Parasitologie-Hygiène<sup>2</sup>Service d'Hépatologie Pédiatrique<sup>3</sup>Service de Réanimation Pédiatrique, CHU de Bicêtre, Le Kremlin-Bicêtre<sup>4</sup>Laboratoire de Microbiologie, Faculté des Sciences Pharmaceutiques et Biologiques<sup>5</sup>Laboratoire de Virologie, GH Pitié-Salpêtrière, Paris, France
- 166/38O Varicella and its complications: a five-year-long retrospective analysis of hospitalized patients.**  
17:00 V. Maresova, M. Maly, J. Kyncl, E. Bronska  
Faculty Hospital Bulovka, Prague, Charles University, Prague, Prague, Czech Republic

<b>167/38O</b>	<b>Improvement of vaccination rates in children and teenagers by a specific intervention program</b>
17:15	H. Roggendorf, P. Freyrik <i>Public Health Service, Essen, Germany</i>

<b>168/38O</b>	<b>Chickenpox complications in Saudi Arabia: Is it time for routine Varicella vaccination?</b>
17:30	M. Almuneef, Z. Memish, H. Balkhy, B. Alotaibi, M. Helmy <i>Departments of Infection Prevention and Control, Pediatrics, and Internal Medicine, King Abdulaziz Medical City-King Fahad National Guard Hospital, Riyadh, Saudi Arabia</i>

Thursday jeudi	2	December décembre	16:00 17:30	ROOM Salle	352A	ORAL SESSION Session Orale	39o
-------------------	---	----------------------	----------------	---------------	------	-------------------------------	-----

## MISCELLANEOUS INFECTIONS 2 INFECTIONS DIVERSES 2

Présidents/Chairpersons : G. Pappas, A. Sefton

<b>169/39O</b>	<b>Human brucellosis in Lebanon: clinical features and therapeutical responses in 92 patients.</b>
16:00	A. Tohmé, B. El Rassi, S. Koussa, R. Nasnas <i>Internal Medicine, Hôtel-Dieu de France, Beirut, Lebanon</i>

<b>170/39O</b>	<b>Chronic infection and restenosis of coronary arteries after percutaneous transluminal coronary angioplasty (PTCA) in Greek patients</b>
16:15	R. Vorou <sup>2</sup> , V. Papavassiliou <sup>2</sup> , V. Petrocheilou-paschou <sup>2</sup> , A. Tzonou <sup>3</sup> , K. Kanellakopoulou <sup>1</sup> , M. Alexandrou <sup>2</sup> , S. Stamatelopoulos <sup>2</sup> , H. Giannarelli <sup>1</sup> <sup>1</sup> 4th Department of Internal Medicine, University General Hospital <sup>2</sup> Department of Clinical Therapeutics, <sup>3</sup> Department of Hygiene and Epidemiology, National and Kapodistrian University of Athens medical school, Athens, Greece

<b>171/39O</b>	<b>A longitudinal prospective study of BK virus infection in 104 renal transplanted patients</b>
16:30	C. Bressollette-Bodin <sup>3-4</sup> , M. Hourmant <sup>2</sup> , M. Coste-burel <sup>3-4</sup> , V. Sebille <sup>1</sup> , B.M. Imbert-Marcille <sup>3-4</sup> <sup>1</sup> Département des statistiques <sup>2</sup> ITERT <sup>3</sup> Laboratoire de Virologie, Hôpital universitaire de Nantes <sup>4</sup> UPRES-JE 2437, UFR Sciences Pharmaceutiques, Nantes, France

<b>172/39O</b>	<b>Management of cellulitis in the community; evaluation of a protocol incorporating intravenous ceftriaxone</b>
16:45	R.A. Seaton, E. Bell, Y. Gourlay, L. Semple <i>Gartnavel General Hospital, Glasgow, United Kingdom</i>

<b>173/39O</b>	<b>Prevalence and characteristics of Guillain-Barré syndromes associated with <i>Campylobacter jejuni</i> and cytomegalovirus in greater Paris</b>
17:00	V. Sivadon-tardy <sup>2</sup> , D. Orlikowski <sup>3</sup> , F. Rozenberg <sup>5</sup> , J.C. Quincampoix <sup>2</sup> , C. Caudie <sup>4</sup> , M.C. Durand <sup>1</sup> , J.L. Fauchère <sup>6</sup> , T. Sharshar <sup>3</sup> , J.C. Raphaël <sup>3</sup> , J.L. Gaillard <sup>2</sup> <sup>1</sup> Explorations Fonctionnelles <sup>2</sup> Laboratoire de Microbiologie <sup>3</sup> Réanimation Médicale, Hôpital Raymond Poincaré, Garches <sup>4</sup> Immunologie et neuro-immunologie, Hôpital neurologique et neurochirurgical, Lyon <sup>5</sup> Laboratoire de Virologie, Hôpital St Vincent de Paul, Paris <sup>6</sup> Laboratoire de Microbiologie, CHRU La Miltrie, Poitiers, France

<b>174/39O</b>	<b>Etiology and therapy of the bacterial meningitis.</b>
17:15	I. Karpov <sup>1</sup> , A. Kachanka <sup>2</sup> , E. Kishkurno <sup>1</sup> <sup>1</sup> Infectious Diseases Hospital, Medical University <sup>2</sup> Infectious Diseases, President's Hospital, Minsk, Belarus

Thursday jeudi	2	December décembre	16:00 17:30	ROOM Salle	353	ORAL SESSION Session Orale	40o
-------------------	---	----------------------	----------------	---------------	-----	-------------------------------	-----

## VIRAL PHYSIOPATHOLOGY PHYSIOPATHOLOGIE VIRALE

Présidents/Chairpersons : J.E. Rockstroh, J. Novak

<b>175/40O</b>	<b>Prevalence and factors associated with hepatic steatosis in HCV-HIV co-infected patients</b>
16:00	D. Neau, M. Winnock, B. Le Bail, L. Castéra, L. Géraut, M. Dupon, J.M. Ragnaud, D. Lacoste, M.E. Lafon, P. Bioulac, F. Dabis <i>CHU et Université Victor Segalen, Bordeaux, France</i>

<b>176/40O</b>	<b>Persistence of HCV -RNA in mononuclear cells after HCV elimination from the serum during interferon therapy</b>
16:15	D. Januszkiewicz <sup>2,3,1</sup> , J. Wysocki <sup>3</sup> , M. Zawada <sup>2</sup> , K. Nowicka <sup>2</sup> , M. Pernak <sup>1</sup> , J. Rembowksa <sup>2</sup> , K. Lewandowski <sup>1</sup> , J. Nowak <sup>2</sup> <sup>1</sup> Department of Medical Diagnostics <sup>2</sup> Polish Academy of Sciences, Institute of Human Genetics <sup>3</sup> University of Medical Sciences, Poznan, Poland

<b>177/40O</b>	<b>The implications of lamivudine therapy in acute viral hepatitis with HAV -B</b>
16:30	V. Arama <sup>2</sup> , V. Molajic <sup>2</sup> , M. Chiotan <sup>2</sup> , A. Streinu Cercel <sup>2</sup> , F. Caruntu <sup>2</sup> , C. Popescu <sup>2</sup> , A. Negoita <sup>2</sup> , M. Podan <sup>2</sup> , O. Patey <sup>1</sup>
	<sup>1</sup> Centre Hospitalier Intercommunal Villeneuve St. Georges, Villeneuve St. Georges, France <sup>2</sup> Prof Dr. Matei Bals Infectious Diseases Institute, Bucharest, Romania
<b>178/40O</b>	<b>Long-term HIV resistance evolution in immunological/virological discordant patients under HAART</b>
16:45	A. Maillard <sup>2</sup> , J.M. Chapplain <sup>1</sup> , C. Arvieux <sup>1</sup> , P. Tattevin <sup>1</sup> , F. Souala <sup>1</sup> , M. Dupont <sup>1</sup> , C. Neveu <sup>2</sup> , O. Guist'hau <sup>2</sup> , C. Michelet <sup>1</sup> , A. Ruffault <sup>2</sup>
	<sup>1</sup> Maladies Infectieuses <sup>2</sup> Virologie, CHU Pontchaillou, Rennes, France
<b>179/40O</b>	<b>Analysis of oncogenes E6 and E7 variants in 78 women infected with HPV-16</b>
17:00	M. Coste-burel <sup>3</sup> , B. Besse <sup>3</sup> , K. Papy <sup>3</sup> , P. Lopes <sup>2</sup> , C. Laboissé <sup>1</sup> , B.M. Imbert-marcille <sup>3</sup>
	<sup>1</sup> Anatomie Pathologique <sup>2</sup> Gynécologie Obstétrique <sup>3</sup> Virologie, CHU Nantes, Nantes, France

Friday vendredi	<b>3</b>	December décembre	09:00 10:30	<b>Salle Bordeaux</b>	SYMPORIUM Symposium	<b>41s</b>
--------------------	----------	----------------------	----------------	-----------------------	------------------------	------------

**UPDATE ON INFLUENZA**  
*ACTUALITÉS SUR LA GRIPPE*

Présidents/Chairpersons : B. Lina, A. Hay

<b>180/41S</b>	<b>Hemagglutinin of Influenzaviruses: structure and function</b>
09:00	<u>B. Lina</u> <i>Laboratoire de Virologie, Domaine Rockefeller, Lyon, France</i>
<b>181/41S</b>	<b>Avian influenza: a threat for the future</b>
09:20	<u>J.C. Manuguerra</u> <i>Institut Pasteur, Paris, France</i>
<b>182/41S</b>	<b>Antiviral agents active against influenza viruses</b>
09:40	<u>A. Hay</u> <i>National Institute for Medical Research, London, United Kingdom</i>
<b>183/41S</b>	<b>New vaccines for influenza</b>
10:00	<u>B. Fritzell</u> <i>Wyeth, Puteaux - La Défense, France</i>

Friday vendredi	<b>3</b>	December décembre	09:00 10:30	<b>ROOM Salle 342A</b>	SYMPORIUM Symposium	<b>42s</b>
--------------------	----------	----------------------	----------------	----------------------------	------------------------	------------

**RESISTANCE OF CANDIDA INFECTIONS TO SYSTEMIC ANTIFUNGAL AGENTS**  
*INFECTIONS À CANDIDA RÉSISTANTES AUX ANTIFONGIQUES SYSTÉMIQUES*  
Organized by the French Society of Mycology

Présidents/Chairpersons : R. Grillot, J. Bille

<b>184/42S</b>	<b>Resistance: definitions and molecular mechanisms</b>
09:00	<u>J. Bille</u> <i>CHU Vaudois, Lausanne, Switzerland</i>
<b>185/42S</b>	<b>Candidemia in Europe: epidemiology and resistance</b>
09:15	<u>A.M. Tortorano</u> <i>Laboratory of Medical Mycology, Milan, Italy</i>
<b>186/42S</b>	<b>Yeast fungemia: current aspect of resistance (CNRMA)</b>
09:30	<u>F. Dromer</u> <i>Institut Pasteur, Paris, France</i>
<b>187/42S</b>	<b>How to detect resistance?</b>
09:45	<u>E. Dannaoui</u> <i>Hôpital Européen Georges Pompidou, Paris, France</i>

<b>188/42S</b>	<b>Clinical consequences: the view of the ICU physician</b>
10:00	P. Montravers <i>Hôpital Bichat Claude Bernard, Paris, France</i>

Friday 3 December décembre 09:00 ROOM Salle 352B SYMPOSIUM Symposium 43s

**IS THERE STILL SOME COLOUR IN TREATMENT OF INFECTION?**  
**RESTE-T-IL DES COULEURS DANS LE TRAITEMENT DES INFECTIONS ?**  
Organized by the International Society of Non-antibiotics

Présidents/Chairpersons : J. Kristiansen, J.M. Decazes

<b>189/43S</b>	<b>Introduction - the continued development of aniline dyes to produce today's antimicrobials (in recognition of the 150th birthday of Paul Ehrlich)</b>
09:00	<u>J. Kristiansen</u> <i>Department of Medical Microbiology, Sonderborg Sygehus, Sonderborg, Denmark</i>

**190/43S** **Concordant pharmacodynamics of the Red, Blue and Yellow**  
J.D. Williams  
*London, United Kingdom*

<b>191/43S</b>	<b>Development of the Red dyes to new therapy for trypanosomiasis</b>
09:30	<u>P. Maeser</u> <i>University of Bern, Bern, Switzerland</i>

<b>192/43S</b>	<b>Antiviral activity of the Blue dyes and provision of safe blood products for transfusion</b>
09:45	<u>J. Kristiansen</u> <i>Department of Medical Microbiology, Sonderborg Sygehus, Sonderborg, Denmark</i>

<b>193/43S</b>	<b>Out of the Yellow cometh the quinolones</b>
10:00	<u>A. Bryskier</u> <i>Aventis Pharma, Romainville, France</i>

Friday 3 December décembre 09:00 ROOM Salle 341 SYMPOSIUM Symposium 44s

**SHOULD WE USE LOCAL ANTIBIOTICS IN THE TREATMENT OF BONE INFECTIONS?**  
**DEVONS-NOUS UTILISER DES ANTIBIOTIQUES LOCAUX DANS LE TRAITEMENT DES INFECTIONS OSSEUSES ?**  
Organized by the Tiresias Group

Présidents/Chairpersons : H. Giamarellou, A. Lortat-Jacob

<b>194/44S</b>	<b>Lessons to be learned from animals and ex vivo models</b>
09:00	<u>E.J. Giamarellos - Bourboulis</u> <i>Athens General Hospital "G Gennimatas", Athens, Greece</i>

<b>195/44S</b>	<b>Continuous bone infection. Is there any place for local antibiotics? A survey of 80 cases</b>
09:20	<u>A. Lortat-Jacob</u> <i>Hôpital Ambroise Paré, Paris, France</i>

<b>196/44S</b>	<b>Current data on use of antibiotic-cements in prostheses</b>
09:40	<u>F. Langlais</u> <i>CHU Hôpital Sud, Rennes, France</i>

<b>197/44S</b>	<b>The bad side of antibiotics in cement</b>
10:00	<u>N. Desplaces</u> <i>Hôpital Croix Saint Simon, Paris, France</i>

**INVESTIGATION AND CONTROL OF EPIDEMICS: A FUNDAMENTAL PUBLIC HEALTH SERVICE!**  
*RECHERCHE ET CONTRÔLE DES ÉPIDÉMIES : UN SERVICE PUBLIC FONDAMENTAL !*  
Organized by the National Institute of Sanitary Vigilance

Présidents/Chairpersons : J.C. Desenclos, I.M. Gould

**198/45S The why and how of investigating epidemics**09:00 H. de Valk  
INVS, Saint Maurice, France**199/45S An epidemic of legionella in Pas de Calais**09:20 D. Illef  
DRASS Pas de Calais, Lille, France**200/45S Transmission of hepatitis C virus through multidose vials**09:40 A. Carbonne  
CCLIN Nord, Paris, France**201/45S The role of the European Union Public Health Center in fight against epidemics**10:00 F. Van Loock  
European Commission, Luxembourg, Luxembourg**SERIOUS BACTERIAL INFECTION WITH THE CHILD**  
*INFECTIONS BACTÉRIENNES GRAVES DE L'ENFANT*

Présidents/Chairpersons : E. Bingen, R. Booy

**202/46O Primitive bacterial meningitis (bm) in the newborn. A prospective study**09:00 Y. Aujard<sup>1</sup>, F. De La Rocque<sup>1</sup>, C. Levy<sup>4</sup>, E. Bingen<sup>1</sup>, E. Varon<sup>3</sup>, J.M. Alonso<sup>2</sup>, H. Dabernat<sup>5</sup>, M. Boucherat<sup>4</sup>, R. Cohen<sup>1</sup>, Pediatricians and Microbiologists Working Group On Bm<sup>4</sup>  
<sup>1</sup>Société Française de Pédiatrie, Groupe Français des Infections Pédiatriques <sup>2</sup>CNRM <sup>3</sup>CNRN, Paris <sup>4</sup>ACTIV, St Maur <sup>5</sup>CNRHi, Toulouse, France**203/46O Three-year multicenter pediatric surveillance of pneumococcal meningitis in France**09:15 E. Bingen<sup>1</sup>, C. Levy<sup>3</sup>, F. De La Rocque<sup>1</sup>, Y. Aujard<sup>1</sup>, E. Varon<sup>2</sup>, M. Boucherat<sup>3</sup>, R. Cohen<sup>1</sup>, Pediatricians And Microbiologists Working Group On Bm.  
<sup>1</sup>Société Française de Pédiatrie, Groupe Français des Infections Pédiatriques <sup>2</sup>CNRP, Paris <sup>3</sup>ACTIV, St Maur, France**204/46O Umbilical cord blood procalcitonin concentration as a marker for the early diagnosis of neonatal infection**09:30 N. Joram<sup>2</sup>, V. Loubersac<sup>1</sup>, N. Winer<sup>3</sup>, J.C. Roze<sup>2</sup>, C. Gras-le Guen<sup>2</sup>  
<sup>1</sup>Laboratoire de biochimie, CHU Nantes <sup>2</sup>Réanimation pédiatrique et néonatale <sup>3</sup>Service de Gynécologie-Obstétrique, Hôpital Mère Enfant, CHU Nantes, Nantes, France**205/46O Infectious complications in paediatric acute myeloid leukaemia: low incidence of bacteraemia due to viridans streptococci in a ten-year retrospective study**09:45 A.S. Brunet<sup>3-2</sup>, C. Ploton<sup>3-1</sup>, C. Galambrun<sup>3-2</sup>, C. Pondarre<sup>3-2</sup>, M.P. Pages<sup>3</sup>, N. Bleyzac<sup>3</sup>, A.M. Freydière<sup>3-1</sup>, G. Barbé<sup>3-1</sup>, Y. Bertrand<sup>3-2</sup>  
<sup>3</sup>Bactériologie <sup>2</sup>Immuno-Hématologie et transplantation de moelle osseuse <sup>3</sup>Hôpital Debrousse, Lyon, France**206/46O Colonization and infection by multidrug-resistant bacteria in hospitalized children - a five-year multicenter study**10:00 J. Raymond<sup>3</sup>, C. Doit<sup>5</sup>, P. Nordmann<sup>2</sup>, B. Vu Thien<sup>7</sup>, M. Guibert<sup>1</sup>, A. Ferroni<sup>4</sup>, Y. Aujard<sup>6</sup>  
<sup>1</sup>Bactériologie, Hôpital A. Béclère, Clamart <sup>2</sup>Bactériologie, Hôpital Bicêtre, Kremlin-Bicêtre <sup>3</sup>Bactériologie, Hôpital Cochin-Saint Vincent de Paul <sup>4</sup>Bactériologie, Hôpital Necker-Enfants Malades <sup>5</sup>Bactériologie <sup>6</sup>Néonatalogie, Hôpital Robert Debré <sup>7</sup>Bactériologie, Hôpital Trousseau, Paris, France**207/46O Diagnostic value of rapid bacterial antigen in children with pneumococcal pleural empyema**10:15 A. Le Monnier<sup>1</sup>, J.R. Zahar<sup>1</sup>, E. Carbonnelle<sup>1</sup>, M. Lebourgais<sup>2</sup>, J. De Blick<sup>2</sup>, P. Berche<sup>1</sup>, A. Ferroni<sup>1</sup>  
<sup>1</sup>Département de Microbiologie <sup>2</sup>Département de Pneumologie Pédiatrique, Necker Enfants -Malades, Paris, France

**MRSA - MICROBIOLOGY**  
**SARM - MICROBIOLOGIE**

Présidents/Chairpersons : T. Fosse, I.M. Gould

**208/47O Genetic variability of the staphylococcal leukotoxin LukE-LukD is associated with its expression**

09:00 E. Etienne, O. Joubert, D. Keller, H. Monteil, G. Prévost  
*Bactériologie - UPRES EA-3432, ULP - CHU, Strasbourg, France*

**209/47O Upregulation of protein a by the Panton Valentine leukocidin phage phiSLT in *Staphylococcus aureus***

09:15 P. Loulergue, G. Lina, A. Tristan, M. Bes, J. Etienne, F. Vandenesch  
*Laboratoire INSERM E0230, Faculté de médecine Laennec, Lyon, France*

**210/47O Unusual methicillin resistant *staphylococcus aureus* isolates susceptible to all non β-lactam antibiotics**

09:30 F. Bureau - Chalot, C. Pierrat - Solans, D. Forte, V. Vernet - Garnier, C. De Champs, O. Bajolet  
*Laboratoire de Bactériologie-Virologie-Hygiène, CHU, Reims, France*

**211/47O Selection of relevant duplicate criteria in the monitoring of *Staphylococcus aureus* methicillin resistance trends**

00:00 P. Grohs<sup>1</sup>, D. Veil<sup>1</sup>, G. Kac<sup>3</sup>  
<sup>1</sup>Société I2a, Montpellier <sup>2</sup>Microbiologie <sup>3</sup>Unité d'Hygiène, Hôpital Européen Georges Pompidou, Paris, France

**212/47O Direct screening of MRSA from swab specimens using duplex real-time PCR assay: implication for antibiotic prophylaxis.**

10:00 L. Desbouchages<sup>1</sup>, V. Serazin<sup>2</sup>, M. Leneveu<sup>1</sup>, G. Rast<sup>1</sup>, Y. Giudicelli<sup>2-1</sup>, J. Merrer<sup>3</sup>  
<sup>1</sup>UF Bactériologie <sup>2</sup>UF Biologie Moléculaire <sup>3</sup>Unité d'Hygiène, Département de Santé Publique, CHI Poissy/St Germain-en-Laye, Poissy, France

**213/47O Observed transformation of methicillin-resistant *Staphylococcus aureus* into methicillin-sensitive strains by a bacterial transforming agent – new anti-infective technology.**

10:15 R. Hill, M. Levey  
*R & D, Pharmaceutica, Worcester, United Kingdom*

**MULTIDRUG RESISTANT TUBERCULOSIS (MDR-TB): HOW TO PREVENT IT, RAPIDLY RECOGNISE IT AND EFFECTIVELY TREAT IT?**

**TUBERCULOSE MULTI-RESISTANTE(TBMR): COMMENT LA PREVENIR, L'IDENTIFIER RAPIDEMENT ET LA TRAITER ?**

**PART ONE**  
**PREVENTION OF MDR-TB**  
**PREMIÈRE PARTIE**  
**PRÉVENTION DE LA MDR-TB**

Organized by the French Society for Tuberculosis, the Turkish Society for Chemotherapy and the Institute of Hygiene and Tropical Medicine

Présidents/Chairpersons : L. Amaral, P. Ferrinho

**221/48S Systems thinking in the global fight against tuberculosis**

09:00 M. Salfinger  
*New York State Department of Health, Albany, United States*

**222/48S WHO recommendations for MDR-TB treatment**

09:20 P. Chaulet  
*Union Internationale contre la Tuberculose et les Maladies Respiratoires, Alger, Algeria*

**223/48S International union against tuberculosis standards for therapy: prerequisite for preventing resistance**

09:40 J. Robert  
*Faculté de Médecine Pitié Salpêtrière, Paris, France*

**224/48S Treatment results of MDR-TB in Turkey**

10:00 O. Tümer

Heybeliada Chest Hospital, Istanbul, Turkey

**PART TWO****RAPID LABORATORY SUPPORT FOR DIAGNOSIS OF MDR-TB AND ALTERNATIVE THERAPIES WHEN ALL ELSE MAY FAIL***DEUXIÈME PARTIE**AIDE ANALYTIQUE RAPIDE AU DIAGNOSTIC DE LA MDR-TB ET TRAITEMENTS ALTERNATIFS EN CAS D'ÉCHEC*

Organized by the French Society for Tuberculosis, the Turkish Society for Chemotherapy and the Institute of Hygiene and Tropical Medicine

Présidents/Chairpersons : O. Ang, J. Robert

**214/48S Active antibiotic regimes against MDR-TB, what to learn from animal models**

11:00 N. Veziris

Faculté de médecine Pitié-Salpêtrière, Paris, France

**215/48S Molecular epidemiology of tuberculosis in a population with high tuberculosis incidence in Turkey**

11:20 A. Alp

Hacettepe Medical Faculty, Ankara, Turkey

**216/48S The fast and faster track TB programme: lab results within 2-5 days**

11:40 M. Viveiros

University of Lisbon, Lisbon, Portugal

**217/48S Prediction of active tuberculosis from panel of markers of T cell immunity**

12:00 D. Ordway

Colorado State University, Fort Collins, United States

**PART THREE****FACTORS THAT COMPLICATE THERAPY OF MDR-TB AND ALTERNATIVE THERAPIES FOR MDR-TB WHEN ALL ELSE FAIL***TROISIÈME PARTIE**FACTEURS COMPLIQUANT LE TRAITEMENT DE LA MDR-TB ET TRAITEMENTS ALTERNATIFS EN CAS D'ÉCHEC*

Organized by the French Society for Tuberculosis, the Turkish Society for Chemotherapy and the Institute of Hygiene and Tropical Medicine

Présidents/Chairpersons : F. Antunes, S. Ozkan

**218/48S Psychological factors affecting outcome of therapy for MDR-TB**

14:00 S. Özkan, D. Sahin

Istanbul Medical Faculty, Istanbul, Turkey

**219/48S The basis for compassionate therapy for infections of *M. tuberculosis* resistant to 4 and 5 drugs**

14:25 L. Amaral

University of Lisbon, Lisbon, Portugal

**220/48S Non-antibiotic approach in TB treatment**

14:50 J. Van der Meer

Department of Hematology, University Hospital, Groningen, The Netherlands

**EPIDEMIOLOGICAL, CLINICAL AND THERAPEUTIC ASPECTS OF TUBERCULOSIS***ASPECTS ÉPIDÉMIOLOGIQUES, CLINIQUES ET THÉRAPEUTIQUES DE LA TUBERCULOSE*

Présidents/Chairpersons : L. Amaral, M. Salfinger

**225/48O Epidemiological survey of a suspected nosocomial case of tuberculosis by spoligotyping**16:00 F. Jauréguy<sup>3</sup>, C. Gutierrez<sup>5</sup>, C. Jean Marie<sup>1</sup>, C. Poirier<sup>4</sup>, S. Panseurieu<sup>2</sup>, J. Pascal<sup>1</sup>, D. Valeyre<sup>4</sup>, B. Picard<sup>3</sup>, V. Vincent<sup>5</sup>, P. Dény<sup>3-1</sup><sup>1</sup>CLIN<sup>2</sup>Service de Médecine du Travail, Hôpital Avicenne <sup>3</sup>Service de Bactériologie, Virologie-Hygiène <sup>4</sup>Service de Pneumologie, Hôpital Avicenne, Université Paris 13, Bobigny <sup>5</sup>Centre National de Référence des Mycobactéries, Institut Pasteur, Paris, France

<b>226/48O</b>	<b>Epidemiology of pulmonary tuberculosis in Athens, Greece</b>
16:15	N. Skarmoutsou <sup>1</sup> , E. Faviou <sup>2</sup> , E. Papafrangas <sup>1</sup> , S. Kanavaki <sup>2</sup> , K. Masselou <sup>3</sup> , A. Tarpatzis <sup>3</sup> , P.T. Tassios <sup>3</sup> , N. Legakis <sup>3</sup> , L. Zerva <sup>3</sup> <sup>1</sup> Laboratory of Clinical Microbiology, Sismanoglou Hospital <sup>2</sup> Laboratory of Clinical Microbiology, Sotiria Hospital <sup>3</sup> Clinical Microbiology, University of Athens, Athens, Greece
<b>227/48O</b>	<b>Tuberculosis of the central nervous system parenchyma: diagnostic and therapeutic features in a series of 23 patients</b>
16:30	H. Man <sup>3</sup> , P. Sellier <sup>3</sup> , M. Boukobza <sup>2</sup> , M. Diemer <sup>3</sup> , L. Raskine <sup>1</sup> , G. Carcelain <sup>6</sup> , C. Picard <sup>6</sup> , G. Lot <sup>4</sup> , J.F. Bergmann <sup>3</sup> <sup>1</sup> Bactériologie-Virologie <sup>2</sup> Médecine A <sup>3</sup> Neurochirurgie <sup>4</sup> Neuroradiologie, Hôpital Lariboisière <sup>5</sup> Unité d'Immuno-Hématologie Pédiatrique, Hôpital Necker-Enfants Malades <sup>6</sup> Laboratoire d'Immunologie Cellulaire, Hôpital Pitié-Salpêtrière, Paris, France
<b>228/48O</b>	<b>The diagnosis of lymph node tuberculosis in Tunisia.</b>
16:45	A. Ghoubontini, F. Zouiten, H. Tiouri, T. Ben Chaabane Infectious Diseases, CHU Ernest Conseil-La Rabta, Tunis, Tunisia
<b>229/48O</b>	<b>Septic shock from <i>Mycobacterium tuberculosis</i> in a patient recently diagnosed with HIV infection.</b>
17:00	E. Magira, T.H. Gounaris, O. Tsopra, P. Gounari, T.H. Arsenoglou, E. Sioula 1ST Department of internal medicine, Evangelismos Hospital, Athens, Greece
<b>230/48O</b>	<b>Tuberculosis treatment in France: from guidelines to practices</b>
17:15	P. Tattevin <sup>6</sup> , J.M. Chapplain <sup>6</sup> , P.H. Lesprit <sup>2</sup> , C.H. Billy <sup>3</sup> , F. Roblot <sup>5</sup> , S. Alfandari <sup>7</sup> , E. Rouveix <sup>1</sup> , E. Bouvet <sup>4</sup> <sup>1</sup> Ambroise Paré, Boulogne <sup>2</sup> Henri Mondor, Créteil <sup>3</sup> François Quesnay, Mantes-La-Jolie <sup>4</sup> Bichat-Claude Bernard, Paris <sup>5</sup> La Milétrie, Poitiers <sup>6</sup> Pontchaillou, Rennes <sup>7</sup> Gustave Dron, Tourcoing, France

Friday vendredi	<b>3</b>	December décembre	09:30 10:00	ROOM Salle	<b>351</b>	STATE OF THE ART State of the art	<b>49SOTA</b>
--------------------	----------	----------------------	----------------	---------------	------------	--------------------------------------	---------------

Président/Chairperson : M. Street

<b>231/49SOTA</b>	<b>Corticotherapy and serious infections</b>
9:30	J. Carlet Hôpital Saint Joseph, Paris, France

Friday vendredi	<b>3</b>	December décembre	09:45 10:30	<b>Salle Havane</b>	EXPERT LECTURE Conférence	<b>50EL</b>
--------------------	----------	----------------------	----------------	---------------------	------------------------------	-------------

Président/Chairperson : C. Olivier

<b>232/50EL</b>	<b>Current status and future prospects for chickenpox immunisation</b>
11:00	J. Seward Office Centers for Disease Control and Prevention, Atlanta, GA, United States

Friday vendredi	<b>3</b>	December décembre	10:00 10:30	ROOM Salle	<b>351</b>	STATE OF THE ART State of the art	<b>51SOTA</b>
--------------------	----------	----------------------	----------------	---------------	------------	--------------------------------------	---------------

Président/Chairperson : R. Canton

<b>233/51SOTA</b>	<b>What's new in infections and tropical dermatology?</b>
10:00	E. Caumes Hôpital Pitié Salpêtrière, Paris, France

**EUROPEAN ACTIONS FOR SURVEILLANCE OF ANTIBIOTICS RESISTANCE**  
**ACTIONS EUROPÉENNES DE SURVEILLANCE DE LA RÉSISTANCE AUX ANTIBIOTIQUES**

Présidents/Chairpersons : V. Jarlier, D. Monnet

**234/52S Resistance in bacteremia (EARSS)**

11:00 D. Monnet

*Statens Serum Institute, Copenhagen, Denmark*

**235/52S Tuberculosis (EUROTB)**

11:20 A. Infuso

*INVS, St. Maurice, France*

**236/52S Antibiotic consumption in Europe**

11:40 H. Goossens

*University Hospital Antwerp, Edegem, Belgium*

**237/52S New European guidelines for surveillance**

12:00 V. Jarlier

*Hôpital Pitié Salpêtrière, Paris, France*

Président/Chairperson : J.A. Garcia-Rodriguez

**238/53EL Climatic changes and infectious diseases**

9:45 E. Drouet

*Université Joseph Fourier, Grenoble I, La Tronche, France*

**ATYPICAL MICROORGANISMS AND RESPIRATORY TRACT INFECTIONS**  
**MICRO-ORGANISMES ATYPIQUES ET INFECTIONS DES VOIES RESPIRATOIRES**

Présidents/Chairpersons : C. Chidiac, R. Canton

**239/54S Atypical organisms in community acquired pneumonia in children**

11:00 D. Gendrel

*Hôpital St Vincent de Paul, Paris, France*

**240/54S Atypical organisms in chronic obstructive airways disease in adults**

11:15 L. Allegra

*University of Milan, Milan, Italy*

**241/54S Critical analysis of microbiological diagnosis of *Chlamydia pneumoniae* and *Mycoplasma pneumoniae* in respiratory tract infections**

11:30 C. Bebear

*Université Victor Segalen Bordeaux 2, Bordeaux, France*

**242/54S In vitro resistance and clinical issue: a paradox**

11:45 C. Chidiac

*Hôpital de la Croix Rousse, Lyon, France*

**243/54S Defining the role for macrolides today**

12:00 R. Canton

*Hospital Ramon y Cajal, Madrid, Spain*

**BACTERIAL EFFLUX SYSTEMS AND INHIBITORS**  
**SYSTÈMES D'EFFLUX BACTÉRIENS ET LEURS INHIBITEURS**

Présidents/Chairpersons : P. Plésiat, O. Lomovskaya

**244/55SOTA Active efflux mechanisms in *Pseudomonas* and related species: practical implications**

11:00 P. Plésiat

*Université de Franche Comté, Besançon, France*

**245/55O Clinical significance of efflux-mediated resistance to FQs in *Pseudomonas aeruginosa* evaluated by Monte -Carlo simulation**

11:30 P. Dupont<sup>1</sup>, D. Hocquet<sup>1</sup>, I. Patry<sup>1</sup>, P. Chavanel<sup>2</sup>, P. Plésiat<sup>1</sup>

<sup>1</sup>Laboratoire de Bactériologie, CHU Jean Minjoz, Besançon<sup>2</sup>Service des Maladies Infectieuses, CHU du Bocage, Dijon, France

**246/55O TolC but not AcrB is essential for multidrug-resistant *Salmonella enterica* serovar- Typhimurium colonisation of chicks**

11:45 S. Baucheron, C. Mouline, K. Praud, E. Chaslus- Dancla, A. Cloeckaert

*Unité BioAgresseurs, Santé et Environnement, Institut National de la Recherche Agronomique, Nouzilly, France*

**247/55O High genetic variation of the multidrug transporter gene cmeB in *Campylobacter jejuni* and *Campylobacter coli***

12:00 C. Caillier, L. Cloix, S. Payot, A. Cloeckaert

*UR086 BioAgresseurs, Santé, Environnement, Institut National de la Recherche Agronomique, Tours-Nouzilly, France*

**248/55O Pharmacomodulation and evaluation of new inhibitors of bacterial efflux pumps.**

12:15 C. Vidaillac<sup>1,2</sup>, J. Guillou<sup>1</sup>, C. Arpin<sup>2</sup>, J. Grellet<sup>3</sup>, C. Jarry<sup>1</sup>, C. Quentin<sup>2</sup>

<sup>1</sup>EA 2962, Laboratoire de Pharmacochimie<sup>2</sup>EA 525, Laboratoire de Microbiologie<sup>3</sup>EA 525, Laboratoire de Pharmacocinétique, Faculté de Pharmacie, Université de Bordeaux 2, Bordeaux, France

**A PORTRAIT OF MEASLES TODAY, IMPACT OF CONCERN OVER MMR**

*Portrait de la rougeole aujourd'hui, l'impact sur le ROR*

Organized by the Pediatric Infectious Disease Group of the French Pediatric Society

Présidents/Chairpersons : D. Floret, R. Booy

**249/56S Update on epidemiology**

11:00 F.X. Hanon

*WHO, Regional Office for Europe, Copenhagen, Denmark*

**250/56S Current status of epidemiology of measles and MMR vaccine in United Kingdom**

11:15 R. Booy

*Pediatrics University, London, United Kingdom*

**251/56S Strategy for eradication**

11:30 D. Floret

*Hopital Edouard Herriot, Lyon, France*

**252/56S Laboratory diagnosis: its role in the surveillance**

11:45 F. Wild

*CERVI Immunité et Vaccination, INSERM U404, Lyon, France*

**253/56S MMR: update on side effects**

12:00 C. Olivier

*Hopital Louis Mourier, Colombes, France*

**URINARY TRACT INFECTIONS**  
*INFECTIONS DE L'APPAREIL URINAIRE*

Présidents/Chairpersons : F. Caron, K. Naber

- 254/57O** **Community-acquired urinary tract infections from 15-65 years old females in France. Aforcopi-bio network 2003**  
11:00 **D. De Mouy<sup>1</sup>, R. Fabre<sup>2</sup>, J.D. Cavallo<sup>2</sup>, J.P. Arzouni<sup>1</sup>, M. Baynat<sup>1</sup>, A. Bicart-see<sup>1</sup>, T. Doeschler<sup>1</sup>, A.M. Gavinet<sup>1</sup>, J.L. Galinier<sup>1</sup>, E. Garrabé<sup>2</sup>, P. Gontier<sup>1</sup>, N. Grillet<sup>1</sup>, G. Larribet<sup>1</sup>, J.P. Lepargneur<sup>1</sup>, I. Naepsels<sup>1</sup>, G. Payro<sup>1</sup>**  
<sup>1</sup>AFORCOPi-BiO, Paris <sup>2</sup>HIA Bégin, Saint-Mandé, France
- 255/57O** **Susceptibility of *Escherichia coli* causing urinary tract infections in the community; evolution over five years and importance of antimicrobial policy.**  
11:15 **C. Freyre, I. Solino, J.R. Leon, M. Enri, A. Dominguez, I. Jesus, S. Perez-ramos, M. Rodriguez-Iglesias**  
*Clinical Microbiology Laboratory, Puerto Real University Hospital, Cadiz, Spain*
- 256/57O** **Biological criteria for the diagnosis of urinary tract infection in male patients with spinal cord injury: a nested cohort analysis**  
11:30 **E. Ronco<sup>1</sup>, P. Denys<sup>3</sup>, I. Laffont<sup>3</sup>, C. Bernède<sup>4</sup>, P. Martel<sup>4</sup>, D. Guillemot<sup>4</sup>, J. Salomon<sup>2</sup>, O. Dizien<sup>3</sup>, B. Bussel<sup>3</sup>, C. Perronne<sup>2</sup>, J.L. Gaillard<sup>1</sup>**  
<sup>1</sup>Laboratoire de Microbiologie <sup>2</sup>Maladies Infectieuses et Tropicales <sup>3</sup>Rééducation Neurologique, Hôpital Raymond Poincaré, Garches <sup>4</sup>Centre de Ressources en Biostatistiques, Epidémiologie et Pharmacoépidémiologie, Institut Pasteur, Paris, France
- 257/57O** **Microbiology of acute prostatitis: a series of 347 hospitalized patients**  
11:45 **M. Etienne<sup>9,10</sup>, P. Grise<sup>10</sup>, F. Michel<sup>5</sup>, H. Portier<sup>4</sup>, H. Levesque<sup>8</sup>, J. Doucet<sup>7</sup>, P. Pfizenmeyer<sup>2</sup>, J. Lorcerie<sup>3</sup>, J.F. Lemeland<sup>6</sup>, C. Neuwirth<sup>1</sup>, F. Caron<sup>9</sup>**  
<sup>1</sup>Bactériologie <sup>2</sup>Gériatrie <sup>3</sup>Médecine Interne <sup>4</sup>Maladies Infectieuses <sup>5</sup>Urologie, CHU Dijon, Dijon <sup>6</sup>Bactériologie <sup>7</sup>Gériatrie <sup>8</sup>Médecine Interne <sup>9</sup>Maladies Infectieuses <sup>10</sup>Urologie, CHU Rouen, Rouen, France
- 258/57O** **Aetiology of chronic prostatitis syndrome**  
12:00 **V. Skerk<sup>1</sup>, I. Krhen<sup>2</sup>, S. Schonwald<sup>1</sup>, V. Cajic<sup>1</sup>, L. Markovinovic<sup>1</sup>, S. Roglic<sup>1</sup>, S. Zekan<sup>1</sup>, V. Skerk<sup>3</sup>, A. Tambic Andrasic<sup>1</sup>, S. Ljubin Sternak<sup>4</sup>**  
<sup>1</sup>Dr Fran Mihaljevic University Hospital for Infectious Diseases <sup>2</sup>Urology Clinic, Rebro Clinical Hospital Centre <sup>3</sup>University of Zagreb, School of Medicine <sup>4</sup>The Croatian Institute of Public Health, Zagreb, Croatia
- 259/57O** **Urinary tract infection (UTI) in geriatric patients: surveillance and impact of an antibiotic management program**  
12:15 **C. Bonnal, M. Mion, B. Baune, L. Armand-lefeuvre, J.C. Lucet, Y. Wolmark**  
*Hôpitaux Bichat Claude Bernard et Bretonneau, Paris, France*

**NOSOCOMIAL INFECTION SURVEILLANCE: UNDERSTANDING AND USE OF RATES**  
*SURVEILLANCE DES INFECTIONS NOSOCOMIALES : COMPRENDRE ET UTILISER LES TAUX*  
Organized by the French Society of Hospital Hygiene

Présidents/Chairpersons : C. Suetens, B. Regnier

- 260/58S** **Surveillance or prevention: what is the priority?**  
11:00 **P. Berthelot**  
*CHU de Saint-Etienne, St. Etienne, France*
- 261/58S** **How to interpret rates of nosocomial infection?**  
11:20 **J. Hajjar**  
*Hôpital de Valence, Valence, France*
- 262/58S** **Making the best use of infection rates**  
11:40 **J.C. Lucet**  
*Hopital Bichat Claude Bernard, Paris, France*
- 263/58S** **European surveillance network: where are we now?**  
12:00 **C. Suetens**  
*ISP Louis Pasteur, Brussels, Belgium*

**LOCAL ANTIBIOTHERAPY: AFSSAPS GOOD PRACTICE RECOMMENDATIONS**  
*ANTIBIOTHÉRAPIE LOCALE : LA BONNE PRATIQUE DE L'AFSSAPS*  
Organized by the AFSSAPS

Présidents/Chairpersons : J.M. Decazes, F. Trémolières

**264/59S Methodology**

11:00 N. Dumarct  
AFSSAPS, Saint Denis, France

**265/59S Local antibiotherapy in dermatology**

11:20 B. Lebrun-Vignes<sup>1</sup>, P. Bernard<sup>2</sup>  
<sup>1</sup>Hôpital Pitié Salpêtrière, Paris <sup>2</sup>Reims, France

**266/59S Local antibiotherapy in ophthalmology**

11:40 P.Y. Robert<sup>2</sup>, I. Cochereau<sup>1</sup>  
<sup>1</sup>Hôpital d'Angers, Angers <sup>2</sup>Hôpital Universitaire Dupuytren, Limoges, France

**267/59S Local antibiotherapy in ENT**

12:00 Ph. Ovetchkine<sup>3</sup>, J.J. Pessey<sup>2</sup>, R. Cohen<sup>1</sup>  
<sup>1</sup>ACTIV, Saint Mau des Fosses <sup>2</sup>CHU Rangeuil, Toulouse, France <sup>3</sup>, Quebec

**PHARMACODYNAMICS OF ANTIINFECTIVE DRUGS**  
*PHARMACODYNAMIE DES ANTIINFECTIEUX*

Présidents/Chairpersons : F. Scaglione, M. Tod

**268/60O Pharmacodynamic of intravenous azithromycin at simulated serum and epithelial lining fluid drug concentrations against macrolide -resistant and -susceptible *Streptococcus pneumoniae***

11:00 O. Echeverría, L. Alou, D. Sevillano, F. Cafini, M.T. López-casila, I. Unzueta, J. Prieto  
Microbiology Dept, School of Medicine. Universidad Complutense de Madrid, Madrid, Spain

**269/60O Continuous versus intermittent infusion of 6g/day ceftazidime against *Pseudomonas aeruginosa*: an in vitro pharmacodynamic simulation**

11:15 L. Alou, M.J. Giménez, D. Sevillano, L. Aguilar, O. Echeverría, M.L. Gómez-lus, J. Prieto  
Microbiology Dept, School of Medicine. Universidad Complutense de Madrid, Madrid, Spain

**270/60O Pharmacodynamic interest of ceftazidime continuous infusion versus intermittent bolus administration in patients with severe nosocomial pneumonia**

11:30 J. Cousson<sup>3</sup>, G. Hoizey<sup>2</sup>, T. Floch<sup>3</sup>, P. Raclot<sup>3</sup>, J.S. Petit<sup>3</sup>, V. Vernet-garnier<sup>1</sup>, D. Lamiable<sup>2</sup>, A. Leon<sup>3</sup>  
<sup>1</sup>Laboratoire de Bactériologie <sup>2</sup>Laboratoire de Pharmacologie <sup>3</sup>Réanimation Polyvalente, CHU Reims, Reims, France

**271/60O Comparative pharmacodynamics of daptomycin and vancomycin with *Staphylococcus aureus* in an in vitro dynamic model: focus on the clinically achievable ratios of area under the curve (AUC) to MIC**

11:45 A.A. Firsov<sup>1</sup>, I. Lubenko<sup>1</sup>, S.V. Vostrov<sup>1</sup>, I.V. Alferova<sup>1</sup>, M. Smirnova<sup>1</sup>, S.H. Zinner<sup>2</sup>  
<sup>1</sup>Department Pharmacokinetics & Pharmacodynamics, Gause Institution of New Antibiotics, Moscow, Russia <sup>2</sup>Harvard Medical School, Mount Auburn Hospital, Cambridge, United States

**272/60O Correlation between Lopinavir/ritonavir (LPV/r) concentrations and plasma lipids changes in HIV infected patients : A 24 week , prospective multicenter study.**

12:00 J.L. Meynard<sup>3</sup>, K. Lacombe<sup>3</sup>, J.M. Poirier<sup>4</sup>, O. Massot<sup>3</sup>, B. Lefebvre<sup>3</sup>, O. Bouchaud<sup>1</sup>, J.B. Guiard-schmidt<sup>5</sup>, C. Vertsuyft<sup>4</sup>, P. Benlian<sup>2</sup>, P.M. Girard<sup>3</sup>  
<sup>1</sup>Maladies Infectieuses, Hôpital Avicenne <sup>2</sup>Biochimie <sup>3</sup>Maladies Infectieuses <sup>4</sup>Pharmacologie, Hôpital Saint-Antoine <sup>5</sup>Maladies Infectieuses, Hôpital Tenon, Paris, France

**273/60O Fluoroquinolones- (FQ) and aminoglycosides- (AG) mutant prevention concentrations (MPCs) of *Pseudomonas aeruginosa* : an approach for evaluating the mutant selection window (MSW) in vivo**

12:15 D. Croisier, B. Martha, C. Dentan, C. Lequeu, L. Piroth, H. Portier, P. Chavanet  
Laboratoire des Maladies Infectieuses, EA 562, Dijon, France

Friday  
vendredi 3 December  
décembre

11:45  
12:30

Salle Havane

EXPERT LECTURE  
Conférence

61EL

Président/Chairperson : W. Rosenbaum

274/61EL AIDS and anti-HIV drugs today

11:45 R. Cauda

Universita Cattolica del Sacro Cuore, Rome, Italy

Friday  
vendredi 3 December  
décembre

14:00  
15:30

Salle Bordeaux

SYMPOSIUM  
Symposium

62s

TOWARDS ANADEQUATE POLICY OF ANTIBIOTIC TREATMENT  
POUR UNE BONNE POLITIQUE DE L'ANTIBIOTHÉRAPIE

Présidents/Chairpersons : B. Schlemmer, M. Struelens

275/62S Results and perspectives of the French campaign

14:00 P. Dellamonica

Hôpital de l'Archet, Nice, France

276/62S Results of various European campaigns

14:20 M. Goossens

University Hospital Antwerp, Edegem, Belgium

277/62S Evolution of drug market: the position of anti-infectious agents

14:40 C. Le Pen

Laboratoire d'Economie et de Gestion des Organisations de Santé, Université Paris IX - Dauphine, Paris, France

278/62S Does pharmaceutical industry have a positive influence on clinical practices?

15:00 C. Lassalle

Les Entreprises du Médicament, Paris, France

Friday  
vendredi 3 December  
décembre

14:00  
14:45

Salle Havane

EXPERT LECTURE  
Conférence

63EL

Président/Chairperson : H. Giamarellou

279/63EL How do bacteria minimize the biological cost of antibiotic resistance?

14:00 P. Courvalin

Unité des Agents Antibactériens, Institut Pasteur, Paris, France

Friday  
vendredi 3 December  
décembre

14:00  
15:30

ROOM  
Salle 342A

SYMPOSIUM  
Symposium

64s

NEW TRENDS IN VARICELLA ZOSTER VIRUS INFECTIONS

NOUVELLES TENDANCES DANS LES INFECTIONS À VZV

Organized by the Educational grant of Aventis Pasteur MSD

Présidents/Chairpersons : J. Seward, P. Weinbreck

280/64S Epidemiology of chickenpox: the French observatory of hospitalised patients

14:00 E. Grimpel

Hôpital Trousseau, Paris, France

281/64S Management of VZV infection: review of current guidelines

14:20 C. Chidiac

	Hopital de la Croix Rousse, Lyon, France
282/64S 14:40	<b>Cost effectiveness of chickenpox vaccine</b> A. Neiss Institute for Medical Statistics and Epidemiology, Munich, Germany
283/64S 15:00	<b>Chickenpox vaccine: which role in European countries?</b> C. Olivier Hopital Louis Mourier, Colombes, France

Friday vendredi	3	December décembre	14:00 15:30	ROOM Salle	351	STATE OF THE ART State of the art	65SOTA
--------------------	---	----------------------	----------------	---------------	-----	--------------------------------------	--------

## HEPATITIS B INFECTION HÉPATITE B

Présidents/Chairpersons : C. Perronne, M. Nelson, J. Beytout

284/65SOTA 14:00	<b>Hepatitis B vaccine: update on safety</b> M. Rosenheim Hôpital Pitié Salpêtrière, Paris, France
285/65O 14:30	<b>Hepatitis B virus genotypes a, c, d are responsible for a more severe hepatic disease than genotype b and e in chronically infected patients</b> E. Gordien <sup>1</sup> , N. Ganne <sup>2</sup> , V. Williams <sup>1</sup> , T. Thar <sup>2</sup> , H. Kaddouri <sup>1</sup> , C. Allou <sup>1</sup> , S. Dziri Mendil <sup>1</sup> , A. Hawajri <sup>1</sup> , J.C. Trinchet <sup>2</sup> , P. Deny <sup>1</sup> , M. Beaugrand <sup>2</sup> <sup>1</sup> Laboratoire de Bacteriologie Virologie, Hopital Avicenne, Bobigny <sup>2</sup> Hépato-gastro-entérologie, Hopital Jean Verdier, Bondy, France
286/65O 14:45	<b>Co-existence of HBV surface antigen and anti-HBS antibodies in chronic hepatitis B virus carriers : influence of 'a' determinant variants</b> O. Lada, Y. Benhamou, T. Poynard, V. Thibault Hôpital Pitié-Salpêtrière, Paris, France
287/65O 15:00	<b>Prevalence of Hepatitis B and C virus infection among patients in Western Attica, Greece</b> K. Masselou <sup>2</sup> , E. Pantaz <sup>2</sup> , A. Tarpatz <sup>2</sup> , S. Chaniotaki <sup>2</sup> , A. Chounta <sup>1</sup> , C. Ellinas <sup>1</sup> , L. Zerva <sup>2</sup> <sup>1</sup> 4th Department of Internal Medicine <sup>2</sup> Laboratory of Clinical Microbiology, Attikon Hospital, University of Athens, Athens, Greece
288/65O 15:15	<b>Phylogenetic characterization of hepatitis B virus reveals predominance of genotype e in Mali</b> I. Maïga <sup>3</sup> , S. Mahot <sup>2,2</sup> , C.P. Muller <sup>2,2</sup> , A. Le Faou <sup>1,1</sup> , V. Venard <sup>1,1</sup> <sup>1</sup> Laboratoire de virologie, UMR 7565 UHP-CNRS, Faculté de Médecine, and CHU de Nancy, Vandoeuvre Lès Nancy, France <sup>2</sup> Département d'Immunologie, Laboratoire National de Santé, Luxembourg, Luxembourg <sup>3</sup> Laboratoire de biologie médicale, Hôpital du point G, Bamako, Mali

Friday vendredi	3	December décembre	14:00 15:30	ROOM Salle	352B	SYMPOSIUM Symposium	66s
--------------------	---	----------------------	----------------	---------------	------	------------------------	-----

## ADVANCES IN THE TREATMENT OF BRUCELLOPSIS AND OTHER ZOONOTIC INFECTIONS AVANCÉES DANS LE TRAITEMENT DE LA BRUCELLOSE ET AUTRES ZOOSES Organized by the Society for study of Brucellosis

Présidents/Chairpersons : N. Akritidis, F. Bricaire

289/66S 14:00	<b>Current situation with tularaemia</b> R. Titball London School of Hygiene and Tropical Medicine, London, United Kingdom
290/66S 14:15	<b>Typhoid/salmonellosis in Europe</b> C. Parry University of Liverpool, Liverpool, United Kingdom
291/66S 14:30	<b>Zoonotic infections and bioterrorism</b> P. Bossi Hôpital Pitié Salpêtrière, Paris, France

**292/66S Molecular pathogenesis of brucellosis and new therapeutic targets**

14:45 J.P. Govej

Centre d'Immunologie de Marseille-Luminy, Marseille, France

**293/66S New approaches to the antibiotic treatment of brucellosis**

15:00 G. Pappas

University Hospital of Ioannina, Ioannina, Greece

Friday 3 December décembre

14:00  
15:30ROOM  
Salle 341SYMPOSIUM  
Symposium

67s

**PROSTATITIS - STILL AN ENIGMA**

LA PROSTATITE - TOUJOURS UNE ÉNIGME

Organized by the European Society for Infection in Urology (European Association of Urology)

Présidents/Chairpersons : M. Grabe, B. Lobel

**294/67S Acute prostatitis**

14:00 J. Palou Redorta

Puigvert Fundation, Barcelona, Spain

**295/67S The role of antibiotics in chronic bacterial prostatitis**

14:20 F. Wagenlehner

Saint Elisabeth Clinic, Straubing, Germany

**296/67S Management of chronic prostatitis/ chronic pelvic pain syndrome (CP/CPPS)**

14:40 B. Lobel

CHU de Pontchaillou, Rennes, France

**297/67S Research priorities in chronic prostatitis / chronic pelvic syndrome (CP/CPPS)**

15:00 W. Weidner

University of Giessen, Giessen, Germany

Friday 3 December décembre

14:00  
15:30ROOM  
Salle 342BORAL SESSION  
Session Orale

68o

**LOWER RESPIRATORY TRACT INFECTIONS**

INFECTIONS RESPIRATOIRES BASSES

Présidents/Chairpersons : M. Garré, M. Cizman

**298/68O Alternative diagnoses in 90 patients admitted for suspicion of severe acute respiratory syndrome (SARS)**14:00 V. Noel<sup>1</sup>, J. Emmanuell<sup>2</sup>, G. Breton<sup>1</sup>, P. Longuet<sup>1</sup>, A. Macrez<sup>1</sup>, B. Rigolli<sup>2</sup>, J.L. Vilde<sup>1</sup>, C. Leport<sup>1</sup><sup>1</sup>Maladies Infectieuses et Tropicales, CHU Bichat - Claude Bernard<sup>2</sup>Institut de Veille Sanitaire, Paris<sup>3</sup>Orthopédie, Centre Hospitalier, Reims, France**299/68O Evaluation of the perception of influenza vaccination by health careworkers in two French university hospitals**14:15 I. Crozet<sup>1,2,4</sup>, P. Vanhems<sup>2</sup>, P. Berthelot<sup>4</sup>, C. Chemorin<sup>2</sup>, O. Robert<sup>1</sup>, M. Moulin<sup>3</sup>, B. Vitrolles<sup>3</sup>, M.A. Denis<sup>1</sup>, B. Pozzetto<sup>4</sup><sup>1</sup>Département de Médecine du Travail, Hôpital Edouard Herriot<sup>2</sup>Laboratoire d'Epidémiologie et de Santé Publique, INSERM U271 & Hôpital Edouard Herriot, Lyon<sup>3</sup>Département de Médecine du Travail, CHU de Saint-Etienne<sup>4</sup>Departement de Microbiology, Faculté de Médecine Jacques Lisfranc, Saint-Etienne, France**300/68O Influenza impact in an hospitalized pediatric population: a pilot study in the Parisian region**14:30 C. Olivier<sup>3</sup>, B. Chevallier<sup>2</sup>, J. Gaudelus<sup>1</sup>, P. Reinert<sup>4</sup><sup>1</sup>Pédiatrie, Hôpital Jean Verdier, Bondy<sup>2</sup>Pédiatrie, Hôpital Ambroise Paré, Boulogne-Billancourt<sup>3</sup>Pédiatrie, Hôpital Louis Mourier, Colombes<sup>4</sup>Pédiatrie, Hôpital Intercommunal, Créteil, France**301/68O Reagrip: a prospective virologic survey of patients admitted to a critical care unit for acute respiratory or cardiac failure during the winters of 2002 and 2003**14:45 F. Carrat<sup>1,2,3</sup>, M. Leruez-ville<sup>1,3</sup>, M. Tonnelier<sup>1,3</sup>, J.L. Baudel<sup>1</sup>, J. Deshayes<sup>2</sup>, P. Meyer<sup>1</sup>, E. Maury<sup>1,2</sup>, J. Galimand<sup>3</sup>, C. Rouzioux<sup>1,3</sup>, G.Offenstadt<sup>1,2,3</sup><sup>1</sup>GHU Est et Ouest, AP-HP<sup>2</sup>U444, INSERM<sup>3</sup>Université Paris 5 (EA3620) and Paris 6, Paris, France

<b>302/68O</b>	<b>Legionnaire's disease : 417 hospitalized cases in French hospitals.</b>
15:00	C. Chidiac <sup>3</sup> , J. Gaillat <sup>3</sup> , C. Michelet <sup>3</sup> , F. Raffi <sup>3</sup> , J. Reynes <sup>3</sup> , C. Lepot <sup>3</sup> , P. Weinbreck <sup>1,2</sup>
	<sup>1</sup> Collège Médical des Maladies Infectieuses <sup>2</sup> Société Française des Maladies Infectieuses <sup>3</sup> Service des Maladies Infectieuses et Tropicales, Hôpital de la Croix-Rousse, Lyon, France
<b>303/68O</b>	<b>Evolution of antibiotic resistance of <i>Streptococcus pneumoniae</i>(Sp) isolated in adults in France in 2001 and 2003</b>
15:15	M. Roussel-Delvallez <sup>10</sup> , V. Vernet-Garnier <sup>20</sup> , S. Bourdon <sup>3</sup> , M. Brun <sup>14</sup> , B. Cattier <sup>25</sup> , C. Chanal <sup>7</sup> , H. Chardon <sup>1</sup> , M. Chomarat <sup>12</sup> , J. Croizé <sup>9</sup> , M.C. Demachy <sup>13</sup> , P.Y. Donnio <sup>21</sup> , P. Dupont <sup>4</sup> , T. Fosse <sup>17</sup> , A. Gravet <sup>15</sup> , B. Grignon <sup>19</sup> , G. Laurans <sup>2</sup> , J. Maugein <sup>5</sup> , A. Péchinot <sup>8</sup> , M.C. Ploy <sup>11</sup> , M.F. Prere <sup>24</sup> , P.H. Thoreux <sup>22</sup> , M. Vergnaud <sup>6</sup> , M. Weber <sup>16</sup> , E. Varon <sup>18</sup> , L. Guttman <sup>18</sup> , B. Coignard <sup>23</sup>
	<sup>1</sup> CH de Aix en Provence, Aix en Provence <sup>2</sup> CHU de Amiens, Amiens <sup>3</sup> CHU de Angers, Angers <sup>4</sup> CHU de Besançon, Besançon <sup>5</sup> CHU de Bordeaux, Bordeaux <sup>6</sup> CHU de Caen, Caen <sup>7</sup> CHU de Clermont-Ferrand, Clermont-Ferrand <sup>8</sup> CHU de Dijon, Dijon <sup>9</sup> CHU de Grenoble, Grenoble <sup>10</sup> CHU de Lille, Lille <sup>11</sup> CHU de Limoges, Limoges <sup>12</sup> CHU de Lyon, Lyon <sup>13</sup> CHU de Meaux, Meaux <sup>14</sup> CHU de Montpellier, Montpellier <sup>15</sup> CH de Mulhouse, Mulhouse <sup>16</sup> CHU de Nancy, Nancy <sup>17</sup> CHU de Nice, Nice <sup>18</sup> CNRP, Paris <sup>19</sup> CHU de Poitiers, Poitiers <sup>20</sup> CHU de Reims, Reims <sup>21</sup> CHU de Rennes, Rennes <sup>22</sup> CH de Saint Brieuc, Saint Brieuc <sup>23</sup> InVS, St Maurice <sup>24</sup> CHU de Toulouse, Toulouse <sup>25</sup> CHU de Tours, Tours, France

Friday vendredi	<b>3</b>	December décembre	14:00 15:30	ROOM Salle	<b>343</b>	ORAL SESSION Session Orale	<b>690</b>
--------------------	----------	----------------------	----------------	---------------	------------	-------------------------------	------------

## HIV INFECTION INFECTION À VIH

Présidents/Chairpersons : J. Lundgren, D. Salmon

<b>304/69O</b>	<b>Epidemiological and clinical characteristics of newly managed HIV -infected patients: Hopital St Antoine, Paris, 2002-2003</b>
14:00	L. Fonquerne <sup>1</sup> , E. Banogo <sup>1</sup> , R.M. Dray-spira <sup>2</sup> , F. Lert <sup>2</sup> , P.M. Girard <sup>1</sup>
	<sup>1</sup> Service des Maladies Infectieuses et Tropicales, Hôpital Saint-Antoine, Paris <sup>2</sup> INSERM U88, Hôpital National de Saint-Maurice, Saint-Maurice, France
<b>305/69O</b>	<b>Determinants of adherence in 138 patients taking antiretroviral chemoprophylaxis after sexual exposure to HIV</b>
14:15	K. Lacombe <sup>2</sup> , V. Lebeau <sup>2</sup> , A. Daguenel-nguyen <sup>1</sup> , P.M. Girard <sup>2</sup> , M.C. Meyohas <sup>2</sup>
	<sup>1</sup> Pharmacie centrale <sup>2</sup> Service de maladies infectieuses, Hôpital Saint-Antoine, Paris, France
<b>306/69O</b>	<b>Importance of an events validation committee in the context of a large prospective cohort of HIV -infected patients</b>
14:30	C. Bareilles <sup>4</sup> , L. Cuzin <sup>7</sup> , C. Brunet <sup>5</sup> , C. Lewden <sup>4</sup> , P. Morlat <sup>3</sup> , M. Dupon <sup>2</sup> , C. Rabaud <sup>8</sup> , S. Herson <sup>6</sup> , X. Duval <sup>1</sup> , G. Chêne <sup>4</sup> , C. Leport <sup>1</sup>
	<sup>1</sup> Service des Maladies Infectieuses, Hôpital Pellegrin-Tripode <sup>2</sup> Service de Médecine Interne, Hôpital St André <sup>3</sup> Inserm U593, Université Bordeaux 2, Bordeaux <sup>4</sup> Service de Médecine Interne, Hôpital de l'Hôtel Dieu, Nantes <sup>5</sup> Service des Maladies Infectieuses et Tropicales, Hôpital Bichat Claude-Bernard <sup>6</sup> Service de Médecine Interne, Hôpital Pitié-Salpêtrière, Paris <sup>7</sup> Service des Maladies Infectieuses, CHU Purpan, Toulouse <sup>8</sup> Service des Maladies Infectieuses et Tropicales, Hôpital de Brabois, Vandoeuvre Les Nancy, France
<b>307/69O</b>	<b>HCV-related factors but not HIV -related factors at baseline predict the response to treatment with peginterferon alfa-2a (40kd)(pegasys) plus ribavirin (copegus) in patients with HIV-HCV co-infection : predictor analysis from the apricot study</b>
14:45	S. Dominguez <sup>4</sup> , D. Cooper <sup>1</sup> , F.J. Torriani <sup>13</sup> , M. Rodriguez-Torres <sup>5</sup> , N. Brau <sup>10</sup> , M. Sulkowski <sup>9</sup> , R. Sola <sup>6</sup> , C. Katlama <sup>4</sup> , N. Clumeck <sup>2</sup> , M.R. Nelson <sup>8</sup> , M.C. Correa <sup>3</sup> , E.W. Godofsky <sup>14</sup> , D. Dieterich <sup>11</sup> , F. Duff <sup>12</sup> , S. Passe <sup>12</sup> , E. Lissen <sup>9</sup>
	<sup>1</sup> University of New South Wales, Sydney, Australia <sup>2</sup> CHU Saint-Pierre, Brussels, Belgium <sup>3</sup> HCFMUSP Casa da AIDS, Sao Paulo, Brazil <sup>4</sup> Hôpital Pitié-Salpêtrière, Paris, France <sup>5</sup> Diego Research Fundation, Santurce, Porto Rico <sup>6</sup> Hospital del Mar, Barcelone <sup>7</sup> Virgen del Rocío University Hospital, Sevilla, Spain <sup>8</sup> Chelsea and Westminster Hospital, London, United Kingdom <sup>9</sup> Johns Hopkins University School of Medicine, Baltimore <sup>10</sup> Bronx VA Medical Center, Bronx <sup>11</sup> Mt Sinai School of Medicine, New York <sup>12</sup> Roche, Nutley <sup>13</sup> University of California, San Diego <sup>14</sup> University of South Florida School of Medicine, Tampa, United States
<b>308/69O</b>	<b>Syphilis revealed by uveitis, in relationship with HIV</b>
15:00	C. Parc <sup>2</sup> , S. Chahed <sup>2</sup> , D. Monnet <sup>2</sup> , D. Salmon Ceron <sup>1</sup> , A. Brezin <sup>2</sup>
	<sup>1</sup> Département de Médecine Interne, Hôpital Cochin <sup>2</sup> Département d'Ophtalmologie, Hôpital Cochin, Paris, France
<b>309/69O</b>	<b>Phospholipases and cationic peptides neutralize <i>Cryptosporidium parvum</i> sporozoite infectivity by either parasiticidal or non-parasiticidal mechanisms</b>
15:15	S. Carryn <sup>2</sup> , D.A. Schaefer <sup>2</sup> , M. Imboden <sup>1</sup> , E.J. Homan <sup>1</sup> , R.D. Bremel <sup>1</sup> , M.W. Riggs <sup>2</sup>
	<sup>1</sup> IoGenetics LLC, Madison, WI <sup>2</sup> Department of Veterinary Science and Microbiology, University of Arizona, Tucson, AZ, United States

**BETA-LACTAMASES 1**  
**BETA-LACTAMASES 1**

Présidents/Chairpersons : G. Arlet, G. Kahlmeter, A. Sefton

- 310/70O Control of an outbreak of VIM-1 and SHV-5-producing strains of *Klebsiella pneumoniae* in a surgical care center in France**  
14:00 N. Kassis-Chikhani<sup>4-5</sup>, F. Saliba<sup>3</sup>, S. Neuville<sup>1</sup>, C. Guérin<sup>4</sup>, N. Castabiuru<sup>3</sup>, P. Colliot<sup>5</sup>, D. Décré<sup>2</sup>, D. Mathieu<sup>5</sup>, D. Castaing<sup>3</sup>, V. Jarlier<sup>1</sup>, E. Dussaix<sup>5</sup>  
<sup>1</sup>Equipe Opérationnelle d'Hygiène, Direction de la Politique Médicale de l'AP-HP<sup>2</sup>Laboratoire de Bactériologie, UPRES EA 2392, Faculté de Médecine Saint Antoine, Paris<sup>3</sup>Centre Hépato-Biliaire<sup>4</sup>Equipe Opérationnelle d'Hygiène<sup>5</sup>Service de Microbiologie, Hôpital Paul Brousse AP-HP, Villejuif, France
- 311/70O VIM-1 metallo-beta-lactamase-producing *Klebsiella pneumoniae* strains in a French university hospital**  
14:15 D. Décré<sup>1</sup>, N. Kassis Chikhani<sup>3</sup>, V. Gautier<sup>1</sup>, B. Burghoffer<sup>1</sup>, F. Saliba<sup>2</sup>, D. Mathieu<sup>3</sup>, J.C. Petit<sup>1</sup>, E. Dussaix<sup>3</sup>, G. Arlet<sup>1</sup>  
<sup>1</sup>Laboratoire de Bactériologie, UPRES EA 2392, Faculté de Médecine Saint-Antoine, Paris<sup>2</sup>Centre Hépato-Biliaire<sup>3</sup>Service de Microbiologie, Hôpital Paul Brousse, Villejuif, France
- 312/70O Outbreak of extended-spectrum beta-lactamase producing *Enterobacter aerogenes* resistant to imipenem.**  
14:30 C.C. Adjidé<sup>3</sup>, M. Biendo<sup>1</sup>, G. Locher<sup>3</sup>, X. Lescure<sup>2</sup>, G. Laurans<sup>1</sup>, J.L. Schmit<sup>2</sup>, F. Eb<sup>1</sup>  
<sup>1</sup>Unité de bactériologie clinique, Laboratoire de bactériologie-hygiène, CHU hôpital Nord<sup>2</sup>Pathologie infectieuse<sup>3</sup>Unité d'hygiène hospitalière et de prévention des infections nosocomiales, Laboratoire de bactériologie-hygiène, CHU, hôpital Nord, Amiens, France
- 313/70O Oxa-60, a chromosomal, inducible and imipenem-hydrolyzing class D β-lactamase from *Ralstonia pickettii***  
14:45 D. Girlich, T. Naas, P. Nordmann  
*Bactériologie, Université Paris-Sud, Hopital de Bicêtre, Le Kremlin-Bicêtre, France*
- 314/70O Characterization of the chromosome-borne class a β-lactamase from *Bordetella bronchiseptica* and *Bordetella parapertussis***  
15:00 M.F. Lartigue, L. Poirel, P. Nordmann  
*Bactériologie-Virologie, Hôpital de Bicêtre, AP/HP, Faculté de Médecine Paris-Sud, Le Kremlin-Bicêtre, France*
- 315/70O Emergence of DHA-1 producing *Klebsiella* spp. in the Paris area : genetic organization of acquired ampC and ampR genes from *Morganella morganii***  
15:15 C. Verdet<sup>1,2</sup>, Y. Benzerara<sup>2</sup>, V. Gautier<sup>1</sup>, G. Arlet<sup>1,2</sup>  
<sup>1</sup>Bactériologie UPRES EA 2392, Faculté de médecine Saint-Antoine, Université Paris VI<sup>2</sup>Bactériologie-Hygiène, Hôpital Tenon, Paris, France

Président/Chairperson : L. Gutmann

- 316/71EL Goodbye genomics - Hello proteomics**  
14:45 P. Larsen  
*University of Southern Denmark, Odense, Denmark*

**VIRAL RESPIRATORY INFECTIONS**  
**LES INFECTIONS RESPIRATOIRES D'ORIGINE VIRALE**

Président/Chairperson : B. Lina

- 317/72S Cocirculation of different influenza A and B lineages since winter 2002**  
16:00 B. Lina  
*Laboratoire de Virologie, Domaine Rockefeller, Lyon, France*
- 318/72S European study on the prevalence of rhinovirus in common cold**  
16:15 G. Billaud  
*Laboratoire de Virologie, Domaine Rockefeller, Lyon, France*

<b>319/72S</b>	<b>The new coronavirus NL</b> A. Vabret <i>CHU de Caen, Caen, France</i>
<b>320/72S</b>	<b>Epidemiological and clinical significance of human Metapneumovirus infection in communautary-acquired respiratory infections: consequences on the virological diagnosis strategy of respiratory infections in hospitalized patients</b> L. Andreoletti <i>CHU Robert Debré, Reims, France</i>
<b>321/72S</b>	<b>Role of adenovirus in severe infections in children with bone marrow transplantation</b> G. Carret <i>Laboratoire de Bactériologie, Hospices Civils de Lyon, Lyon, France</i>

Friday 3 December décembre 16:00 17:30 ROOM Salle 352B SYMPOSIUM Symposium 73s

**ANTIMICROBIAL RESISTANCE IN SOUTHEASTERN EUROPE**  
**RÉSISTANCE ANTIMICROBIENNE EN EUROPE DU SUD EST**  
Organized by the Hellenic Society of Microbiology

Présidents/Chairpersons : N. Legakis, J. Soussy

<b>322/73S</b>	<b>Carbapenem-resistant acinetobacters: an emerging hospital epidemic</b> A. Tsakris <i>National University of Athens, Athens, Greece</i>
<b>323/73S</b>	<b>Evolution of resistance to macrolides in Gram-positive bacteria</b> J. Papaparaskervas <i>National University of Athens, Athens, Greece</i>
<b>324/73S</b>	<b>Recent trends of resistance to antibiotics in the mycobacterium tuberculosis complex</b> E. Papafrangas <i>Hellenic Society for Microbiology, Athens, Greece</i>
<b>325/73S</b>	<b>Antibiotic usage and the evolution of antibiotic resistance. Treatment options for antibiotic-resistant bacteria</b> A. Pefanis <i>Sotiria General Hospital, Athens, Greece</i>

Friday 3 December décembre 16:00 17:30 ROOM Salle 341 SYMPOSIUM Symposium 74s

**NOSOCOMIAL URINARY TRACT INFECTION**  
**INFECTIONS URINAIRES NOSOCOMIALES**  
Organized by the European Society for Infection in Urology (European Association of Urology)

Présidents/Chair persons : H. Botto, K. Naber

<b>326/74S</b>	<b>Emerging resistance of uropathogens</b> J.D. Cavallo <i>Hôpital d'Instruction des Armées Bégin, Saint Mandé, France</i>
<b>327/74S</b>	<b>Pan-European Prevalence study</b> T.E. Bierklund Johansen <i>University of Tromsø, Porsgrunn, Norway</i>
<b>328/74S</b>	<b>Catheter related urinary tract infection</b> P. Tenke <i>Hungarian Society of Urology, Budapest, Hungary</i>
<b>329/74S</b>	<b>A French view on communicable disease center (CDC) guidelines</b> H. Botto <i>Hôpital Foch, Suresnes, France</i>

**A CRITICAL LOOK AT PK/PD CORRELATIONS OF ANTIFUNGAL DRUGS AND ROLE OF COMBINATION THERAPY IN SYSTEMIC INFECTIONS**  
**REGARD CRITIQUE SUR LES CORRÉLATIONS PK/PD DES ANTIFONGIQUES ET LE RÔLE DES TRAITEMENTS COMBINÉS DANS LES INFECTIONS SYSTÉMIQUES**  
Organized by the Société Italienne de Chimiothérapie

Président/Chairperson : T. Mazzei

**330/75S Pharmacological aspects**

16:00 A. Novelli  
University of Florence, Florence, Italy

**331/75S Clinical aspects**

16:45 M. Tod  
Hôpital Cochin - Saint Vincent de Paul, Paris, France

**HIV INFECTION: TREATMENT**  
**TRAITEMENT DE L'INFECTION À VIH**

Présidents/Chairpersons : C. Leport, S. de Wit

**332/76O Polymorphism and drug-selected mutations in the HIV-1 Reverse Transcriptase gene in naive and treated patient isolates from the Seine-Saint-Denis district in France: differences between B and non-B subtypes**

16:00 N. Al Hawairi<sup>2</sup>, E. Gault<sup>2</sup>, C. Allouï<sup>2</sup>, E. Gordien<sup>2</sup>, T. Drugan<sup>3</sup>, L. Maisonneuve<sup>1</sup>, F. Le Gal<sup>2</sup>, S. Dziri-mendil<sup>2</sup>, P. Dény<sup>2</sup>  
<sup>1</sup>Hôpital d'Aulnay, Aulnay-Sous-Bois <sup>2</sup>Hôpital Avicenne, AP-HP, EA3406 ATHSCO, UFR SMBH, Université Paris 13, Bobigny, France, Laboratoire de bactériologie, virologie-hygiène, Bobigny, France <sup>3</sup>University of Medicine and Farmacy, Cluj, Romania

**333/76O Outcome of HIV-infected patients started on a protease-inhibitor (PI) containing regimen: results at 5 years of the APROCO-COPILOTE Cohort Study.**

16:15 G. Chêne<sup>1</sup>, C. Leport<sup>5</sup>, B. Spire<sup>2</sup>, C. Lewden<sup>1</sup>, J. Pierret<sup>8</sup>, G. Peytavin<sup>7</sup>, F. Brun-Vezinet<sup>6</sup>, V. Le Moing<sup>3</sup>, R. Salamon<sup>1</sup>, F. Raffi<sup>4</sup>, and the Aproco-co-piloté Study Group<sup>5-1</sup>  
<sup>1</sup>Unité 593, Bordeaux <sup>2</sup>Unité 379, INSERM, Marseille <sup>3</sup>Service des Maladies Infectieuses et Tropicales, Hôpital Gui de Chauliac, Montpellier <sup>4</sup>Service de maladies infectieuses, Hôtel Dieu, Nantes <sup>5</sup>Laboratoire de Recherche en Pathologie Infectieuse, Faculté Xavier Bichat <sup>6</sup>Laboratoire de virologie <sup>7</sup>Pharmacie, Hôpital Bichat, Paris <sup>8</sup>CERMES, CNRS, Villejuif, France

**334/76O Efficacy and safety of zidovudine, lamivudine, and tenofovir combination in antiretroviral naive, HIV-1 infected patients.**

16:30 D. Rey, M. Krebs, M. Partisan, G. Hess-kempf, C. Cheneau, M. Priester, C. Bernard-henry, E. De Mautort, J.M. Lang  
CISIH - Clinique Médicale A, Hôpitaux Universitaires, Strasbourg, France

**335/76O Virologic outcome and adherence data in treatment naive HIV-1 infected patients (pts) treated by FosAmprenavir (FPV) in the SOLO study.**

16:45 F.R. Raffi<sup>3</sup>, Z. Antoun<sup>2</sup>, C. Le Camus<sup>1</sup>  
<sup>1</sup>Vertex Pharmaceuticals (Europe), Courbevoie <sup>2</sup>GlaxoSmithKline, Marly Le Roy <sup>3</sup>Service des Maladies Infectieuses, CHU Hotel Dieu, Nantes, France

**336/76O Clinical and virological follow-up of a cohort of HIV-1 infected patients receiving enfuvirtide.**

17:00 B. Bienvenu<sup>2</sup>, A. Krivine<sup>1</sup>, G. Spiridon<sup>2</sup>, M.P. Pietr<sup>2</sup>, V. Lebaut<sup>2</sup>, D. Sicard<sup>2</sup>, P. Lebon<sup>1</sup>, D. Salmon<sup>2</sup>, O. Launay<sup>2</sup>  
<sup>1</sup>Laboratoire de Virologie <sup>2</sup>Service de Médecine Interne, Groupe Hospitalier Cochin-Saint Vincent de Paul, Paris, France

**337/76O Incidence of and risk factors for hepatotoxicity associated with nevirapine in HIV-1 infected patients.**

17:15 O. Launay<sup>2</sup>, N. Boukl<sup>5</sup>, J.M. Tréluyer<sup>4</sup>, L. Roudiere<sup>2</sup>, E. Rey<sup>4</sup>, R. Urbinelli<sup>1</sup>, F.A. Allaert<sup>1</sup>, E. Caumes<sup>3</sup>  
<sup>1</sup>Cenbiotech, Dijon <sup>2</sup>Médecine Interne, Cochin Hospital <sup>3</sup>Maladies Infectieuses, Pitie-Salpêtrière Hospital <sup>4</sup>Pharmacologie, St-Vincent de Paul Hospital, Paris <sup>5</sup>Boehringer Ingelheim, Reims, France

**BETA-LACTAMASES 2**  
**BETA-LACTAMASES 2**

Présidents/Chairpersons : R. Bonnet, D. Williams, A. Sefton

- 338/77O** **Extended-spectrum β-lactamase-producing enterobacteria in the community setting: clinical and molecular analysis.**  
16:00 C. Arpin<sup>1</sup>, V. Dubois<sup>1</sup>, J. Jullin<sup>2</sup>, B. Dutilh<sup>2</sup>, J.P. Brochet<sup>2</sup>, G. Larribet<sup>2</sup>, I. Fischer<sup>2</sup>, J. Maugein<sup>3</sup>, C. Quentin<sup>1,2</sup>  
<sup>1</sup>EA 525, Laboratoire de Microbiologie, Faculté de Pharmacie, Université de Bordeaux 2<sup>2</sup>Laboratoires Privés du Réseau Aquitaine, Bordeaux<sup>3</sup>Laboratoire de Bactériologie, Hôpital Haut-Levêque, Pessac, France
- 339/77O** **Spread of novel expanded-spectrum beta-lactamases in enterobacteriaceae in an university hospital in the Paris area, France**  
16:15 M.F. Lartigue, N. Fortineau, P. Nordmann  
Bactériologie-Virologie, Hôpital de Bicêtre, AP/HP, Faculté de Médecine Paris-Sud, Le Kremlin-Bicêtre, France
- 340/77O** **Countrywide spread of extended-spectrum β-lactamase (ctx-m-15)-producing enterobacteriaceae in lebanon**  
16:30 C. Moubareck<sup>2</sup>, Z. Daoud<sup>8-10</sup>, N. Hakimé<sup>8</sup>, M. Hamzé<sup>5,6</sup>, N. Mangeney<sup>2</sup>, H. Matta<sup>3</sup>, J. Mokhbat<sup>5-7</sup>, R. Rohban<sup>9</sup>, D. Karam Sarkis<sup>4</sup>, F. Doucet-populaire<sup>1,2</sup>  
<sup>1</sup>CH de Versailles, Le Chesnay<sup>2</sup>Microbiologie, UFR des Sciences Pharmaceutiques et Biologiques, Paris, France<sup>3</sup>Arz Hospital<sup>4</sup>Hotel Dieu de France Hospital<sup>5</sup>Lebanese University<sup>6</sup>Nini Hospital<sup>7</sup>Rizk Hospital<sup>8</sup>Saint George Hospital<sup>9</sup>Saint Joseph Hospital<sup>10</sup>University of Balamand, Lebanon
- 341/77O** **Characterization of two new complex mutants of TEM-1 β-lactamase produced by two clinical isolates of *Escherichia coli*.**  
16:45 F. Robin, J. Delmas, C. Chanal, R. Bonnet, D. Sirot, J. Sirot  
Laboratoire de bactériologie, Faculté de médecine, Clermont-Ferrand, France
- 342/77O** **Emergence of CTX-M-9 producing multiresistant strains of *Salmonella* Virchow in poultry and human in France**  
17:00 A. Brisabois<sup>1</sup>, F.X. Weill<sup>3</sup>, R. Lailler<sup>1</sup>, K. Praud<sup>4</sup>, A. Kérouanton<sup>1</sup>, L. Fabre<sup>3</sup>, P.A.D. Grimont<sup>3</sup>, A. Cloeckaert<sup>2</sup>  
<sup>1</sup>AFSSA LERQAP, Maisons Alfort<sup>2</sup>INRA, Nouzilly<sup>3</sup>CNR des Salmonella, Institut Pasteur, Paris, France
- 343/77O** **Outbreak of *Aeromonas caviae* producing the extended-spectrum beta-lactamase PER-3**  
17:15 C. Neuwirth<sup>2</sup>, E. Parisi<sup>1</sup>, L. Clerget<sup>1</sup>, C. Beauchaton<sup>1</sup>, I. Gravet<sup>1</sup>, R. Heller<sup>1</sup>, D. De Briel<sup>1</sup>, E. Siebor<sup>2</sup>  
<sup>1</sup>Hôpital, Colmar<sup>2</sup>Bactériologie, CHU, Dijon, France

**MULTIRESISTANCE IN GRAM POSITIVE COCCI**  
**MULTIRÉSISTANCE CHEZ LES COCCI À GRAM POSITIF**

- 344/78P** **Multiclonality of methicillin-resistant *Staphylococcus aureus* in a multidisciplinary hospital.**  
00:00 N. Ben Saida, H. Ben Abdallah, N. Hannachi, J. Boukadida  
MICROBIOLOGY - UR 16/02, CHU F. HACHED, Sousse, Tunisia
- 345/78P** **Results of protocol of methicillin resistant staphylococcus control at the intensive care unit of the emergency center**  
00:00 B. Jovanovic, N. Mazic, V. Moljevic, S. Jovanovic, J. Obrenovic  
Hospital Epidemiology and Microbiology, Clinical Center of Serbia, Belgrade, Yugoslavia
- 346/78P** **Control of methicillin-resistant *Staphylococcus aureus* outbreak in an intensive care unit**  
00:00 A. Willke, V. Dundar, S. Gundes, M. Meric  
Infectious Diseases and Clinical Microbiology, Kocaeli University Hospital, Izmit, Turkey
- 347/78P** **Treatment of knee prosthesis with oral linezolid: *Staphylococcus epidermidis* reported to be teicoplanin resistant**  
00:00 R. Pérez Ferri, F. Romero Candau, J.M. Madrigal  
Unit of Bone and Joint Infection, Hospital FREMAP, Seville, Spain
- 348/78P** **First infection with VanD-Type glycopeptide-resistant *Enterococcus faecium* in a French university hospital**  
00:00 J.P. Lavigne<sup>2,4</sup>, H. Marchandin<sup>1,4</sup>, N. Bouziges<sup>2,4</sup>, S. Michaux-charachon<sup>2,4</sup>, B. Richard<sup>3</sup>, A. Sotto<sup>3,4</sup>  
<sup>1</sup>Laboratoire de Bactériologie, Centre Hospitalo-Universitaire Arnaud de Villeneuve, Montpellier<sup>2</sup>Laboratoire de Bactériologie-Virologie<sup>3</sup>Service de Médecine Interne B, Centre Hospitalo-Universitaire de Carêmeau<sup>4</sup>Laboratoire Universitaire d'Antibiologie, Faculté de Médecine Montpellier-Nîmes, Nîmes, France
- 349/78P** **Analysis of 62 episodes of bacteremia caused by vancomycin sensitive and vancomycin resistant enterococci in an Intensive Care Unit.**  
00:00

E. Paramythiotou, F. Kontopidou, D. Mylona - Petropoulou, A. Karabinis  
ICU and Microbiology department, George Gennimatas General Hospital, Athens, Greece

**350/78P Cerebrospinal spinal fluid shunt infection four decades after the insertion of the device.**

00:00 E. Magira, T.H. Gounaris, A.C.H. Abouhanditzi, T.H. Arsenoglou, E. Sioula  
1ST Department of internal medicine, Evangelismos Hospital, Athens, Greece

**351/78P First vancomycin-resistant blood isolate of *Enterococcus faecium* in a children's hospital and molecular analysis of surveillance cultures**

00:00 B. Altun<sup>2</sup>, A.B. Cengiz<sup>3</sup>, A. Kara<sup>3</sup>, M. Ceyhan<sup>3</sup>, S. Ünal<sup>2</sup>, G. Seçmeir<sup>3</sup>, G. Kanra<sup>3</sup>, D. Gur<sup>1</sup>

<sup>1</sup>Children's Hospital, Clinical Microbiology Lab. <sup>2</sup>Department of Medicine, Section of Infectious Diseases <sup>3</sup>Department of Pediatric Infectious Diseases, Hacettepe University, Faculty of Medicine, Ankara, Turkey

Thursday 2 December  
jeudi 2 décembre

00:00  
00:00

ROOM  
Salle

POSTER  
Poster

79P

**RESISTANT GRAM-POSITIVE BACTERIA**  
**BACTÉRIES GRAM POSITIVE RÉSISTANTES**

**352/79P MRSA incidence as an indicator of infection control practices, do the results reflect the reality?**

00:00 D. Talon, A. Muller, M. Thouverez, X. Bertrand  
Hygiène Hospitalière, CHU, Besançon, France

**353/79P Is methicillin-resistant *Staphylococcus aureus* (MRSA) frequently encountered in the emergency ward (SAU)?**

00:00 N. Afferay<sup>1</sup>, B. Tequi<sup>2</sup>, V. Prendki<sup>2</sup>, M.E. Juvin<sup>2</sup>, F. Raffi<sup>3</sup>, H.B. Drugeon<sup>2</sup>, G. Potel<sup>1</sup>  
<sup>1</sup>Accueil-Urgences <sup>2</sup>Bactériologie et Hygiène <sup>3</sup>Médecine Interne, Hotel Dieu, Nantes, France

**354/79P Evaluation of MRSA cross transmission risk in an emergency ward (SAU) using the MRSA-LS<sub>A</sub> phenotype as epidemiological indicator.**

00:00 N. Afferay<sup>1</sup>, V. Prendki<sup>2</sup>, B. Tequi<sup>2</sup>, M.E. Juvin<sup>2</sup>, F. Raffi<sup>3</sup>, H.B. Drugeon<sup>2</sup>, G. Potel<sup>1</sup>  
<sup>1</sup>Accueil-Urgences <sup>2</sup>Bactériologie et Hygiène <sup>3</sup>Médecine Interne, Hotel Dieu, Nantes, France

**355/79P Detection of nasal colonization methicillin-resistant *Staphylococcus aureus* (MRSA): a prospective study comparing IDI-MRSA™ real-time PCR assay versus chromogenic Chromagar™ and ORSA media.**

00:00 J.C. Nguyen Van<sup>1</sup>, M.D. Kitzis<sup>1</sup>, A. Ly<sup>1</sup>, J.M. Baldor<sup>1</sup>, S. Ho Tam Chay<sup>3</sup>, A. Sournia<sup>1</sup>, J. Gonot<sup>3</sup>, A. Chalfine<sup>3</sup>, J. Carlet<sup>2</sup>, A. Ben Ali<sup>1</sup>, F. Goldstein<sup>1</sup>  
<sup>1</sup>Clinical Microbiology Laboratory <sup>2</sup>Infection Control Committee <sup>3</sup>Infection Control Unit, Saint-Joseph Hospital, Paris, France

**356/79P Evaluation of MRSA Select, a new chromogenic medium, for the detection of nasal carriage of methicillin- resistant *Staphylococcus aureus***

00:00 S. Ben Nsira, M. Dupuis, R. Leclercq  
Service de Microbiologie, CHU Côte de Nacre, Caen, France

**357/79P In vitro and in vivo abilities of an *Enterococcus faecium* clinical isolate to transfer vancomycin resistance to some lactic acid bacteria**

00:00 D.D.G. Mater, C. Bray, P. Langella, G. Corthier, M.J. Flores Sanabria  
ARTRADI project". European contract QLK2-CT-2002-00843 - Unité d'Ecologie et de Physiologie du Système Digestif, Institut National de la Recherche Agronomique, Jouy-En-Josas, France

**358/79P An indicator for the follow-up of MRSA (methicillin resistant staphylococcus aureus)**

00:00 L. May-michelangel<sup>2</sup>, Y. Roberto<sup>2</sup>, B. Le Falher<sup>2</sup>, L. Martin<sup>2</sup>, A. Scanvic<sup>1</sup>, F. Le Turdu<sup>1</sup>  
<sup>1</sup>Biologie <sup>2</sup>Equipe opérationnelle d'hygiène, Hopital Victor Dupouy, Argenteuil, France

**359/79P Enterococcal infection: speciation and drug resistance in the General Hospital of Chania, Greece, during the year 2003**

00:00 E. Papadomanolaki<sup>2</sup>, G. Aleuraki<sup>2</sup>, A. Tsafarakis<sup>2</sup>, A. Tsouris<sup>2</sup>, P. Karagianni<sup>1</sup>, F. Axioti<sup>1</sup>, S. Kastanakis<sup>1</sup>  
<sup>1</sup>1st Internal Medicine Department <sup>2</sup>Microbiology Department, 'St. George' General Hospital, Chania, Greece

**360/79P Presence and expression of virulence genes in *vanA* enterococci of human, animal, and food origin**

00:00 B. Facinelli<sup>1</sup>, F. Biavasco<sup>1</sup>, G. Foglia<sup>1</sup>, C. Paoletti<sup>1</sup>, G. Donelli<sup>2</sup>, E. Guaglianone<sup>2</sup>, A. Sundsfjord<sup>3</sup>, C. Pruzzo<sup>1</sup>, G. Magi<sup>1</sup>  
<sup>1</sup>Institute of Microbiology and Biomedical Sciences, Università Politecnica delle Marche, Ancona <sup>2</sup>Dept of Technologies and Health, Istituto Superiore di Sanità, Rome, Italy <sup>3</sup>Institute of Medical Biology, University of Tromso, Tromso, Norway

**361/79P Disk approximation test for detection of inducible clindamycin resistance in staphylococci.**

00:00 E. Van Gastel, I. Wybo, D. Piérard, S. Lauwers  
Microbiology, A.Z. Vrije Universiteit Brussel, Brussels, Belgium

- 362/79P** The spread of community-acquired methicillin resistant *Staphylococcus aureus* carrying Panton-Valentine leukocidin genes in Algerian hospital.  
 00:00 N. Ramdani-bouquessa<sup>1</sup>, A. Benachour<sup>1</sup>, M. Bès<sup>2</sup>, M. Tazir<sup>1</sup>, J. Etienne<sup>2</sup>  
<sup>1</sup>Service de Microbiologie, centre Hospitalo-Universitaire d'Alger Centre Mustapha Bacha, Alger, Algeria <sup>2</sup>Centre National de Référence des Staphylocoques, INSERM0230, IFR62, Lyon, France
- 363/79P** Analysis of community-acquired MRSA isolated in three different Swiss cantons  
 00:00 N. Liassine<sup>2</sup>, M.C. Descombes<sup>2</sup>, A. Laurent<sup>2</sup>, A. Lehmann<sup>3</sup>, J. Wust<sup>4</sup>, D. Luescher<sup>4</sup>, J. Etienne<sup>1</sup>  
<sup>1</sup>Centre National de Référence des Staphylocoques, INSERM E0230, Lyon, France <sup>2</sup>Bioanalytique-Riotton, Genève <sup>3</sup>Unilabs Lausanne, Lausanne <sup>4</sup>Diagnostica, Zürich, Switzerland
- 364/79P** VanA genotype in vancomycin-resistant enterococci with low levels of teicoplanin resistant in a Spanish teaching hospital  
 00:00 A. Perez De Ayala, T. Alarcon, D. Domingo, E. Aznar, D. Monclús, B. Buendia, M. Lopez-brea  
*Microbiology, Hospital de la Princesa, Madrid, Spain*
- 365/79P** Screening of Methicillin-resistant *Staphylococcus aureus* directly from clinical specimens by real-time PCR  
 00:00 A. Louahabi, N. Hougardy, P. Goffinet  
*Service de Biologie Clinique, Cliniques du Sud Luxembourg, Arlon, Belgium*
- 366/79P** Detection of vanB2 in *Enterococcus gallinarum* in Moscow, Russia  
 00:00 G.A. Kliasova<sup>2</sup>, S.V. Sidorenko<sup>3</sup>, L.L. Speranskaja<sup>2</sup>, A.V. Mironova<sup>2</sup>, V.G. Savchenko<sup>2</sup>, S.P. Rezvan<sup>3</sup>, E.E. Davydova<sup>1</sup>, V.V. Fedorchuk<sup>1,3</sup>, V.I. Tishkov<sup>1,3</sup>  
<sup>1</sup>Moscow State Univ. <sup>2</sup>Natl. Res. Ctr. for Hematology <sup>3</sup>Natl. Res. Ctr. of Antibiotics, Moscow, Russia
- 367/79P** Multiple antimicrobial resistance in *Enterococcus faecium* isolated from chickens  
 00:00 O. Petsaris, F. Myszak, M. Gicquel - Bruneau, A. Perrin - Guyomard, F. Humbert, P. Sanders, R. Leclercq  
*Service de Microbiologie, CHU Côte de Nacre, Caen, France*

Thursday jeudi	2	December décembre	00:00 00:00	ROOM Salle	—	POSTER Poster	80P
-------------------	---	----------------------	----------------	---------------	---	------------------	-----

## S. PNEUMONIAE: EPIDEMIOLOGY, SUSCEPTIBILITY

S. PNEUMONIAE: EPIDÉMIOLOGIE, SENSIBILITÉ

- 368/80P** In vitro activity of telithromycin against erythromycin-susceptible and resistant pneumococci.  
 00:00 I. Katsarolis, G. Poulakou, I. Matthaiopoulos, P. Panagopoulos, and. Hellenic Study Group For The Susceptibility Of Streptococcus Pneumoniae 2004  
*4th Department of Internal Medicine, ATTIKON University General Hospital, Athens, Greece*
- 369/80P** Pneumococcal resistance to antibiotics in Bourgogne in 2003  
 00:00 A. Péchinot, S. Valot, J.M. Duez, E. Siebor, C. Neuwirth  
*Laboratoire Bactériologie, CHU Le Bocage, Dijon, France*
- 370/80P** Evolution of antimicrobial-drug resistance of *Streptococcus pneumoniae*(Sp) in the North of France from 2001 to 2003  
 00:00 M. Roussel-delvallez<sup>2</sup>, R. Laporte<sup>2</sup>, F. Delpierre<sup>2</sup>, M. Caillaux<sup>1</sup>, C. Cattoen<sup>1</sup>, V. Chieux<sup>1</sup>, A. Decoster<sup>1</sup>, D. Descamps<sup>1</sup>, N. Gravelines<sup>1</sup>, S. Hendrix<sup>1</sup>, J.C. Herbaut<sup>3</sup>, M. Marcolin<sup>1</sup>, M. Menouar<sup>1</sup>, J.M. Pannecouck<sup>1</sup>, J.G. Paul<sup>1</sup>, C. Roland<sup>1</sup>, S. Samaille<sup>1</sup>, F. Templier<sup>1</sup>, C. Tiry<sup>1</sup>, A. Vachée<sup>1</sup>, M. Vasseur<sup>1</sup>, A. Verhaeghe<sup>1</sup>, R.J. Courcol<sup>2</sup>  
<sup>1</sup>Biologistes des Hôpitaux Généraux du Nord- Pas de Calais <sup>2</sup>Laboratoire de Bactériologie-Hygiène, CHRU Lille <sup>3</sup>LAM BioLille, Lille, France
- 371/80P** Pneumococcus surveillance (ORP-Centre) in the regional Centre in 2003  
 00:00 B. Cattier<sup>1</sup>, M. Adam<sup>6</sup>, J. Akli<sup>3</sup>, P. Amirault<sup>8</sup>, M. Bacheler<sup>4</sup>, L. Bret<sup>9</sup>, M. Cahiez<sup>13</sup>, J. Carbonnelle<sup>7</sup>, F. Cotty<sup>2</sup>, J. Graveron<sup>12</sup>, P. Harriau<sup>14</sup>, P. Laudat<sup>10</sup>, J. Loulergue<sup>1</sup>, D. Poitvin<sup>11</sup>, A. Secher<sup>5</sup>, A. Goudeau<sup>1</sup>  
<sup>1</sup>lab, CH Bourges <sup>2</sup>lab, LABM St Amand M., (18) <sup>3</sup>lab, CH Chartres Le Coudray <sup>4</sup>lab, CH Dreux, (28) <sup>5</sup>lab, CH Vierzon <sup>6</sup>lab, LABM Lescaroux Châteauroux, (36) <sup>7</sup>lab, bactériologie CHU Tours <sup>8</sup>lab, CH Amboise <sup>9</sup>lab, LABM Arnaud Tours <sup>10</sup>lab, LABM Beaumont en V., (37) <sup>11</sup>lab, CH Blois, (41) <sup>12</sup>lab, CH Montargis <sup>13</sup>lab, CHR Orléans <sup>14</sup>lab, LABM La Présentation Fleury Les A., (45), France
- 372/80P** Observatoire du Pneumocoque 1995-2003 : antimicrobial susceptibility of invasive *Streptococcus pneumoniae* among adults in Franche-Comté (France)  
 00:00 P. Dupont<sup>10-11</sup>, I. Patry<sup>10</sup>, J. Schneider<sup>10</sup>, J. Falin<sup>10</sup>, M. Bonnin<sup>7</sup>, L. Bruand<sup>4</sup>, P. Chantelat<sup>9</sup>, C. Febvre<sup>6</sup>, G. Julianne<sup>1</sup>, E. Louvrier<sup>3</sup>, F. Mermet<sup>8</sup>, P. Moritz<sup>5</sup>, N. Petitboulanger<sup>2</sup>, P. Plésiat<sup>10</sup>  
<sup>1</sup>CHG Belfort <sup>2</sup>CHG Dole <sup>3</sup>CHG Gray <sup>4</sup>CHG Lons le Saunier <sup>5</sup>CHG Lure Luxeuil <sup>6</sup>CHG Montbéliard <sup>7</sup>CHG Pontarlier <sup>8</sup>CHG Saint Claude <sup>9</sup>CHG Vesoul <sup>10</sup>CHU Besançon <sup>11</sup>Laboratoire CBM25, Besançon, France
- 372a/80P** Antimicrobial susceptibilities and serotypes of *Streptococcus pneumoniae* isolated from children in Franche-Comté (France) : 1995 - 2003  
 00:00 P. Dupont<sup>10-11</sup>, L. Patry<sup>10</sup>, J. Schneider<sup>10</sup>, J. Falin<sup>10</sup>, M. Bonnin<sup>7</sup>, L. Bruand<sup>4</sup>, P. Chantelat<sup>9</sup>, C. Febvre<sup>6</sup>, G. Julianne<sup>1</sup>, E. Louvrier<sup>3</sup>, F. Mermet<sup>8</sup>, P. Moritz<sup>5</sup>, N. Petitboulanger<sup>2</sup>, P. Plésiat<sup>10</sup>  
<sup>1</sup>CHG Belfort <sup>2</sup>CHG Dole <sup>3</sup>CHG Gray <sup>4</sup>CHG Lons le Saunier <sup>5</sup>CHG Lure-Luxeuil <sup>6</sup>CHG Montbéliard <sup>7</sup>CHG Pontarlier <sup>8</sup>CHG Saint-Claude <sup>9</sup>CHG Vesoul <sup>10</sup>CHU Besançon <sup>11</sup>LABM CBM25, Besançon, France

- 373/80P** **Antibiotic resistance and serotypes of *Streptococcus pneumoniae*: results from the Brittany registry for 2003.**  
 00:00 P.Y. Donnio, S. Mignard, J. Vaucel, M.L. Abalain, M. Anguill, J.P. Aubry, L. Desbordes, M.J. Dufour, J.Y. Esvant, O. Gaillot, F. Gangneux, F. Geffroy, A. Gougeon, J.L. Laborie, C. Lebrun, A. Legac, G. Lelay, A.L. Lerestif-Gautier, A. Le Meur, J. Minet, O. Morvan, P. Plessis, P. Pouedras, J. Rome, D. Tandé, A. Valogne, C. Voisine, J.F. Ygout, (BCB, Bactériocercle Breton)  
*Centres Hospitaliers Généraux & Universitaires, Laboratoires de Microbiologie, Région Bretagne, France*
- 374/80P** **Trends in antimicrobial resistance of *Streptococcus pneumoniae* in the Ile-de-France area in France between 2001 and 2003.**  
 00:00 M.C. Demachy<sup>1</sup>, F. Faibis<sup>1</sup>, E. Varon<sup>3</sup>, And The Group of Microbiologists of Orp Ile-de-France Est<sup>2</sup>  
<sup>1</sup>CH Meaux <sup>2</sup>ORP IDF-EST, Meaux <sup>3</sup>CNR des Pneumocoques, HEGP, Paris, France
- 375/80P** **The pneumococcal observatory of Alsace region: surveillance of penicillin susceptibility of *Streptococcus pneumoniae* in 2003**  
 00:00 A. Gravet<sup>1</sup>, V. Murbach<sup>2</sup>, P. Barrand<sup>3</sup>, A. Boulenc<sup>3</sup>, M. Chabot<sup>5</sup>, D. De Briel<sup>3</sup>, J.M. Delarbre<sup>6</sup>, J.C. Drzewinski<sup>10</sup>, O. Feugeas<sup>10</sup>, J.L. Flipo<sup>11</sup>, J.M. Gathrat<sup>6</sup>, I. Grawey<sup>3</sup>, T. Guedet<sup>10</sup>, A. Heidt<sup>4</sup>, D. Izraelewicz<sup>4</sup>, F. Jehl<sup>2</sup>, P. Kientz<sup>4</sup>, V. Lantz<sup>9</sup>, C. Lemble<sup>7</sup>, L. Linger<sup>2</sup>, C. Monsch<sup>3</sup>, P. Pierrot<sup>6</sup>, D. Riehm<sup>10</sup>, J. Roth<sup>10</sup>, A. Trevoux<sup>6</sup>, F. Tytgat<sup>8</sup>  
<sup>1</sup>Observatoire du Pneumocoque Alsace - Laboratoire de Microbiologie, CH de Mulhouse <sup>2</sup>Institut de Bactériologie, CHU de Strasbourg <sup>3</sup>Colmar <sup>4</sup>Haguenau <sup>5</sup>Lutterbach <sup>6</sup>Mulhouse <sup>7</sup>Sélestat <sup>8</sup>Saverne <sup>9</sup>Soultz <sup>10</sup>Strasbourg <sup>11</sup>Wissembourg, Alsace, France
- 376/80P** **Antibiotic resistance and serogroup analysis of clinical *Streptococcus pneumoniae*(Sp) isolated in 2003 from French children.**  
 00:00 M. Vergnaud<sup>9</sup>, B. Cattier<sup>21</sup>, S. Bourdon<sup>6</sup>, M. Brun<sup>16</sup>, C. Chanal<sup>10</sup>, H. Chardon<sup>1</sup>, M. Chomarat<sup>15</sup>, J. Croizé<sup>12</sup>, M.C. Demachy<sup>2</sup>, P.Y. Donnio<sup>20</sup>, P. Dupont<sup>1</sup>, A. Gravet<sup>3</sup>, B. Grignon<sup>18</sup>, G. Laurans<sup>5</sup>, J. Maugein<sup>8</sup>, A. Pechinot<sup>11</sup>, M.C. Ploy<sup>14</sup>, M. Roussel-delvallez<sup>13</sup>, P.H. Thoreux<sup>4</sup>, E. Varon<sup>22</sup>, V. Vernet-garnier<sup>19</sup>, M. Weber<sup>17</sup>, A.N.D. I.N.V.S Saint Maurice  
<sup>1</sup>CH Aix en Provence <sup>2</sup>CH Meaux <sup>3</sup>CH Mulhouse <sup>4</sup>CH St Brieuc <sup>5</sup>CHU Amiens <sup>6</sup>CHU Angers <sup>7</sup>CHU Besançon <sup>8</sup>CHU Bordeaux <sup>9</sup>CHU Caen <sup>10</sup>CHU Clemont-Ferrand <sup>11</sup>CHU Dijon <sup>12</sup>CHU Grenoble <sup>13</sup>CHU Lille <sup>14</sup>CHU Limoges <sup>15</sup>CHU Lyon <sup>16</sup>CHU Montpellier <sup>17</sup>CHU Nancy <sup>18</sup>CHU Poitiers <sup>19</sup>CHU Reims <sup>20</sup>CHU Rennes <sup>21</sup>CHU Tours <sup>22</sup>C.N.R.P. - H.E.G.P., Paris, France
- 377/80P** **Analysis of epidemic pneumococcal infections in a closed community in Tunisia**  
 00:00 E. Mehiri-zghal<sup>2</sup>, J.W. Decousser<sup>1</sup>, W. Mahjoubi<sup>2</sup>, P. Allouch<sup>1</sup>, N.L. Slim-saidi<sup>2</sup>  
<sup>1</sup>Service d'Hygiène, Centre Hospitalier de Versailles Lechesnay, Paris, France <sup>2</sup>Laboratoire de Microbiologie, Hopital de Pneumologie A. Mami Ariana, Tunis, Tunisia
- 378/80P** **Microbiology of pneumonia in the elderly (PITE) at the university hospital of Montpellier**  
 00:00 F. Raschilas<sup>1</sup>, I. Collet<sup>1</sup>, E. Barbotte<sup>2</sup>, H. Jean-pierre<sup>3</sup>, D. Bonnet<sup>1</sup>, C. Jeandel<sup>1</sup>  
<sup>1</sup>Service de Médecine Interne et Soins Aigus Gériatriques, Centre Antonin Balmès <sup>2</sup>Département d'information médicale <sup>3</sup>Laboratoire de Microbiologie, Hôpital Arnaud de Villeneuve, Montpellier, France
- 378a/80P** **In Vitro Activity of Cefpodoxime (CPD) against *Streptococcus Pneumoniae*(SP) isolated from Adult Respiratory Tract Infections (RTI) in France in 2003**  
 00:00 H.B. Drugeon<sup>2</sup>, N. Moniot-ville<sup>3</sup>, A. Bensalah<sup>1</sup>, And The French Study Group<sup>1</sup>  
<sup>1</sup>Quintiles Levallois-Perret, Levallois-Perret <sup>2</sup>Hôpital Laennec, Nantes <sup>3</sup>Laboratoire Aventis, Paris, France

Thursday jeudi	2	December décembre	00:00 00:00	ROOM Salle	—	POSTER Poster	81P
-------------------	---	----------------------	----------------	---------------	---	------------------	-----

### SURVEILLANCE OF RESISTANCE SURVEILLANCE DE LA RESISTANCE

- 379/81P** **Analysis of the serotype distribution and beta-lactam antibiotic susceptibility of *Streptococcus pneumoniae* isolates recovered from blood, cerebrospinal fluid (CSF) and ear samples in 2003 from five regions of Southern France with regard to the composition of the Prevenar conjugate vaccine.**  
 00:00 M. Brun<sup>3</sup>, C. Segonds<sup>5</sup>, J. Texier-maugein<sup>4</sup>, C. Chanal<sup>1</sup>, C. Romaszko<sup>1</sup>, M.C. Ploy<sup>2</sup>, P. Clavel-batut<sup>5</sup>, G. Chabanon<sup>5</sup>  
<sup>1</sup>Laboratoire de Bactériologie, Hotel-Dieu, Clermont-Ferrand <sup>2</sup>Laboratoire de Bactériologie-Virologie, Hôpital Dupuytren, Limoges <sup>3</sup>Laboratoire de Bactériologie-Virologie, Hôpital Arnaud de Villeneuve, Montpellier <sup>4</sup>Laboratoire de Bactériologie, Hôpital Haut-Levêque, Pessac <sup>5</sup>Laboratoire de Bactériologie-Hygiène, Hôpital de Rangueil, Toulouse, France
- 380/81P** **Evolution of antibiotic resistance of *Streptococcus pneumoniae*(Sp) in French Arc Alpin -Val de Rhône Region in 2001 and in 2003**  
 00:00 J. Croizé<sup>13</sup>, C. Recule<sup>13</sup>, D. Champelovier<sup>13</sup>, S. Bland<sup>1</sup>, P. Clergeau<sup>8</sup>, P. Delmas<sup>5</sup>, D. Fasquelle<sup>10</sup>, V. Gauduchon<sup>4</sup>, M. Giraud<sup>2</sup>, A. Mandjee<sup>7</sup>, P. Marthelet<sup>6</sup>, J. Sartre<sup>11</sup>, J. Tous<sup>3</sup>, J. Thoreux<sup>9</sup>, E. Varon<sup>14</sup>, P. Verger-hirtz<sup>15</sup>, I. Vray<sup>12</sup>  
<sup>1</sup>CH Annecy <sup>2</sup>CH Annemasse <sup>3</sup>CH St Brieuc <sup>4</sup>CH Briançon, Briançon <sup>5</sup>CH Chambéry, Chambéry <sup>6</sup>CH Gap, Gap <sup>7</sup>CHU Grenoble, Grenoble <sup>8</sup>LAM Meylan, Meylan <sup>9</sup>CH Montélimar, Montélimar <sup>10</sup>CNRP, Paris <sup>11</sup>CH Romans, Romans <sup>12</sup>CH Sallanches, Sallanches <sup>13</sup>CH Thonon, Thonon <sup>14</sup>CH Valence, Valence <sup>15</sup>CH Voiron, Voiron, France
- 381/81P** **Evolution of the antibiotic resistance of *S. pneumoniae* from 1999 to 2003: Results from the Rhône-Forez Pneumococcus Regional Registry (PRR).**  
 00:00 M. Agallal, I. Fredenucci, G. Barbé, R. Bercion, Y. Boucaud-maitre, B. Boyer, A. Carricajo, M. Célard, F. Delubac, D. Fèvre, A.M. Freydère, B. Gravagna, M. Helfre, M.N. Letouzey, H. Lelièvre, R. Meley, J.D. Perrier-gros-claude, N. Ploton, N.E. Reverdy, A. Ros, C. Roure, O. Sabot, S. Smati, J. Thierry, E. Zaoui, M. Chomarat  
*Laboratoire Bactériologie CHLS, ORP Rhône-Forez, Peirre-Bénite, France*

- 382/81P** In vitro activity of levofloxacin (LVX) against *Streptococcus pneumoniae* (Spn) and detection of fluoroquinolone(FQ)-reduced susceptibility strains in france during 2003 : third year of survey.  
 00:00 E. Varon<sup>3</sup>, H. Drugeon<sup>2</sup>, S. Grondin<sup>3</sup>, L. Gutmann<sup>3</sup>, The Multicenter Group<sup>1</sup>  
<sup>1</sup>., The Multicenter Group<sup>2</sup>Department of Microbiology, Hotel Dieu Hospital, Nantes <sup>3</sup>National Reference Center for Pneumococci, European Georges Pompidou Hospital, Paris, France
- 383/81P** Comparative in vitro activity of telithromycin (TEL) against viridans group streptococci (VGS)  
 00:00 C.J. Soussy<sup>1</sup>, H.B. Drugeon<sup>2</sup>, C. Lascols<sup>1</sup>, C. Dib<sup>3</sup>, N. Moniot-ville<sup>3</sup>  
<sup>1</sup>Laboratoire de Bactériologie-Virologie-Hygiène, CHU Henri Mondor, Créteil <sup>2</sup>Hôpital Laennec, Nantes <sup>3</sup>Laboratoire Aventis, Paris, France
- 384/81P** In vitro activity of pristinamycin against *Streptococcus pneumoniae* isolated in France in 2003 from respiratory tract infections  
 00:00 H.B. Drugeon<sup>2</sup>, N. Moniot-ville<sup>3</sup>, A. Bensalah<sup>1</sup>, and the French Study Group  
<sup>1</sup>Quintiles Levallois Perret, Levallois-Perret<sup>2</sup>Hôpital Laennec, Nantes <sup>3</sup>Laboratoire Aventis, Paris, France
- 385/81P** Macrolide resistance among pharyngeal viridans streptococci in healthy individuals.  
 00:00 M.S. Hernández Iglesias<sup>1</sup>, M.R. Marín Jiménez<sup>1</sup>, J.L. Muñoz Bellido<sup>1,2</sup>, J.A. García Rodríguez<sup>1,2</sup>  
<sup>1</sup>Departamento de Microbiología, Hospital Universitario de Salamanca<sup>2</sup>Departamento de Medicina Preventiva, Salud Pública y Microbiología Médica., Universidad de Salamanca, Salamanca, Spain
- 386/81P** Profile of antibiotic resistance in *S. pneumoniae* for community-acquired pneumonia.  
 00:00 K. Alena<sup>1,1</sup>, Karpov. Igor<sup>2</sup>, Kazatchenko. Maja<sup>1</sup>  
<sup>1</sup>Infectious Diseases, President's Hospital <sup>2</sup>Infectious Diseases, State Medical University, Minsk, Belarus
- 387/81P** Clarithromycin (CLA) efficacy and potency in an era of increased macrolide-resistant *Streptococcus pneumoniae* (Spn)  
 00:00 K. Devcich, C. Olson, D. Shortridge, G. Notario  
<sup>1</sup>Anti-Infectives, GPRD, Abbott Laboratories, Abbott Park, IL, United States
- 388/81P** Susceptibility to penicillin of *Streptococcus pneumoniae* isolates from cerebrospinal fluid, 1991-2003  
 00:00 O. Dulovic, M. Jovanovic, B. Milosevic, J. Dragojlovic, E. Gvozdenovic  
<sup>1</sup>Neuroinfections, Institute for Infectious and Tropical Diseases, Belgrade, Yougoslavia
- 389/81P** Comparative in vitro activity of cefprozil against respiratory isolates of *Streptococcus pneumoniae*, *Haemophilus influenzae*, and *Moraxella catarrhalis* results of a multicenter study  
 00:00 U. Hasdemir<sup>4</sup>, D. Gur<sup>2</sup>, H. Akgun<sup>3</sup>, F.P. Study Group<sup>1</sup>  
<sup>1</sup>Selcuk University, Osman Gazi University, Numune Hospital, Istanbul University, Ondokuz Mayis University, Erciyes University, Ege University, Akdeniz University<sup>2</sup>Microbiology, Hacettepe University, Children Hospital, Ankara <sup>3</sup>Antibiotics, Bristol Myers Squibb <sup>4</sup>Microbiology, Marmara University, School of Medicine, Istanbul, Turkey
- 390/81P** Serotypes and antibiotic resistance of *Streptococcus pneumoniae* isolated from children and adults in Northwestern Greece  
 00:00 S. Levidiotou, V. Papatolis, G. Vrioni, C. Pappa, H. Gesouli, D. Papamichail  
<sup>1</sup>Department of Microbiology, Medical School, University of Ioannina, Ioannina, Greece
- 391/81P** Phenotypic and genotypic characterization of *Streptococcus pneumoniae* resistant to macrolides, lincosamides and streptogramins  
 00:00 I. Boutiba-ben Boubaker, M. Rachdi, M. Saidani, R. Ghazzi, A. Kammoun, S. Ben Redieb  
<sup>1</sup>Laboratoire "Résistance aux antibiotiques", Faculté de Médecine, Tunis, Tunisia
- 392/81P** Serotype and subtype characterization of Group B streptococcus in Hong Kong.  
 00:00 M. Ip<sup>2</sup>, E.S.C. Cheuk<sup>2</sup>, M.H.Y. Tsui<sup>3</sup>, F. Kong<sup>1</sup>, T.N. Leung<sup>3</sup>, G.L. Gilbert<sup>1</sup>, D.J. Lyon<sup>2</sup>  
<sup>1</sup>Centre for Infectious Diseases and Microbiology Laboratory Services, Institute of Clinical Pathology and Medical Research, Westmead, NSW, Australia <sup>2</sup>Dept of Microbiology <sup>3</sup>Dept of Obstetrics and Gynaecology, Chinese University of Hong Kong, Shatin, Hong Kong, China
- 393/81P** Molecular characterization of fluoroquinolone-resistance determinants in *Streptococcus pneumoniae* in Hong Kong  
 00:00 M. Ip, D.J. Lyon, S.L. Chau, L. Tsang, A.F.B. Cheng  
<sup>1</sup>Dept of Microbiology, Chinese University of Hong Kong, Shatin, Hong Kong, China
- 394/81P** Incidence of penicillin nonsusceptible *Streptococcus pneumoniae* clinical isolates in Hungary  
 00:00 B. Libisch, M. Gacs, T. Tirczka, Z. Vegh, M. Fuzi  
<sup>1</sup>Department of Bacteriology, National Center for Epidemiology, Budapest, Hungary
- 395/81P** The evolution of resistance to beta-lactams of *Streptococcus pneumoniae* isolated in Romania between 1973-2003  
 00:00 M. Pana<sup>4</sup>, M. Ghita<sup>4</sup>, V. Ungureanu<sup>4</sup>, R. Papageorghe<sup>5</sup>, N. Popescu<sup>6</sup>, O. Dorobat<sup>10</sup>, I. Nistor<sup>8</sup>, S. Iacob<sup>1</sup>, M. Andrei<sup>7</sup>, S. Botea<sup>1</sup>  
<sup>1</sup>Clinical Lab., M.Bals Institute, Portugal <sup>2</sup>Microbiology <sup>3</sup>Microbiology, Cantacuzino Institute <sup>5</sup>Clinical Lab. <sup>6</sup>Clinical Lab., Coltea Hospital <sup>7</sup>Clinical Lab., Emergency Hospital <sup>8</sup>Clinical Lab., Gr.Alexandrescu Hospital <sup>9</sup>Clinical Lab., M.Bals Institute <sup>10</sup>Clinical Lab., V.Babes Hospital, Bucharest, Romania
- 396/81P** A comparison of cefprozil, clarithromycin, amoxicillin / clavulanate and benzathine penicillin G in the treatment of group A beta-hemolytic streptococcal pharyngitis. Advantage of cefprozil with less inhibitory effect on alpha-hemolytic streptococci in normal throat flora  
 00:00 I. Yildirim<sup>1</sup>, M. Ceyhan<sup>1</sup>, D. Gür<sup>2</sup>, I. Kaymakoglu<sup>2</sup>  
<sup>1</sup>Pediatric infectious diseases <sup>2</sup>Pediatric microbiology laboratory, Hacettepe university medical school, Ankara, Turkey

- 397/81P** **Antimicrobial resistance profiles of *Streptococcus pneumoniae* isolated in the infectious diseases hospital of Algiers.**  
 00:00 M.N. Ouar-korichi, D. Mohammedi, N. Kerrad, D. Ouerdane, S. Kara, S. Khaled  
*Service de Microbiologie, EHS EL LAADI FLICI (El Kettar), Alger, Algeria*
- 398/81P** **Antimicrobial susceptibility of *Streptococcus pneumoniae* in Tunisia: results of a multicentric study (2000-2003)**  
 00:00 F. Mahjoubi, D. Mkaouar, H. Smaoui, I. Boutiba, A. Kechrid, A. Hammami, S. Ben Redjeb  
*Laboratoire "Résistance aux Antibiotiques", Faculté de Médecine, Tunis, Tunisia*
- 399/81P** **Nasopharyngeal *Streptococcus pneumoniae* colonization and antibiotic resistance rates in different age groups in Izmir-Turkey**  
 00:00 T. Huseyin, N. Cakir, A. Yuce  
*infectious diseases and clinical microbiology, dokuz eylul university, Izmir, Turkey*
- 400/81P** **Susceptibility of *Pseudomonas aeruginosa* to antimicrobials: a 2004 French multicenter hospital study**  
 00:00 M. Roussel-delvallez<sup>6</sup>, C. Bébérard<sup>1</sup>, P. Brisou<sup>14</sup>, R. Bismuth<sup>2</sup>, J. Caillou<sup>8</sup>, C. Chanal<sup>5</sup>, M. Chomarat<sup>11</sup>, F. Delpierre<sup>6</sup>, R. Fabre<sup>12</sup>, R. Leclercq<sup>4</sup>, H. Marchandin<sup>7</sup>, C. Muller<sup>9</sup>, C. Poyart<sup>10</sup>, P. Plésiat<sup>3</sup>, C. Segonds<sup>15</sup>, J.M. Scheftel<sup>13</sup>, J.D. Cavallo<sup>12</sup>  
<sup>1</sup>CHU Jean-Minjoz, Besançon<sup>2</sup>CHR Pellegrin, Bordeaux<sup>3</sup>CHRU Côte-de-nacre, Caen<sup>4</sup>CHU Gabriel-Montpied, Clermont-Ferrand<sup>5</sup>CHRU Calmette, Lille<sup>6</sup>CHU Arnaud de Villeneuve, Montpellier<sup>7</sup>CHU Laennec, Nantes<sup>8</sup>CHU Bichat<sup>9</sup>CHU Cochin<sup>10</sup>Pitié-Salpêtrière, Paris<sup>11</sup>CH Lyon Sud, Pierre-Bénite<sup>12</sup>HIA Bégin, Saint-Mandé<sup>13</sup>UFR des Sciences médicales, Strasbourg<sup>14</sup>HIA Saint-Anne, Toulon<sup>15</sup>CHU Rangueil, Toulouse, France
- 401/81P** **Nine cases of lung colonisation with *Burkholderia gladioli*: microbiological features and antimicrobial susceptibility profiles.**  
 00:00 C. Segonds, G. Chabanon  
*Observatoire Burkholderia cepacia/Vaincre la Mucoviscidose, Hôpital Rangueil, Toulouse, France*
- 402/81P** **In vitro susceptibility of *Pasteurella* spp. isolated from humans between 1996 and 2003 in Nancy**  
 00:00 C. Lion<sup>1-2</sup>, M.C. Conroy<sup>1</sup>, A.M. Carpentier<sup>2</sup>, A. Lozniewski<sup>1-2</sup>  
<sup>1</sup>CHU, Laboratoire du Bactériologie, 54000 Nancy<sup>2</sup>Faculté de Médecine de Nancy, Laboratoire de Bactériologie-Virologie, UMR-CNRS 7565, 54500 Vandoeuvre-Lès-Nancy, France
- 403/81P** **Spread of a *Klebsiella pneumoniae* strain producing a plasmid-mediated ACC-1 AmpC β-lactamase in a teaching hospital admitting disabled patients**  
 00:00 S. Ohana<sup>4</sup>, V. Leflon<sup>1</sup>, E. Ronco<sup>4</sup>, M. Rottman<sup>4</sup>, D. Guillemot<sup>5</sup>, S. Lortat-jacob<sup>2</sup>, P. Denys<sup>2</sup>, G. Loubert<sup>3</sup>, M.H. Nicolas-chanoine<sup>1</sup>, J.L. Gaillard<sup>4</sup>, C. Lawrence<sup>4</sup>  
<sup>1</sup>Laboratoire de microbiologie, Hôpital A. Paré, Boulogne<sup>2</sup>Département de médecine physique et réadaptation<sup>3</sup>Département de réanimation chirurgicale<sup>4</sup>Laboratoire de microbiologie, Hôpital R. Poincaré, Garches<sup>5</sup>Unité des agents antibactériens, Institut Pasteur, Paris, France
- 404/81P** **Carbapenem-hydrolysing VIM-1 from a Nosocomial Isolate of *Pseudomonas aeruginosa* in the teaching Hospital of Grenoble (France)**  
 00:00 C. Recule<sup>2</sup>, J. Delmas<sup>1</sup>, D. Sirot<sup>1</sup>, J. Croizé<sup>2</sup>, M. Maurin<sup>2</sup>, P.A. Falzonnet<sup>2</sup>, M.R. Mallaret<sup>3</sup>, B. Imbert<sup>4</sup>  
<sup>1</sup>Bactériologie, CHU Clermont Ferrand, Clermont Ferrand<sup>2</sup>Bactériologie<sup>3</sup>Hygiène Hospitalière<sup>4</sup>Médecine Interne, CHU Grenoble, Grenoble, France
- 405/81P** **Methicillin resistant *staphylococcus aureus* bacteraemia: six years of survey in a French general hospital**  
 00:00 M. Thibault, G. Blanchard, P. Martres  
*Laboratoire de Bactériologie-Virologie-Hygiène, Centre Hospitalier René Dubos, Pontoise, France*
- 406/81P** **In vitro activity of temocillin and other antimicrobials agents against extended-spectrum β-lactamase producing *Escherichia coli***  
 00:00 H. Rodriguez Villalobos, S. Cuvelier, R. De Mendonça, J. Francard, C. Nonhoff, M. Struelens  
*Microbiology Department, Hôpital Erasme-ULB, Bruxelles, Belgium*
- 407/81P** **Emergence of CTX-M-15 beta-lactamase in clinical isolates of Enterobacteriaceae from three hospitals in Lisbon.**  
 00:00 A. Duarte, T. Conceição, A. Brizio, S. Vasco, M. Serejo  
*Microbiology, Faculty of Pharmacy, Lisboa, Portugal*
- 408/81P** **First report of metallo-beta-lactamase production in *P.aeruginosa* strains isolated in different regions of Russia**  
 00:00 L. Stratchounski, V. Kretchikov, I. Edelshtein, I. Kozlova, M. Edelshtein  
*Institute of Antimicrobial Chemotherapy, Smolensk, Russia*
- 409/81P** **Antimicrobial susceptibility of *Achromobacter xylosoxidans*(AXX) isolated from patients with cystic fibrosis (CF).**  
 00:00 J. Caillou, C. Jacqueline, X. Wuilleme, V. Le Mabecque, A.F. Miegeville, A. Haloun, G. Potel  
*UPRES EA 1156, Lab. Antibiose, Nantes, France*
- 410/81P** **Epidemiology of multiresistant *K.pneumoniae* cases using Serial Temporal Models**  
 00:00 O. Lupi<sup>2-1</sup>, T. Campos<sup>1</sup>, E. Faria<sup>1</sup>, L. Kalab<sup>1</sup>, B. Pereira<sup>3</sup>, P. Brazil<sup>2</sup>  
<sup>1</sup>ICT, Hospital Barra D'or<sup>2</sup>Medicina Tropical, Instituto Oswaldo Cruz<sup>3</sup>NESC, Universidade Federal do Rio de Janeiro, Rio De Janeiro, Brazil

- 411/81P Characterization of *Pseudomonas aeruginosa* strains isolated from bacteraemia in a French multicentric study conducted in 1999 and 2001: association between *exoU* and *exoS* genes and O serotypes.**
- 00:00 P. Berthelot<sup>2</sup>, F. Grattard<sup>2</sup>, B. Pozzetto<sup>2</sup>, P. Plésiat<sup>1</sup>, A.N.D. GESPA : Groupe d'Etudes des septicémies à *P. aeruginosa*  
<sup>1</sup>Laboratory of microbiology, University hospital, Besançon <sup>2</sup>Laboratory of microbiology, University Hospital, Saint-Etienne, France
- 412/81P Comparative analysis of antimicrobial susceptibility of *Pseudomonas aeruginosa* nosocomial sinusitis and other nosocomial infections with the same epidemiological characteristics**
- 00:00 O. Lupi<sup>1,2</sup>, T. Campos<sup>2</sup>, E. Faria<sup>2</sup>, L. Kalab<sup>2</sup>, J. Saluh<sup>2</sup>, J. Verdeal<sup>2</sup>  
<sup>1</sup>Medicina Tropical, Fundação Oswaldo Cruz <sup>2</sup>ICT/ICU, Hospital Barra D'or, Rio De Janeiro, Brazil
- 413/81P Antibiotic resistance among isolates of *Enterobacteriaceae* and *Acinetobacter baumannii* in health care centers served by private laboratories: a 6-month study in the Aquitaine area.**
- 00:00 J. Fischer<sup>1</sup>, F. Grobost<sup>1</sup>, B. Dutilh<sup>1</sup>, J.F. Couture<sup>1</sup>, J. Jullin<sup>1</sup>, S. Fourmaux<sup>1</sup>, A. Ducastaing<sup>1</sup>, I. Lagrange<sup>1</sup>, P. Noury<sup>1</sup>, H.P. Doermann<sup>1</sup>, C. André<sup>2</sup>, C. Recondo<sup>2</sup>, C. Arpin<sup>2</sup>, C. Quentin<sup>1,2</sup>  
<sup>1</sup>Aquitaine Network, Private Laboratories <sup>2</sup>EA 525, Laboratory of Microbiology, University of Bordeaux 2, Faculty of Pharmacy, Bordeaux, France
- 414/81P Susceptibility of *Escherichia coli* to the amoxicillin-clavulanate combination: which recommendations should be used to provide relevant information to clinicians?**
- 00:00 X. Bertrand<sup>2</sup>, I. Patry<sup>1</sup>, D. Hocquet<sup>1</sup>, P. Plésiat<sup>1</sup>, D. Talon<sup>2</sup>  
<sup>1</sup>Bactériologie <sup>2</sup>Hygiène hospitalière, CHU Besançon, Besançon, France
- 415/81P Efficacy of erythromycin and spiramycin on periopathogens in aggressive periodontitis. An *in vitro* comparative study.**
- 00:00 M. Sixou, N. Lakhssassi  
Service d'Epidémiologie, Université Paul-Sabatier. Faculté Chirurgie Dentaire, Toulouse, France
- 416/81P Antimicrobial susceptibility of bacterial strains isolated from patients with bloodstream infections : a French prospective national survey.**
- 00:00 J.W. Decousser, F. Picot, C. Hanoun, P. Allouch, C.O.L. Bvh  
Hygiène Hospitalière, C.H. Versailles, Le Chesnay, France
- 417/81P *In vitro* susceptibility of Ertapenem (Invanz®) on community-acquired Gram negative bacilli isolated from respiratory, abdominal and peritoneal specimen collected in 46 clinical bacteriology laboratories in France during 2003.**
- 00:00 Y. Péan<sup>2</sup>, R. Gauzit<sup>1</sup>, J. Robert<sup>4</sup>, O. Lalaude<sup>3</sup>  
<sup>1</sup>Intensive Care Unit, Jean Verdier hospital, Bondy <sup>2</sup>Microbiology, L'Institut Mutualiste Montsouris <sup>3</sup>Merck Sharp & Dohme-Chibret <sup>4</sup>Microbiology, Pitié-Salpêtrière hospital, Paris, France
- 418/81P *In vitro* susceptibility of Ertapenem (Invanz®) on community-acquired Gram positive cocci isolated from respiratory, abdominal and peritoneal specimen collected in 46 clinical bacteriology laboratories in France during 2003.**
- 00:00 E. Varon<sup>2</sup>, Y. Péan<sup>3</sup>, R. Gauzit<sup>1</sup>, J. Robert<sup>5</sup>, O. Lalaude<sup>4</sup>  
<sup>1</sup>Intensive Care Unit, Jean Verdier hospital, Bondy <sup>2</sup>Centre National de Référence des Pneumocoques <sup>3</sup>Microbiology, L'Institut Mutualiste Montsouris <sup>4</sup>Merck Sharp & Dohme-Chibret <sup>5</sup>Microbiology, Pitié-Salpêtrière hospital, Paris, France
- 419/81P Activity of several antibiotics against *Legionella pneumophila* Paris strains in broth and in THP-1 cells**
- 00:00 N. Roch, P.A. Falconnet, J. Croize, M. Maurin  
Service de bactériologie-virologie, CHU de Grenoble, Grenoble, France
- 420/81P Antibiotic resistance in bacteria isolated from blood-cultures in French teaching hospitals in 2003.**
- 00:00 M. Archambaud<sup>6</sup>, L. Armand Lefebvre<sup>1,3</sup>, F. Bert<sup>8</sup>, P.Y. Donnio<sup>5</sup>, P. Girardo<sup>12</sup>, B. Heym<sup>1</sup>, M.E. Juvin<sup>3</sup>, V. Lalande<sup>15</sup>, P. Legrand<sup>9</sup>, J.P. Romazko<sup>1</sup>, E. Ronco<sup>10</sup>, M. Roussel Delvallez<sup>2</sup>, V. Vernet Garnier<sup>4</sup>, R.P. Gilibert<sup>11-12</sup>, C.J. Soussy<sup>9</sup>, V. Jarlier<sup>14</sup>, D. Trystram<sup>14</sup>  
<sup>1</sup>CHU Clermont-Ferrand <sup>2</sup>CHU Lille <sup>3</sup>CHU Nantes <sup>4</sup>CHU Reims <sup>5</sup>CHU Rennes <sup>6</sup>CHU Toulouse <sup>7</sup>Hôpital Ambroise-Pare, Boulogne / Seine <sup>8</sup>CHU Beaujon, Clichy <sup>9</sup>CHU Henri-Mondor, Creteil <sup>10</sup>Hôpital Raymond Poincaré, Garches <sup>11</sup>Association Panoart <sup>12</sup>CHU Edouard Herriot, Lyon <sup>13</sup>CHU Bichat-CI-Bernard <sup>14</sup>CHU Pitié-Salpêtrière <sup>15</sup>CHU St-Antoine, Paris, France
- 421/81P Patterns of resistance to beta-lactam antibiotics in *Escherichia coli* isolates**
- 00:00 S. Réjiba<sup>1</sup>, S. Belhadj<sup>1</sup>, A. Kechrid<sup>2</sup>, A.O. Bel Hadj.<sup>1</sup>  
<sup>1</sup>Laboratoire de Biochimie et Technobiologie, Faculté des Sciences de Tunis <sup>2</sup>Laboratoire de Bactériologie, Hôpital d'Enfants, Tunis, Tunisia
- 422/81P Blessed water: bacteriological quality of drinking water obtained from mosques in Tripoli-Libya**
- 00:00 K.S. Ghenghesh, K. Belhaj, A. Algoui, E. Alturki, A. Eltomi  
Dept. of Medical Microbiology, Faculty of Medicine, Al-Fateh University, Tripoli, Libya
- 423/81P Investigating the distribution of antibiotic resistance across Europe by the use of a macroarray system.**
- 00:00 A.J. Patterson, H.J. Flint, K.P. Scott, "ARTRADI project: European contract QLK2-CT-2002-00843"  
Gut Microbiology and Immunology, The Rowett Research Institute, Aberdeen, United Kingdom
- 424/81P Erythromycin,clindamycin and tetracycline resistance of *Propionibacterium acnes* strains after antibiotic treatment**
- 00:00 H.B. Hrisi Bahar, M.M.T. Müzeyyen Mamal Torun  
Microbiology & Clinical Microbiology, Istanbul University, Istanbul, Turkey

- 425/81P** **Antimicrobial susceptibility variation of anaerobic periopathogens in aggressive periodontitis. An inter-individual & intra individual variability study.**  
 00:00 N. Lakhssassi, M. Sixou  
*Service d'Epidémiologie, Université Paul-Sabatier. Faculté Chirurgie Dentaire, Toulouse, France*
- 426/81P** **Susceptibility of *Borrelia afzelii* strains to antimicrobial agents**  
 00:00 E. Ruzic - Sabljic<sup>1</sup>, T. Podreka<sup>1</sup>, V. Maraspin<sup>2</sup>, F. Strle<sup>2</sup>  
<sup>1</sup>Institute of Microbiology and Immunology, Medical Faculty <sup>2</sup>Department of Infectious Diseases, University Medical Centre, Ljubljana, Slovenia
- 427/81P** **Prevalence of nontuberculous mycobacteria species in cystic fibrosis: a prospective study in three Parisian centers**  
 00:00 C. Pierre-audigier<sup>5</sup>, A. Ferroni<sup>5</sup>, I. Sermet-gaudelus<sup>4</sup>, M. Le Bourgeois<sup>4</sup>, C. Offredo<sup>5</sup>, H. Vu-thien<sup>3</sup>, B. Fauroux<sup>2</sup>, P. Mariani<sup>7</sup>, A. Munck<sup>6</sup>, E. Bingen<sup>7</sup>, D. Guillemot<sup>8</sup>, G. Quesne<sup>5</sup>, V. Vincent<sup>9</sup>, P. Berche<sup>5</sup>, J.L. Gaillard<sup>1</sup>  
<sup>1</sup>Laboratoire de Microbiologie, Hôpital Raymond Poincaré, Garches <sup>2</sup>Département de Pédiatrie <sup>3</sup>Laboratoire de Microbiologie, Hôpital Armand Trousseau <sup>4</sup>Département de Pédiatrie <sup>5</sup>Laboratoire de Microbiologie, Hôpital Necker-Erfants Malades <sup>6</sup>Département de Pédiatrie <sup>7</sup>Laboratoire de Microbiologie, Hôpital Robert Debré <sup>8</sup>Centre de Ressources en Biostatistiques, Épidémiologie et Pharmacoépidémiologie <sup>9</sup>Centre National de Référence des Mycobactéries, Institut Pasteur, Paris, France
- 428/81P** **Antimicrobial resistance in patients treated for cancer at medical dept. of St. Elizabeth Cancer Institute: Results from Jun 1999 till May 2002.**  
 00:00 O. Babelova, R. Babela, V. Krcmery  
*School of Public Health, University of Trnava, Trnava, Slovakia*
- 429/81P** **Bacteremia caused by *Prevotella* sp. with reduced susceptibility to metronidazole**  
 00:00 F. Mory<sup>1</sup>, J.P. Carlier<sup>3</sup>, M. Thouvenin<sup>2</sup>, H. Schuhmacher<sup>4</sup>, A. Lozniewski<sup>1</sup>  
<sup>1</sup>CHU, Laboratoire de Bactériologie, Nancy <sup>2</sup>CH, Laboratoire de Biologie, Neufchâteau <sup>3</sup>Institut Pasteur, CNR des Bactéries Anaérobies, Paris <sup>4</sup>CHU, Service des Maladies Infectieuses et Tropicales, Vandoeuvre-Les-Nancy, France
- 430/81P** **Isolation, identification and antimicrobial resistance patterns of *E. coli* isolated from chicken flocks**  
 00:00 A. Nasirian, R. Rafiei Tabatabaei  
*Microbiology, Azad University, Tehran, Iran*
- 431/81P** **Indicators of antimicrobial usage and resistance using aggregated data in 9 ICUs (intensive-care units) over a 3-year period**  
 00:00 L. Maulin<sup>1</sup>, A. Lepape<sup>1</sup>, S. Tigaud<sup>1,2</sup>, M. Chomarat<sup>1</sup>, A. Jolivet<sup>1</sup>, D. Peyramond<sup>1</sup>, C. Chidiac<sup>1</sup>, and the members of the Antimicrobial Committee of Hospices Civils De Lyon and the ICU Study Group  
<sup>1</sup>Antimicrobial Committee <sup>2</sup>Observatoire du Collège de Bactériologie et Virologie, Hospices Civils de Lyon, Lyon, France
- 432/81P** **Effect of fusafungine on normal oropharyngeal and faecal commensal microflora in healthy volunteers**  
 00:00 B. Rouveix<sup>4</sup>, Y. Donazollo<sup>2</sup>, Y. Guez<sup>1</sup>, H. Drugeon<sup>3</sup>  
<sup>1</sup>IRIS, Courbevoie <sup>2</sup>Optimed Clinical Research, Gieres <sup>3</sup>Service de Bactériologie, CHRU Hôtel-Dieu, Nantes <sup>4</sup>Service de Pharmacologie Clinique, GH Cochin-St Vincent de Paul, Paris, France
- 432a/81P** **Evaluation of the *in vitro* activity of fusafungine**  
 00:00 R. Leclercq, M. Auzou  
*Université de Caen, Caen, France*
- 433/81P** ***Helicobacter pylori* colonization status in outpatients with gastroduodenal diseases**  
 00:00 L. Ivanova, T. Stoeva  
*Microbiology and Virology, Medical University, Varna, Bulgaria*
- 434/81P** **Aetiology of community-acquired pneumonia in children**  
 00:00 L.G. Boronina  
*Ural State Medical Academy, Yekaterinburg, Russia*
- 435/81P** **Antimicrobial susceptibility of *Helicobacter pylori* strains isolated from children and adults in Poland during 2001 - 2003 – multicentre study**  
 00:00 K. Dzierzanowska - Fangrat<sup>3</sup>, E. Rozynek<sup>3</sup>, P. Jozwiak<sup>3</sup>, D. Celinska - Cedro<sup>3</sup>, M. Jarosz<sup>4</sup>, J. Pawlowska<sup>2</sup>, A. Budzynska<sup>1</sup>, D. Dzierzanowska<sup>3</sup>  
<sup>1</sup>Gastroenterol, Silesian Academy of Medicine, Katowice <sup>2</sup>Microbiol, District Hospital, Plock <sup>3</sup>Clin Microbiol, Gastroenterol, Children's Memorial Health Institute <sup>4</sup>Gastroenterol, Food and Nutrition Institute, Warsaw, Poland

**RESISTANCE IN GRAM NEGATIVE BACILLI**  
**RÉSISTANCE CHEZ LES BACILLES À GRAM NÉGATIF**

- 436/82P** Antimicrobial resistance of gram-negative bacilli isolated from nosocomial infections:comparison of before and after national antimicrobial control program in hospitals  
00:00  
A. Wilke, H. Uckardes, Z. Yumuk, S. Gundes, M. Meric  
*Infectious Diseases and Clinical Microbiology, Kocaeli University Hospital, Izmit, Turkey*
- 437/82P** Distribution of extended-spectrum beta-lactamases in clinical isolates of Gram-negative bacteria at Hotel Dieu de France, a university hospital in Lebanon  
00:00  
A. Adaime<sup>2</sup>, S. Lebel<sup>1</sup>, T. Lambert<sup>1</sup>, D. Karam Sarkis<sup>2-3</sup>  
<sup>1</sup>Faculté de Pharmacie, Université Paris XI, Châtenay-Malabry, France <sup>2</sup>Faculté de Pharmacie, Université Saint Joseph <sup>3</sup>Laboratoire de Microbiologie, Hôpital Hôtel Dieu de France, Beyrouth, Lebanon
- 438/82P** Emerging colistin resistance (COL R) in *Klebsiella pneumoniae* strains isolated from intensive care unit (ICU) patients.  
00:00  
G. Poulakou<sup>2</sup>, F.V. Kontopidou<sup>2</sup>, A. Antoniadou<sup>2</sup>, M. Souli<sup>2</sup>, P. Kopterides<sup>1</sup>, I. Galani<sup>2</sup>, A. Armaganidis<sup>1</sup>, H. Giamarellou<sup>2</sup>  
<sup>1</sup>2nd Department of Intensive Care <sup>2</sup>4th Department of Internal Medicine, ATTIKON University General Hospital, Athens University Medical School, Athens, Greece
- 439/82P** Antimicrobial resistance of most frequently isolated bacterial pathogens from patients in 5 ICUs for the period January 2002,2003 to June 2004  
00:00  
K. Bojkova, T. Stoeva, V. Kaludova, V. Kamenova, V. Russev  
*Microbiology and Virology, Medical University, Varna, Bulgaria*
- 440/82P** Nosocomial infections to *Acinetobacter* and resistance to antibiotics  
00:00  
C.H. Bentchouala, H. Alleg, K. Benlabeled, H. Laouar, A. Lezzar, F. Smati  
*Microbiologie, Laboratoire de Microbiologie CHU Ben Badis, Constantine, Algeria*
- 441/82P** Evolution of *Acinetobacter baumannii* susceptibility to 8 antimicrobials during a three years period.  
00:00  
E. Garcia-peñuela, T. Alarcón, D. Monclús, M.S. Abanades, M. Serrano, A. Perkins, M. López-brea  
*Microbiology, Hospital Univ. de la Princesa, Madrid, Spain*
- 442/82P** Occurrence of imipenem resistant *Acinetobacter baumanii* ICU Isolates in a University Hospital  
00:00  
R. Vatcheva-dobrevsky, J. Doncheva, E. Savov  
*Clinical Microbiology, Military Medical Academy, Sofia, Bulgaria*
- 443/82P** Resistance of *P.aeruginosa* strains in intensive care unit (ICU) of 1000-beds Cancer Hospital  
00:00  
N.V. Dmitrieva, E.S. Malysheva, E.V. Kulaga, Z.V. Volkova, S.P. Sviridova, I.N. Petukhova  
*NN Blokhin Cancer Res Ctr, Moscow, Russia*
- 444/82P** Imipenem resistance of *Pseudomonas aeruginosa* isolates from a Polish paediatric hospital  
00:00  
J. Patzer, D. Dzierzanowska  
*Clinical Microbiology and Immunology, Children's Memorial Health Institute, Warsaw, Poland*
- 445/82P** Characterization of extended-spectrum beta-lactamases in *Pseudomonas aeruginosa*.  
00:00  
L. Wybo, I. Mast, G. Muldermans, D. Piérard, S. Lauwers  
*Microbiology, A.Z. Vrije Universiteit Brussel, Brussels, Belgium*

**BORRELIAE, BRUCELLAE, PASTEURELLAE, RICKETTSIAE, TYPHUS ETC.**  
**BORRELIAE, BRUCELLAE, PASTEURELLAE, RICKETTSIAE, TYPHUS ETC.**

- 446/83P** Retrospective study of Lyme borreliosis positive serologies in 2003  
00:00  
E. Ferquel<sup>2</sup>, D. Postic<sup>2</sup>, S. Trombert-Paolantoni<sup>1</sup>  
<sup>1</sup>95066, Laboratoire Pasteur-Cerba, Cergy Pontoise<sup>2</sup>75015, Institut Pasteur, Paris, France
- 447/83P** Acute brucellosis: Do we need to screen family members?  
00:00  
S. Alsubaie, M. Almuneef, M. Alshaalan, H. Balkhy, E. Albanyan, S. Alola, B. Alotaibi, Z. Memish  
*Departments of Pediatrics, Infection Prevention and Control, and Internal Medicine, King Abdulaziz Medical City-King Fahad National Guard Hospital, Riyadh, Saudi Arabia*

<b>448/83P</b>	<b>Epidemic of human brucellosis in Ain Tagrourt Algeria.</b>
00:00	A. Lachebeb <sup>2</sup> , A. Ouyahia <sup>2</sup> , S. Mechakra <sup>2</sup> , B. Nouasria <sup>2</sup> , W. Guenif <sup>2</sup> , A. Gasmi <sup>2</sup> , M. Tiouri <sup>2</sup> , M. Houari <sup>2</sup> , F. Sahli <sup>1</sup> <sup>1</sup> Laboratoire de Microbiologie Maladies Infectieuses, CHU, Sétif, Algeria
<b>449/83P</b>	<b>Brucellosis - a retrospective study in a rural endemic area in Greece</b>
00:00	F. Rozi, D. Rousos, P. Dimakouleas, A. Keramida, G. Andrianopoulos, D. Karamountzos Internal Medecine, G.N ARGOUS, Argos, Greece
<b>450/83P</b>	<b>Haematologic changes in patients with human brucellosis</b>
00:00	M. Zezski Department for infectious diseases, Medical Center, Prilep, Macedonia
<b>451/83P</b>	<b>Clinical profile of brucellosis in North-Western Greece</b>
00:00	C. Gousis, L. Raptis, M. Mastora, I. Liappis, O. Gioti, N. Gizas, N. Akritidis Internal Medicine Clinic, General Hospital G. Hatzicosta, Ioannina, Greece
<b>452/83P</b>	<b>Infections due to <i>Pasteurella</i> spp : experience in our hospital over the last 9 years.</b>
00:00	R. Gomez Fernandez <sup>1</sup> , R. Fernandez <sup>1</sup> , J. Marnotes <sup>1</sup> , A. Tinajas <sup>2</sup> , V. Aneiros <sup>1</sup> , I. Paz <sup>2</sup> , J. Lopez <sup>1</sup> , O. Fernandez <sup>1</sup> <sup>1</sup> internal medicine, complejo hospitalario de orense <sup>2</sup> microbidogy, complejo hospitalario de orense, Orense, Spain
<b>453/83P</b>	<b>Mediterranean spotted fever in Tunisia</b>
00:00	A. Ghoubontini, K. Bouabidi, T. Ben Chaabane Maladies Infectieuses, CHU Ernest Conseil-La Rabta, Tunis, Tunisia
<b>454/83P</b>	<b>Ano-rectal lymphogranuloma venerum : 18 cases reported in a sexually transmited diseases centre in paris</b>
00:00	P. Sednaoui <sup>2</sup> , M. Herida <sup>3</sup> , B. De Barbeyrac <sup>1</sup> , B. Halioua <sup>2</sup> <sup>1</sup> Centre National de Référence des Chlamydiae, Bordeaux <sup>2</sup> Institut Alfred Fournier, Paris <sup>3</sup> Institut de Veille Sanitaire, Saint Maurice, France
<b>455/83P</b>	<b>Liver biochemical abnormalities in murine typhus: a study of 119 cases</b>
00:00	S. Kastanakis, S. Doukakis, A. Xini, G. Polimili, D. Triantafillidou, K. Bambili, I. Bompolaki, K. Nikiforakis First Medical Department, 'Saint Georges', Chania, Greece
<b>456/83P</b>	<b>Thrombocytopenia in murine typhus: a study of 119 cases.</b>
00:00	S. Kastanakis, S. Doukakis, D. Triantafillidou, G. Polimili, K. Bambili, V. Anargirou, K. Koukoutsi, K. Nikiforakis First Medical Department, 'Saint George', Chania, Greece
<b>457/83P</b>	<b>Demographic features of 119 cases of murine typhus on the island of Crete.</b>
09:45	S. Kastanakis, S. Doukakis, K. Konstantinidis, D. Triantafillidou, A. Galis, V. Anargirou, I. Bompolaki, G. Polimili, K. Nikiforakis First Medical Department, 'Saint George', Chania, Greece
<b>458/83P</b>	<b>Anemia in murine typhus: a study of 119 cases.</b>
00:00	S. Doukakis, K. Koukoutsi, L. Kalogeraki, P. Karagianni, G. Polimili, I. Bompolaki, F. Axioti, S. Kastanakis First Medical Department, 'Saint George', Chania, Greece
<b>459/83P</b>	<b>Hyponatremia in murine typhus: a study of 119 cases.</b>
00:00	S. Doukakis, D. Triantafillidou, G. Polimili, K. Bambili, B. Katsomitrou, K. Koukoutsi, K. Nikiforakis, S. Kastanakis First Medical Department, "Saint George" Chania General Hospital, Chania, Greece

Thursday 2 December 00:00 ROOM POSTER  
jeudi décembre 00:00 Salle Poster 84P

#### LOWER RESPIRATORY TRACT INFECTIONS INFECTIONS RESPIRATOIRES BASSES

<b>460/84P</b>	<b>Detection of <i>Bordetella pertussis</i> and <i>Bordetella parapertussis</i> in nasopharyngeal swabs by real time PCR over a period of 18 months in Strasbourg.</b>
00:00	S. De Martino, J. Debs-durrenberger, C. Barthel, J.M. Schef tel, Y. Piemont, H. Monteil, B. Jaulhac Laboratoire de Bacteriologie, Hopital Universitaire et Faculté de Medecine, Strasbourg, France
<b>461/84P</b>	<b>RESPIMED: Management of 879 low respiratory tract infections (LRTI) in French Hospitals</b>
00:00	J. Reynes <sup>1</sup> , M.C. Legrand <sup>2</sup> , and the Respimed Group <sup>1</sup> CHU Montpellier, Montpellier <sup>2</sup> Harris Médical, Paris, France

<b>462/84P</b>	<b>Management of respiratory infections in the out patient department (OPD), July-August 2004</b>
00:00	R. Rivera Gorospe College of Medicine and Surgery, Cagayan State University, Tuguegarao City, Philippines
<b>463/84P</b>	<b>Once-daily short course therapy with clarithromycin extended-release (CLA-ER) is as effective and better tolerated than 7 day, twice-daily therapy with clarithromycin immediate-release (CLA-IR) in acute bacterial exacerbation of chronic bronchitis (ABECB)</b>
00:00	M. Gotfried <sup>2</sup> , T. Busman <sup>1</sup> , R. Palmer <sup>1</sup> , G. Notario <sup>1</sup> , J. Spiller <sup>1</sup> , C. Olson <sup>1</sup> <sup>1</sup> Anti-Infectives, GPRD, Abbott Laboratories, Abbott Park, IL <sup>2</sup> Pulmonary Associates PA, Phoenix, AZ, United States
<b>464/84P</b>	<b>Clarithromycin extended-release (CLA-ER) once-daily is equally effective and better tolerated than comparator twice-daily therapy for the treatment of acute bacterial exacerbation of chronic bronchitis (ABECB)</b>
00:00	C. Olson, T. Busman, R. Palmer, G. Notario Anti-Infective GPT, GPRD, Abbott Laboratories, Abbott Park, IL, United States
<b>465/84P</b>	<b>Efficacy and tolerability of a 5-day course of clarithromycin extended release (CLA-ER) versus telithromycin (TELI) for the treatment of acute bacterial exacerbation of chronic bronchitis (ABECB)</b>
00:00	C. Perronne <sup>1</sup> , J. Filipecki <sup>4</sup> , H. Drugeon <sup>3</sup> , P. Zuck <sup>2</sup> , N. Vincent-lacaze <sup>4</sup> , G. Goldfarb <sup>4</sup> , P. Léophonte <sup>5</sup> <sup>1</sup> Infectious Diseases Dept, Raymond Poincaré Hospital, Garches <sup>2</sup> Pneumology Dept, Metz Hospital, Metz <sup>3</sup> Microbiology Dept, Hôtel-Dieu, Nantes <sup>4</sup> Abbott France, Rungis <sup>5</sup> Pneumology Dept, Larrey Hospital, Toulouse, France
<b>466/84P</b>	<b>Compared efficacy and safety of pristinamycin (PRI) versus amoxicillin (AMX) in community-acquired pneumonia (CAP) adults</b>
00:00	F. Tremolieres <sup>1</sup> , C. Mayaud <sup>2</sup> , Y. Mouton <sup>4</sup> , P. Weber <sup>5</sup> , C. Chone <sup>3</sup> , F. Dellatolas <sup>3</sup> , E. Caulin <sup>3</sup> <sup>1</sup> Hôpital F.Quesnay, Mantes-La-Jolie <sup>2</sup> Hôpital Tenon <sup>3</sup> Laboratoire Aventis, Paris <sup>4</sup> CHR de Tourcoing, Tourcoing <sup>5</sup> Laboratoire BIOVSM, Vaires-Sur-Marne, France
<b>467/84P</b>	<b>Effect of annual number of episodes of acute exacerbations of chronic bronchitis on patient autonomy</b>
00:00	P. Zuck <sup>1</sup> , F.A. Allaert <sup>2</sup> , S. Anteur <sup>3</sup> <sup>1</sup> Cenbiotech, Dijon <sup>2</sup> Centre Hospitalier Régional, Metz <sup>3</sup> Laboratoires Aventis France, Paris, France
<b>468/84P</b>	<b>Study of 12 epidemical cases of legionnaire's disease occurred in Meurthe-et-Moselle (France) between July and August 2004</b>
00:00	F. Duhoux <sup>2</sup> , L. Thomas <sup>2</sup> , S. Bevilacqua <sup>2</sup> , C. Lion <sup>1</sup> , P.H. Hartemann <sup>3</sup> , E. Piquet <sup>4</sup> , C.H. Rabaud <sup>2</sup> , T.H. May <sup>2</sup> <sup>1</sup> Laboratoire de Bactériologie <sup>2</sup> Maladies Infectieuses <sup>3</sup> Service d'Hygiène Hospitalière, CHU de NANCY <sup>4</sup> DDASS de Meurthe et Moselle, Nancy, France
<b>469/84P</b>	<b>Therapeutic efficacy of simulated human-like sustained-release 2000 mg amoxicillin treatment for experimental pneumonia caused by <i>S.pneumoniae</i> with different amoxicillin MICs.</b>
00:00	M. Gracia, C. Martínez- Marín, L. Huelves, M.J. Gimenez, L. Aguilar, C. Ponte, F. Soriano Medical Microbiology, Fundacion Jimenez Diaz, Madrid, Spain
<b>470/84P</b>	<b>Peculiarities of antibacterial therapy of respiratory infections in patients with bronchial asthma.</b>
00:00	N. Tumanova, E. Shmelev TB Research Institute, Moscow, Russia

Thursday jeudi	<b>2</b>	December décembre	00:00 00:00	ROOM Salle	-----	POSTER Poster	<b>85P</b>
-------------------	----------	----------------------	----------------	---------------	-------	------------------	------------

### **UPPER RESPIRATORY TRACT INFECTIONS INFECTIONS HAUTES DE L'APPAREIL RESPIRATOIRE**

<b>471/85P</b>	<b>Etude des critères prédictifs de l'angine streptococcique</b>
00:00	P. Bastien, Y. Valentin, J.L. Gallais MGForm Lorraine, Gerardmer, France
<b>472/85P</b>	<b>Evaluating of immunity to diphtheria in adults in Izmir, Turkey</b>
00:00	S. Alp Cavus, V. Avkan Oguz, A. Yuce Infectious Diseases and Clinical Microbiology, Dokuz Eylul University, Izmir, Turkey
<b>473/85P</b>	<b>Evolution of clinical symptomatology of patients with acute maxillary sinusitis managed by general practitioners.</b>
00:00	P. Dellamonica <sup>1</sup> , E. Serrano <sup>3</sup> , S. Brin <sup>2</sup> , C. Soyez <sup>2</sup> <sup>1</sup> Hôpital l'Archet, Nice <sup>2</sup> Laboratoire Aventis, Paris <sup>3</sup> Hôpital de Rangueil, Toulouse, France
<b>474/85P</b>	<b>The experience of ENT and 1st Internal Medicine Depts of St. George Hospital Chania in treating 82 cases of chronic otitis media</b>
00:00	E. Proimos <sup>1</sup> , E. Theodoraki <sup>1</sup> , G. Perogamvrasik <sup>1</sup> , P. Karagianni <sup>2</sup> , A. Galis <sup>2</sup> , K. Koukoutsis <sup>2</sup> , A. Xini <sup>2</sup> , V. Anargyrou <sup>2</sup> , S. Kastanakis <sup>2</sup> <sup>1</sup> 1st Internal Medicine Department <sup>2</sup> ENT, General Hospital of Chania, Chania, Greece

<b>475/85P</b>	<b>Once-daily therapy with clarithromycin extended-release (CLA-ER) is equally effective and better tolerated than twice -daily comparator therapy in acute maxillary sinusitis (AMS)</b>
00:00	C. Olson, R. Palmer, T. Busman, J. Valdes Anti-Infectives, GPRD, Abbott Laboratories, Abbott Park, IL, United States
<b>476/85P</b>	<b>Clinical and bacteriological outcomes in a comparative study of the efficacy and tolerability of once-daily clarithromycin extended-release (CLA-ER) vs. twice -daily amoxicillin/clavulanate (A/C) for the treatment of subjects with acute maxillary sinusitis (AM S)</b>
00:00	E. Riffel <sup>2</sup> , R. Palmer <sup>1</sup> , J. Spiller <sup>1</sup> , T. Busman <sup>1</sup> , J. Valdes <sup>1</sup> , C. Olson <sup>1</sup> <sup>1</sup> Anti-Infectives, GPRD, Abbott Laboratories, Abbott Park, IL <sup>2</sup> Central Phoenix Medical Center, LLC, Phoenix, AZ, United States
<b>477/85P</b>	<b>Bacteriologic outcomes of clarithromycin extended-release (CLA-ER) vs. amoxicillin/clavulanate (A/C) for the treatment of patients with acute maxillary sinusitis (AMS)</b>
00:00	D. Shortridge, T. Busman, J. Valdes, C. Olson Anti-Infectives, GPRD, Abbott Laboratories, Abbott Park, IL, United States

Thursday 2 December 2004 00:00 ROOM Salle — POSTER Poster 86P

## EPIDEMIOLOGICAL, CLINICAL AND THERAPEUTIC ASPECTS OF TUBERCULOSIS AND ATYPICAL MYCOBACTERIA INFECTIONS ASPECTS ÉPIDÉMIOLOGIQUES, CLINIQUES ET THÉRAPEUTIQUES DE LA TUBERCULOSE ET DES INFECTIONS À MYCOBACTÉRIES ATYPIQUES

<b>478/86P</b>	<b>Intra sellar tuberculoma : Two cases reports</b>
00:00	B. Hammami <sup>2-2</sup> , I. Maalouf <sup>2-2</sup> , N. Ben Arab <sup>2</sup> , D. Lahiani <sup>2</sup> , N. Rekik <sup>1</sup> , H. Ghorbel <sup>2</sup> , M. Abid <sup>1</sup> , M. Ben Jemaa <sup>2</sup> <sup>1</sup> Endocrinologie <sup>2</sup> Maladies Infectieuses, CHU Hédi Chaker, Sfax, Tunisia
<b>479/86P</b>	<b>Isolated splenic tuberculosis in an immunocompetent patient: a case report</b>
00:00	V. Grammelis <sup>1</sup> , A. Tzoumani <sup>1</sup> , G. Tsakes <sup>1</sup> , G. Pesmatzoglou <sup>2</sup> , D. Papaventis <sup>1</sup> , N. Tsogas <sup>1</sup> , V. Laopodis <sup>2</sup> , M.C. Lazanas <sup>1</sup> <sup>1</sup> 3rd Dept. of Internal Medicine & Infectious Diseases Unit <sup>2</sup> Dept. of Surgery, Red Cross Hospital, Athens, Greece
<b>480/86P</b>	<b>Spinal co-infection with <i>Mycobacterium tuberculosis</i> and <i>Rhodotorula minuta</i> in an immunocompetent patient: a case report</b>
00:00	V. Grammelis <sup>1</sup> , G. Tsakes <sup>1</sup> , A. Velegraki <sup>2</sup> , P. Tserpe <sup>1</sup> , M. Boboli <sup>1</sup> , N. Flessas <sup>1</sup> , C. Michalakeas <sup>1</sup> , N. Tsogas <sup>1</sup> , M.C. Lazanas <sup>1</sup> <sup>1</sup> 3rd Dept. of Internal Medicine & Infectious Diseases Unit, Red Cross Hospital <sup>2</sup> Mycology Reference Laboratory, Hellenic Centre for Diseases Control, Dept. of Microbiology, University of Athens, Athens, Greece
<b>481/86P</b>	<b>Severe hypercalcemia resulting from miliary tuberculosis in a patient with AIDS : unusual manifestation of the immune reconstitution syndrom (IRS)</b>
00:00	C. Rapp, P. Imbert, M. Jagou, D. Corberand, T. Debord Maladies infectieuses et tropicales, Hôpital militaire Bégin, Saint-Mandé, France
<b>482/86P</b>	<b>Health Care workers who are to progress to active TB disease present a panel of T Cell immune markers predicting such progression.</b>
00:00	C. Leandro <sup>2</sup> , D. Ordway <sup>2-1</sup> , M.S. Martins <sup>2</sup> , M. Viveiros <sup>2</sup> , L. Pinto <sup>1</sup> , M.J. Arroz <sup>1</sup> , F.A. Ventura <sup>1</sup> , H.M. Dockrell <sup>3</sup> , L. Amaral <sup>2</sup> <sup>1</sup> Center of Malaria and Other Tropical Diseases (CMDT) <sup>2</sup> Unit of Mycobacteriology, Centre for Parasitology & Medical Microbiology (UPMM), Institute of Hygiene & Tropical Medicine, Universidade Nova de Lisboa, Lisbon, Portugal <sup>3</sup> Unit of Immunology, London School of Hygiene & Tropical Medicine, London, United Kingdom
<b>483/86P</b>	<b>The infection of human macrophages by <i>Mycobacterium tuberculosis</i> induce the expression of granulysin.</b>
00:00	J.F. Bourge <sup>2</sup> , A. Soulie <sup>2</sup> , M. Sasportes <sup>2</sup> , P.H. Lagrange <sup>1</sup> , A. Wargnier <sup>1-2</sup> <sup>1</sup> Service de Microbiologie, Hôpital Saint Louis, Paris <sup>2</sup> Unité Inserm 462, Institut Universitaire d'Hématologie, Paris 7, France
<b>484/86P</b>	<b>An algorithm for molecular characterisation of mycobacteria in medical practice</b>
00:00	V. Cattoir <sup>1-2</sup> , A. Billoët <sup>1</sup> , G. Paul <sup>1</sup> <sup>1</sup> Bactériologie, CHU Cochin-Port royal, Paris <sup>2</sup> Bactériologie-Virologie, CHU Pontchaillou, Rennes, France
<b>485/86P</b>	<b>Role of the country of birth in the prevalence of resistance to antituberculosis drugs in France - Azay Mycobacteria study group</b>
00:00	E. Guerrin-tran, V. Jarlier, J. Robert CHU Pitié-Salpêtrière, Université Pierre et Marie Curie, CNR de la Résistance des Mycobactéries aux antibiotiques, laboratoire de bactériologie, Paris, France
<b>486/86P</b>	<b>Tigecycline for Multiresistant <i>Mycobacterium chelonae</i> Infection</b>
00:00	G. Poulikou <sup>1</sup> , A. Papadopoulos <sup>1</sup> , M. Kollia <sup>1</sup> , S. Tsiodras <sup>1</sup> , I. Boletis <sup>2</sup> , D. Korres <sup>1</sup> , E. Demertz <sup>2</sup> , A. Scroubelou <sup>3</sup> , G.L. Daikos <sup>2</sup> , A. Avlamis <sup>2</sup> , H. Giannarellou <sup>1</sup> <sup>1</sup> 4th Department of Internal Medicine, ATTIKON University General Hospital, Athens University Medical School <sup>2</sup> Laiko General Hospital <sup>3</sup> Sotiria General Hospital, Athens, Greece
<b>487/86P</b>	<b>Thioridazine: Evidence supporting its use as alternative therapy for MDR-TB.</b>
00:00	L. Amaral, D. Ordway, M. Viveiros, M.S. Martins, C. Leandro Unit Mycobacteriology; Centre Parasitology & Medical Microbiology, Institute of Hygiene & Tropical Medicine, Lisbon, Portugal

CASE REPORTS  
CAS CLINIQUES

## 488/87P Acute meningitis due to sandfly fever toscana virus imported to France

00:00 G. Defuente<sup>2,1</sup>, C. Rapp<sup>1,2</sup>, P. Imbert<sup>1,2</sup>, J.P. Durand<sup>1</sup>, T. Debord<sup>1,2</sup><sup>1</sup>Unité de Virologie, Laboratoire associé au CNR des Arbovirus, IMTSSA, Marseille<sup>2</sup>Maladies infectieuses et tropicales, Hôpital militaire Bégin, Saint-Mandé, France489/87P *Kytococcus schroeteri* is an emerging cause for prosthetic endocarditis.00:00 C. Le Brun<sup>1</sup>, J. Bouet<sup>2</sup>, P. Gautier<sup>1</sup>, J.L. Avril<sup>1</sup>, O. Gaillot<sup>1</sup><sup>1</sup>Laboratoire de Bactériologie-Virologie<sup>2</sup>Service des Maladies Infectieuses, Centre Hospitalier Universitaire, Rennes, France

## 490/87P Case of diphtheria after a stay in Madagascar

00:00 H. Montell<sup>2</sup>, E. Schneider<sup>3</sup>, D. Eyer<sup>3</sup>, P. Riegel<sup>2</sup>, A. Le Flèche<sup>1</sup>, Y. Piémont<sup>2</sup><sup>1</sup>C.N.R. de C. diphtheriae, Institut Pasteur, Paris<sup>2</sup>Institut de Bactériologie, Faculté de Médecine, Université Louis Pasteur<sup>3</sup>Service de Pédiatrie, Hôpitaux Universitaires, Strasbourg, France491/87P *Streptococcus suis* II meningo-encephalitis : one case and literature review00:00 E. Lecuyer<sup>3</sup>, H. Bentayeb<sup>3</sup>, C. Dayen<sup>3</sup>, F.X. Lescure<sup>1</sup>, M.T. Albertini<sup>2</sup>, B. Vidal<sup>1</sup>, Y. Douadi<sup>3</sup><sup>1</sup>Maladies Infectieuses, Centre hospitalier Universitaire<sup>2</sup>Pneumologie, CH, Amiens<sup>3</sup>Bactériologie, Centre Hospitalier<sup>4</sup>Pneumologie-Maladies Infectieuses, Centre hospitalier, Saint Quentin, France492/87P Midgestation abortion due to an ungroupable strain of *Streptococcus porcinus*00:00 R. Theodose<sup>2</sup>, L. Mihaila-amrouche<sup>3</sup>, C. Olive<sup>2</sup>, J. Volumenie<sup>1</sup>, J. Jouannelle<sup>2</sup>, B. Schaub<sup>1</sup>, S. Vigot<sup>1</sup>, J. Loubinoux<sup>3</sup>, A. Bouvet<sup>3</sup><sup>1</sup>Gynecology<sup>2</sup>Microbiology, University hospital, Fort De France<sup>3</sup>National Reference Center for Streptococci, Hôtel Dieu, Paris V, Paris, France

## 493/87P Persistent neutrophilic meningitis: an unusual presentation of intracranial dermoid cyst

00:00 S. Jaffuel<sup>1</sup>, S. Ansart<sup>1</sup>, P. Hutin<sup>3</sup>, M. Coustans<sup>4</sup>, P. Diraison<sup>4</sup>, G. Besson<sup>2</sup>, M. Garre<sup>1</sup><sup>1</sup>Maladies Infectieuses<sup>2</sup>Neurochirurgie, CHU Cavale Blanche, Brest<sup>3</sup>Médecine Interne et Maladies Infectieuses<sup>4</sup>Neurologie, CH Laennec, Quimper, France494/87P First clinical isolate of *Faecalibacterium prausnitzii*, the tip of the iceberg ?00:00 A. Le Coustumer<sup>1</sup>, N. Wilhelm<sup>1</sup>, A. Le Fleche<sup>3</sup>, J.C. Valery<sup>2</sup>, C. Grasmick<sup>1</sup>, P.A.D. Grimont<sup>3</sup><sup>1</sup>Laboratoire<sup>2</sup>Service de dialyse, Centre Hospitalier, Cahors<sup>3</sup>Centre d'Identification Moléculaire des Bactéries, Institut Pasteur, Paris, France495/87P Subacute myositis of the iliopsoas and abdominal wall muscles caused by *Escherichia coli* and *Bacteroides* following a sigmoid abscess.00:00 H.K. Ea<sup>3</sup>, V. Zeller<sup>3</sup>, V. Chicheportiche<sup>4</sup>, J.P. Hellier<sup>3</sup>, P. Chazerain<sup>3</sup>, R. Houdart<sup>1</sup>, N. Desplaces<sup>2</sup>, J.M. Ziza<sup>3</sup><sup>1</sup>Chirurgie Viscérale<sup>2</sup>Laboratoire de Biologie<sup>3</sup>Service de Médecine Interne et Rhumatologie, GH Diaconesses Croix Saint Simon<sup>4</sup>Service de Radiologie, GH Diaconesses-Croix Saint Simon, Paris, France496/87P *Nocardia spondylodiscitis* in a hemodialysis patient previously a recipient of a renal transplant00:00 B. Vidal<sup>2</sup>, Y. Douadi<sup>4,2</sup>, B. Coevoet<sup>4</sup>, R. Makdassi<sup>3</sup>, P.F. Westeel<sup>3</sup>, F. Daoudi<sup>1</sup>, J.L. Schmit<sup>2</sup>, G. Choukroun<sup>1</sup><sup>1</sup>Bactériologie<sup>2</sup>Infectiologie<sup>3</sup>Nephrologie, CHU, Amiens<sup>4</sup>Pneumologie-infectiologie, Centre hospitalier, Saint Quentin, France497/87P Bilateral empyema due to *Yersinia enterocolitica*

00:00 K. Ainine, E. Le Magrex Debar, F. Fadel, D. Forte, L. Brasme, S. Lavaud, V. Vernet Garnier, J.H.M. Cohen, C. De Champs

CHU Robert Debré, 51092 Reims Cedex, France

## 498/87P Diagnostic approach to patient with recurrence of bacterial meningitis

00:00 G. Polimili<sup>2</sup>, N. Gyrousis<sup>2</sup>, A. Galis<sup>2</sup>, P. Karagianni<sup>2</sup>, K. Babil<sup>2</sup>, D. Triantafyllidou<sup>2</sup>, K. Nikiforakis<sup>2</sup>, G. Arhodakis<sup>1</sup>, S. Kastanakis<sup>2</sup><sup>1</sup>Neurosurgery Department, "St. George" General Hospital<sup>2</sup>1st Internal Medicine Department, " St. George" General Hospital, Chania, Greece

## 499/87P Autologous stem cell transplantation in patient with juvenile idiopathic arthritis. I.- clinical course of the disease

00:00 F. Matecka<sup>1,2</sup>, S. Blazickova<sup>1,2</sup>, J. Rovensky<sup>1</sup>, V. Krcmery<sup>2</sup><sup>1</sup>National Institute of Rheumatic Disease, Piestany<sup>2</sup>School of Health Care and Social Work, Trnava University, Trnava, Slovakia500/87P *Neisseria mucosa* endocarditis00:00 N. Hammami<sup>7</sup>, B. Mnif<sup>7</sup>, F. Mahjoubi<sup>7</sup>, S. Moalla<sup>7</sup>, E. Turki<sup>7</sup>, D. Lahiani<sup>7</sup>, S. Kamoun<sup>8</sup>, A. Hammami<sup>7</sup><sup>1</sup>Laboratoire de Microbiologie<sup>2</sup>Laboratoire de Microbiologie<sup>3</sup>Laboratoire de Microbiologie<sup>4</sup>Laboratoire de Microbiologie<sup>5</sup>Laboratoire de Microbiologie<sup>6</sup>Laboratoire de Microbiologie<sup>7</sup>Laboratoire de Microbiologie, CHU Habib BOURGUIBA<sup>8</sup>Cardiologie, CHU Hedi CHEKER, Sfax, Tunisia

## 501/87P Early re-operation for prosthetic valve endocarditis after Bentall-type procedure

00:00 G. Aggeletopoulos<sup>2</sup>, E. Giannitsioti<sup>1</sup>, M. Kokladou<sup>2</sup>, G. Chlorogiannis<sup>2</sup>, S. Tsiodras<sup>1</sup>, D. Plachouras<sup>1</sup>, H. Giannarellou<sup>1</sup><sup>1</sup>4th Dept of Internal Medicine, Attiko University Hospital, Haidari<sup>2</sup>Cardiology, Sismanoglio General Hospital, Maroussi, Greece

<b>502/87P</b>	<b>Streptococcus sinensis, a causative organism of infective endocarditis.</b>
00:00	I. Uckay, P. Rohner, J. Garbino, D. Lew, J. Schrenzel HUG, Div. des Maladies Infectieuses, Genève, Switzerland
<b>503/87P</b>	<b>Complicated course of secondary bacterial meningitis</b>
00:00	A. Zjevikova <sup>1</sup> , I. Orsagova <sup>1</sup> , J. Chmelova <sup>2</sup> <sup>1</sup> Department of Infectious Diseases <sup>2</sup> Institute of Radiodiagnostics, University Hospital, Ostrava, Czech Republic
<b>504/87P</b>	<b>Fever and bradycardia in a young man</b>
00:00	E. Magira, T.H. Gounaris, S.P. Papandreou, E. Sioula 1ST Department internal medicine, Evangelismos Hospital, Athens, Greece
<b>505/87P</b>	<b>Acute gastro-enteritis due to infectious mononucleosis of atypical onset: diagnosis by ultrasound</b>
00:00	L. Tarantino, M.D. Iannece, V. Pezzella, P. Rosario, S. Quaranta, A. Sullo, R. Pempinello V Division, D.Cotugno Hospital, Naples, Italy
<b>506/87P</b>	<b>Recurrent bacteraemia with <i>Helicobacter cinaedii</i> in an immune-competent host</b>
00:00	I. Uckay, P.Y. Dietrich, J. Garbino, B. Kuzoe, P. Rohner, V. Jacomo HUG, Div. des Maladies Infectieuses, Genève, Switzerland

Thursday 2 December 2004 00:00 ROOM Salle — POSTER Poster 88P

**MALARIA - PARASITIC INFECTIONS: PHYSIOPATHOLOGY AND CLINICS**  
PALUDISME - INFECTIONS PARASITAIRES : ASPECTS PHYSIOPATHOLOGIQUES ET CLINIQUES

<b>507/88P</b>	<b>Quality evaluation of the health information on travel medicine web sites</b>
00:00	C. Rapp, D. Corberand, P. Imbert, T. Debord Maladies infectieuses et tropicales, Hôpital militaire Bégin, Saint-Mandé, France
<b>508/88P</b>	<b>Imported cases of malaria in Tunisia</b>
00:00	L. Ammari <sup>1</sup> , H. Tiouri <sup>1</sup> , B. Kilani <sup>1</sup> , A. Goubantini <sup>1</sup> , C. Marrakchi <sup>1</sup> , E. Chaker <sup>2</sup> , T. Ben Chaabane <sup>1</sup> <sup>1</sup> Department of infectious diseases <sup>2</sup> Department of parasitology and mycology, Rabta hospital, Tunis, Tunisia
<b>509/88P</b>	<b>The epidemiology of urban malaria in Parsabad-e-Moghan, Iran</b>
00:00	M. Assmar <sup>3</sup> , A. Raeisi <sup>2</sup> , S.H. Arshi <sup>1</sup> , M. Razavi <sup>3</sup> , S.R. Naddaf <sup>3</sup> , H. Nahrevanian <sup>3</sup> , A. Hovanesian <sup>3</sup> , M. Farahmand <sup>3</sup> , M. Ranjbar <sup>2</sup> <sup>1</sup> Faculty of Medicine, Ardebil university of Medical Sciences, Ardebil <sup>2</sup> Center for Communicable Disease Control, ministry of health <sup>3</sup> Parasitology Dept., Pasteur Institute of Iran, Tehran, Iran
<b>510/88P</b>	<b>Immunodetection of <i>Plasmodium</i> lactate dehydrogenase for <i>in vitro</i> drug susceptibility testing.</b>
00:00	H. Kaddouri, F. Martineau, J. Le Bras Laboratoire de Parasitologie, CNR Chimiosensibilité du Paludisme - Hôpital Bichat-Claude Bernard, Paris, France
<b>511/88P</b>	<b>Detection of a minority mutant population by a clamping probe assay using a locked nucleic acid: demonstration on the <i>Pfcrt</i> K76T mutation of <i>Plasmodium falciparum</i></b>
00:00	A. Berry <sup>1</sup> , A. Senescau <sup>1</sup> , F. Benoit Vical <sup>1,2</sup> , J. Lelièvre <sup>1,2</sup> , R. Fabre <sup>1</sup> , S. Cassaing <sup>1</sup> , J.F. Magnaval <sup>1</sup> <sup>1</sup> Parasitologie-Mycologie, CHU Rangueil <sup>2</sup> Chimie de Coordination, CNRS, Toulouse, France
<b>512/88P</b>	<b>Investigation on nitric oxide induction as a novel immunological target in malaria infected patients from endemic areas of Iran</b>
00:00	H. Nahrevanian <sup>2</sup> , J. Gholizadeh S. <sup>3</sup> , M. Farahmand <sup>2</sup> , M. Abolhassani <sup>1</sup> , M. Assmar <sup>2</sup> <sup>1</sup> Department of Immunology <sup>2</sup> Department of Parasitology <sup>3</sup> Education Unit, Pasteur Institute of Iran, Tehran, Iran
<b>513/88P</b>	<b>Quinine treatment failure during <i>Plasmodium falciparum</i> infection from Central Africa</b>
00:00	A. Berry <sup>2</sup> , M. Alvarez <sup>1</sup> , F. Benoit Vical <sup>2,4</sup> , J. Levière <sup>2,4</sup> , M. Lavit <sup>3</sup> , B. Marchou <sup>1</sup> , P. Massip <sup>1</sup> , J.F. Magnaval <sup>2</sup> <sup>1</sup> Maladies Infectieuse et Tropicales <sup>2</sup> Parasitologie-Mycologie <sup>3</sup> Pharmacocinétique et de Toxicologie Clinique, CHU Toulouse <sup>4</sup> Chimie de Coordination, CNRS, Toulouse, France
<b>514/88P</b>	<b>Impairment of quinine accumulation in the placenta of <i>Plasmodium berghei</i>-infected mice.</b>
00:00	E. Pussard <sup>2</sup> , F. Lirussi <sup>2</sup> , E. Fouquet <sup>1</sup> , P. Bourée <sup>1</sup> <sup>1</sup> Parasitologie <sup>2</sup> Pharmacologie, CHU Bicêtre, Le Kremlin Bicêtre, France
<b>515/88P</b>	<b>Asymptomatic amebic enteritis : unexpected ultrasound findings suggesting the diagnosis</b>
00:00	L. Tarantino, M.D. Iannece, A. Sullo, V. Pezzella, P. Rosario, S. Quaranta, R. Pempinello V Division, D.Cotugno Hospital, Naples, Italy

<b>516/88P</b>	<b>Amebic liver abscess: epidemiological aspects of a patients series treated in a single institution in Naples area</b>
00:00	L. Tarantino, M.D. Iannece, A. Sullo, P. Rosario, V. Pezzella, S. Quaranta, R. Pempinello <i>V Division, D.Cotugno Hospital, Naples, Italy</i>
<b>517/88P</b>	<b>Clinical aspects of toxoplasmosis in the Republic of Belarus.</b>
00:00	M. Kazatchenko <sup>2</sup> , I. Karpov <sup>1</sup> , A. Kachanka <sup>1</sup> Infectious Diseases, Medical University <sup>2</sup> Infectious Diseases, President's Hospital, Minsk, Belarus
<b>518/88P</b>	<b>Ultra Sound-guided spleen Fine Needle Aspiration Biopsy FNAB in the diagnosis of visceral leishmaniasis</b>
00:00	L. Tarantino, R. Pempinello, M.D. Iannece, P. Rosario, V. Pezzella, S. Quaranta, A. Sullo <i>V Division, D.Cotugno Hospital, Naples, Italy</i>
<b>519/88P</b>	<b>Resistant postkala-azar dermal leishmaniasis in an HIV infected patient</b>
00:00	I. Meyer-andrieux <sup>3</sup> , B. Hirscher <sup>3</sup> , V. Schiffer <sup>3</sup> , F. Chappuis <sup>4</sup> , C. Michon <sup>1</sup> , V. Piguet <sup>2</sup> , J.H. Saurat <sup>2</sup> , L. Toutous-trellu <sup>2</sup> <sup>1</sup> Division Infectious Diseases, Annecy Hospital, Annecy, France <sup>2</sup> Division Dermatology <sup>3</sup> Division Infectious Diseases <sup>4</sup> Travel and Migration Unit, Geneva Hospital, Geneva, Switzerland
<b>520/88P</b>	<b>Case report: multilevel neurocysticercosis in a 69 years old woman</b>
00:00	D. Kavatha <sup>1-1</sup> , A. Xyteri <sup>1-1</sup> , R. Staffensky <sup>1-2</sup> , S. Savanis <sup>1-1</sup> , H. Giamarellou <sup>1-1</sup> <sup>1</sup> 4th Department of Internal Medicine, . National and Capodistrian University of Athens. Athens Medical School. General Hospital . <sup>2</sup> General Hospital Herakleio Dynan., Athens, Greece

Thursday jeudi	2	December décembre	00:00 00:00	ROOM Salle	—	POSTER Poster	89P
-------------------	---	----------------------	----------------	---------------	---	------------------	-----

## DIVERSE INFECTIONS INFECTIONS DIVERSES

<b>521/89P</b>	<b>Treatment of acne patients with Isotretinoin: related changes in skin microbiota.</b>
00:00	R.A. Dixon <sup>2</sup> , A.E. Thomas <sup>2</sup> , T. Watts <sup>1</sup> , N.C. Hepburn <sup>1</sup> , D.R. Williams <sup>2</sup> <sup>1</sup> Dermatology, Lincoln County Hospital <sup>2</sup> Forensic and Biomedical Sciences, University of Lincoln, Lincoln, United Kingdom
<b>522/89P</b>	<b>Aeromonas community-acquired wound infections</b>
00:00	C. Harf - Monteil <sup>2</sup> , J. Gaudias <sup>1</sup> , P. Riegel <sup>2</sup> , J.M. Scheftel <sup>2</sup> , H. Monteil <sup>2</sup> <sup>1</sup> Infectiologie, Centre de Traumatologie et d'Orthopédie, Illkirch-Graffenstaden <sup>2</sup> Institut de Bactériologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
<b>523/89P</b>	<b>Management of brain abscesses caused by the streptococci of the milleri group.</b>
00:00	N.H. O' Connell <sup>1</sup> , P. Kowlessar, R. Mitchell, T.S. Elliott <i>Microbiology and Neurosurgery, UHB, Birmingham, United Kingdom</i>
<b>524/89P</b>	<b>In vitro study of antibiotics as second-line therapy for the eradication of <i>Helicobacter pylori</i> isolated from children and adults</b>
00:00	S. Fujimura <sup>2</sup> , S. Kato <sup>3</sup> , T. Kawamura <sup>1</sup> <sup>1</sup> Gastroenterology <sup>2</sup> Microbiology, Miyagi University, Miyagi Pref. <sup>3</sup> Pediatrics, Tohoku University School of Medicine, Sendai, Japan
<b>525/89P</b>	<b>Risk factors for atrophic chronic gastritis in a European population at entry and after a three year follow-up.</b>
00:00	F. Richy <sup>3</sup> , P. Sipponen <sup>1-2</sup> , N. Broutet <sup>4</sup> , F. Mégraud <sup>3</sup> , Eurohepygast Study Group <sup>3</sup> <sup>1</sup> Helsinki District University Hospital, Jorvi Hospital, Espoo <sup>2</sup> Research Laboratories, Biohit Plc, Helsinki, Finland <sup>3</sup> Laboratoire de Bactériologie, Université Victor Segalen Bordeaux2, Bordeaux, France <sup>4</sup> Department of Reproductive Health and Research World Health Organization, Geneva, Switzerland
<b>526/89P</b>	<b>Risk factors for development of infections in patients with systemic lupus erythematosus</b>
00:00	F. Mateicka <sup>1-2</sup> , S. Blazickova <sup>1-2</sup> , J. Rovensky <sup>1</sup> <sup>1</sup> National Institute of Rheumatic Diseases, Piestany <sup>2</sup> School of Health Care and Social Work, Trnava University, Trnava, Slovakia
<b>527/89P</b>	<b>Correlations of in vitro susceptibility profiles to thrombin-induced platelet microbicidal protein and distribution of virulence factor genes in <i>Staphylococcus aureus</i> isolates from patients with definite infective endocarditis</b>
00:00	X. Duval <sup>1</sup> , G. Lina <sup>1</sup> , F. Alla <sup>1</sup> , F. Vandenesch <sup>1</sup> , T. Lecompte <sup>1</sup> , I. Béguinot <sup>1</sup> , B. Hoen <sup>1</sup> , J. Etienne <sup>1</sup> , C. Leport <sup>1</sup> , M.R. Yeaman <sup>2</sup> , A.S. Bayer <sup>2</sup> <sup>1</sup> Maladies Infectieuses, Bactériologie, CHU, Paris, Lyon, Nancy, Reims, Besançon, France <sup>2</sup> UCLA, Harbor, Torance, United States
<b>528/89P</b>	<b>Data-base of endocarditis in Greece: Trends of natural valve endocarditis (NVE) and prosthetic valve endocarditis (PVE) from 2000-2004</b>
00:00	E. Giannitsioti, I. Skiadas, A. Antoniadou, K. Kanavos, H. Giamarellou, And The Hellenic Endocarditis Study Group <i>University of Athens, ATTIKON University General Hospital, 4th Department of Internal Medicine, Athens, Greece</i>

<b>529/89P</b>	<b>Staphylococcus aureus</b> bloodstream infections in 2004 in the central region of France: wide diffusion of a TSST-1-producing methicillin-resistant <i>S. aureus</i> clone
00:00	N.L. Van Der Mee-marquet <sup>1,2</sup> , A.S. Domelier <sup>1</sup> , R. Quentin <sup>1,2</sup> , A.N.D. The Bloodstream Infection Study Group Of The Relais D'hygiène Du Centre <sup>1</sup>
	<sup>1</sup> Service de Bactériologie et d'Hygiène, Hôpital Trousseau, Centre Hospitalier Universitaire <sup>2</sup> UFR Médecine, Département de Microbiologie médicale et Moléculaire, EA 3250, F37034 Tours, France
<b>530/89P</b>	<b>Incidence of Lactobacillus bacteraemia and correlation with probiotic strains</b>
00:00	Å. Sullivan, C.E. Nord Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden
<b>531/89P</b>	<b>Clinical and microbiological features of the little-known genus <i>Dialister</i></b>
00:00	F. Morio <sup>3</sup> , H. Marchandin <sup>3</sup> , E. Jumas-bilak <sup>2</sup> , L. Dubreuil <sup>1</sup> , S. Roux <sup>3</sup> , L. Calvet <sup>1</sup> , H. Jean-pierre <sup>3</sup> <sup>1</sup> Laboratoire de Bactériologie, Lille <sup>2</sup> Laboratoire de Bactériologie, Faculté de Pharmacie <sup>3</sup> Laboratoire de Bactériologie, Hôpital Arnaud de Villeneuve, Montpellier, France
<b>532/89P</b>	<b>Evaluation of immunity to tetanus in adults</b>
00:00	B. Yildiz Karaca, N. Yapar, A. Yuce infectious diseases and clinical microbiology, dokuz eylul university, Izmir, Turkey
<b>533/89P</b>	<b>Varicella in France : national survey of complications and hospitalizations</b>
00:00	E. Grimpel <sup>1</sup> , F. De La Rocque <sup>1</sup> , C. Levy <sup>2</sup> , B. Soubeyrand <sup>1</sup> , R. Cohen <sup>1</sup> , M. Boucherat <sup>2</sup> , J. Gaudelus <sup>1</sup> , Pediatricians Working Group <sup>1</sup> GPIP: Pediatric Infectious Disease Group of the French Pediatric Society, France <sup>2</sup> ACTIV, St Maur, France
<b>534/89P</b>	<b>Expression and novel implication of Survivin in liver diseases</b>
00:00	S. Guo, Q. Xie, S. Jiang, H. Zhou Shanghai Ruijin Hospital, Second Medical University, Shanghai, China

Thursday jeudi	2	December décembre	00:00 00:00	ROOM Salle	—	POSTER Poster	90P
-------------------	---	----------------------	----------------	---------------	---	------------------	-----

**FUNGAL INFECTIONS: PHYSIOPATHOLOGY, DIAGNOSTIC AND TREATMENT**  
**INFECTIONS FONGIQUES : PHYSIOPATHOLOGIE, DIAGNOSTIC ET THÉRAPEUTIQUE**

<b>535/90P</b>	<b>Effect of rhG - CSF and rhGM - CSF on the candidacidal activity of neutrophils in patients with hematologic tumor.</b>
00:00	Z.N. Nikiforova NN Blokhin Cancer Res Ctr, Moscow, Russia
<b>536/90P</b>	<b>Clinical Isolates of <i>Candida</i> sp. from blood samples, vascular catheters and urine in a 6 year period at Hospital Barra D'or (HBD), Rio de Janeiro, Brazil</b>
00:00	O. Lupi <sup>2,1</sup> , T. Campos <sup>1</sup> , E. Faria <sup>1</sup> , L. Kalab <sup>1</sup> , D. Salgado <sup>1</sup> , J. Verdeal <sup>1</sup> <sup>1</sup> ICT/ICU, Hospital Barra D'or <sup>2</sup> Medicina Tropical, Instituto Oswaldo Cruz, Rio De Janeiro, Brazil
<b>537/90P</b>	<b>Successful treatment of chronic disseminated candidiasis with prednisone and antifungal therapy in a patient with leukemia</b>
00:00	S. Fournier, A.M. Zagdanski, P. Bertheau, C. Lacroix, E. Raffoux, J.M. Molina Hôpital Saint Louis, Paris, France
<b>538/90P</b>	<b>Microsatellite typing for the investigation of a <i>Candida albicans</i> candidemia cluster</b>
00:00	S. Beretta Tempelhoff <sup>2</sup> , J.P. Fulgencio <sup>3</sup> , S. El Metaoua <sup>3</sup> , C. Bernard <sup>1</sup> , M. Denis <sup>4</sup> , F. Bonnet <sup>3</sup> , C. Hennequin <sup>2</sup> <sup>1</sup> Laboratoire Commun de Biologie Moléculaire, Hopital St Antoine <sup>2</sup> Laboratoire de Parasitologie-Mycologie <sup>3</sup> Reanimation Chirurgicale <sup>4</sup> Unité d'Hygiène, Hopital Tenon, Paris, France
<b>539/90P</b>	<b>Susceptibility of <i>Candida glabrata</i> and <i>Candida krusei</i> isolates to fluconazole and voriconazole in Russia</b>
00:00	A. Veselov <sup>7</sup> , L. Stratchounski <sup>7</sup> , G. Kliasova <sup>4</sup> , E. Agapova <sup>2</sup> , I. Multih <sup>3</sup> , V. Ilyina <sup>6</sup> , N. Klimko <sup>8</sup> , M. Sukhorukova <sup>7</sup> , S. Rozanova <sup>1</sup> , N. Dmitrieva <sup>5</sup> <sup>1</sup> Diagnostic Center, Ekaterinburg <sup>2</sup> Regional Pediatric Hospital, Irkutsk <sup>3</sup> City Hospital #2, Krasnodar <sup>4</sup> Hematology Research Center <sup>5</sup> Oncology Research Center, Moscow <sup>6</sup> Regional Hospital, Novosibirsk <sup>7</sup> Institute of Antimicrobial Chemotherapy, Smolensk <sup>8</sup> Research Institute of Medical Mycology, St. Petersburg, Russia
<b>540/90P</b>	<b>Voriconazole in the treatment of <i>Fusarium chlamydosporum</i> fungemia</b>
00:00	D.R. Csiszár Károly <sup>3</sup> , D.R. Medve László <sup>2</sup> , D.R. Demján Mónika <sup>2</sup> , D.R. Kiss Katalin <sup>1</sup> , D.R. Zala Judit <sup>1</sup> <sup>1</sup> Mycology, Johann Béla National Epidemiological Center, Budapest <sup>2</sup> ICU, County Hospital <sup>3</sup> Bacteriology, Public Health Institute, Salgótarján, Hungary
<b>541/90P</b>	<b>First therapy with voriconazole in a <i>Fusarium</i> peritonitis after renal transplantation</b>
00:00	J. Garbino <sup>2</sup> , I. Uçkay <sup>2</sup> , P. Rohner <sup>1</sup> , D. Lew <sup>2</sup> , C. Van Delden <sup>2</sup> <sup>1</sup> Clinical Microbiology Laboratory <sup>2</sup> Division of Infectious Diseases, University Hospitals of Geneva, Geneva, Switzerland

<b>542/90P</b>	<b><i>Paecilomyces variotii</i> fungemia in a patient with multiple myeloma, case report and literature review.</b>
00:00	E. Lecuyer <sup>3</sup> , V. Salle <sup>1</sup> , T. Chouaki <sup>2</sup> , B. Vidal <sup>1</sup> , C. Dayen <sup>3</sup> , F.X. Lescure <sup>1</sup> , A. Smail <sup>1</sup> , J.L. Schmit <sup>1</sup> , J.P. Ducroix <sup>1</sup> , Y. Douadi <sup>3</sup>
	<sup>1</sup> Medecine Interne Maladies Infectieuses, Centre hospitalier Universitaire <sup>2</sup> Parasitologie, Centre Hospitalier Universitaire, Amiens <sup>3</sup> Pneumologie-Maladies Infectieuses, Centre Hospitalier Général, Saint Quentin, France
<b>543/90P</b>	<b>Two different cases of zygomycosis infection in transplant patients.</b>
00:00	I. Uckay <sup>2</sup> , J. Garbino <sup>2</sup> , P. Rohner <sup>1</sup> , C. Van Delden <sup>2</sup>
	<sup>1</sup> Maladies Infectieuses, Laboratoire de Microbiologie <sup>2</sup> Maladies Infectieuses, Genève, Switzerland
<b>544/90P</b>	<b>Successful use of posaconazole in the treatment of <i>Absidia</i> spp infection</b>
00:00	J. Garbino <sup>1</sup> , I. Uçkay <sup>1</sup> , M. Puppo <sup>1</sup> , D. Lew <sup>1</sup> , K. Amini <sup>2</sup> , M. Richter <sup>2</sup>
	<sup>1</sup> Division of Infectious Diseases <sup>2</sup> Division of Reconstructive Surgery, University of Geneva Hospitals, Geneva, Switzerland
<b>545/90P</b>	<b>Entomophthoromycose fronto-nasale A propos de deux nouveaux cas diagnostiqués à Mayotte</b>
00:00	M.C. Receveur <sup>2</sup> , C. Roussin <sup>3</sup> , B. Mienniel <sup>3</sup> , O. Gasnier <sup>3</sup> , D. Malvy <sup>2</sup> , O. Lortholary <sup>1</sup>
	<sup>1</sup> Médecine interne, maladies infectieuses et tropicales, Hôpital Avicenne, Bobigny <sup>2</sup> Médecine interne et tropicale, Hôpital St André, Bordeaux <sup>3</sup> Médecine, Center Hospitalier de Mayotte, Mamoudzou, France
<b>546/90P</b>	<b>Posaconazole in a patient with refractory <i>Rhizopus</i> spp. infection and relapsed acute myelogenous leukemia (AML)</b>
00:00	A.J. Ullmann <sup>1</sup> , H. Hebart <sup>2</sup> , H. Einsele <sup>2</sup> , G. Corcoran <sup>3</sup> , C. Hardalo <sup>3</sup> , C. Huber <sup>1</sup>
	<sup>1</sup> 3rd Medical Department, Klinikum Johannes Gutenberg-Universität, Mainz <sup>2</sup> Department of Internal Medicine II, University Hospital of Tübingen, Tübingen, Germany <sup>3</sup> Schering-Plough Research Institute, Kenilworth, New Jersey, United States
<b>547/90P</b>	<b>Cryptococcosis at a department of infectious diseases between 1997 and 2003</b>
00:00	J. Fernandes, A. Pereira, H. Carmona, G. Carmo
	Infectious Diseases, Santa Maria Hospital, Lisboa, Portugal
<b>548/90P</b>	<b>Successful treatment of rhinocerebral zygomycosis and pulmonary aspergillosis in a patient with thymic acute lymphoblastic leukemia</b>
00:00	R. Kuehnbach <sup>2</sup> , A. Muth <sup>2</sup> , M. Dellian <sup>3</sup> , S. Boeck <sup>2</sup> , X. Schiel <sup>2</sup> , B. Grabein <sup>1</sup> , E. Hiller <sup>2</sup>
	<sup>1</sup> Max von Pettenkofer-Institute of Hygiene and Medical Microbiology, Ludwig-Maximilians-University <sup>2</sup> Department of Internal Medicine III <sup>3</sup> Department of Otorhinolaryngology, University Hospital Grosshadern, Ludwig-Maximilians-University, Munich, Germany
<b>549/90P</b>	<b>Evaluation of a new generation of Sabouraud Gentamicin Chloramphenicol medium for the isolation of fungi in clinical specimens</b>
00:00	J.P. Bouchara <sup>1</sup> , D. Chabasse <sup>1</sup> , N. Velay <sup>2</sup> , F. Villeval <sup>2</sup>
	<sup>1</sup> Mycology laboratory, French University Hospital Center, Angers <sup>2</sup> R&D microbiology, bioMérieux, Craponne, France
<b>550/90P</b>	<b>Analysis of patients with invasive fungal infection (IFI) treated with initial amphotericin B deoxycholate (AmBd): therapeutic strategies, adverse events and clinical outcomes</b>
00:00	J. Garbino <sup>1</sup> , L. Markham <sup>1</sup> , R. Matulionyte <sup>1</sup> , D. Lew <sup>1</sup> , V.P. Rives <sup>2</sup> , J.M. Arduino <sup>2</sup> , W.C. Gerth <sup>2</sup>
	<sup>1</sup> Division of Infectious Diseases, University Hospitals of Geneva, Geneva, Switzerland <sup>2</sup> Merck & Co., Inc., New Jersey, United States
<b>551/90P</b>	<b>Adverse events due to amphotericin B deoxycholate (AmB) are associated with unfavorable clinical response and increased hospital resource utilization in neutropenic cancer patients</b>
00:00	O. Marchetti <sup>1</sup> , A.K. Lapointe <sup>1</sup> , T. Calandra <sup>1</sup> , V.P. Rives <sup>2</sup> , J.M. Arduino <sup>2</sup> , W.C. Gerth <sup>2</sup>
	<sup>1</sup> Infectious Diseases Service, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland <sup>2</sup> Merck & Co., Inc., Whitehouse Station, NJ, United States

Friday vendredi	<b>3</b>	December décembre	00:00 00:00	ROOM Salle	POSTER Poster	<b>91P</b>
--------------------	----------	----------------------	----------------	---------------	------------------	------------

#### **LABORATORY METHODS** **MÉTHODES D'ANALYSE**

<b>552/91P</b>	<b><i>Burkholderia cepacia</i> Selective Agar (BCSA) for the isolation of <i>Burkholderia cepacia</i> from sputum in pediatric patients with cystic fibrosis</b>
00:00	C. Ploton, A.M. Freydiere, I. Verdier, F. Vandenesch Laboratoire de Bactériologie, Hôpital Debrousse, Hospices Civils de Lyon, Lyon, France
<b>553/91P</b>	<b>Evaluation of a new GVPC medium for detection of <i>Legionella</i> in clinical samples</b>
00:00	M. Reyrolle, S. Jarraud, J. Freney, J. Etienne Centre National de Référence des Legionnelles, Hopital Edouard Herriot, Lyon, France

- 555/91P Evaluation of Chocolate Haemophilus 2 medium for the detection of *Haemophilus* species from clinical human specimens**  
 00:00 M. Maurin, J. Croizé, J.M. Roche  
*Laboratoire de Bactériologie, CHU A. Michallon, Grenoble, France*
- 556/91P Comparison of disks of cefotaxime, ceftazidime and cefepime combined with clavulanic acid for the detection of extended-spectrum  $\beta$ -lactamases**  
 00:00 F. Bert<sup>1</sup>, M. Juvin<sup>2</sup>, V. Gautier<sup>3</sup>, E. Keller<sup>2</sup>, N. Lambert<sup>1</sup>, G. Arlet<sup>3</sup>  
<sup>1</sup>*Microbiologie, Hôpital Beaujon, Clichy* <sup>2</sup>*Bio-Rad, Marne-La-Coquette* <sup>3</sup>*Microbiologie, Hôpital Tenon, Paris, France*
- 557/91P Rapid identification and susceptibility testing by direct inoculation from blood bottles culture Bactec® into Vitek 2®**  
 00:00 T. Gueudet, M. Saez, C. Christophe  
*Microbiologie, LABM Biosphere, Strasbourg, France*
- 558/91P Antimicrobial susceptibility testing, A new item in the field of European standardisation (Directive 98/79/EC on *in vitro* medical devices).**  
 00:00 N. Charlier-bret, F. Poisson, N. Thevenet  
*Unité Evaluation et Contrôle du Marché des Dispositifs Médicaux de Diagnostic *in vitro* (UECM/DIV), Agence Française de Sécurité Sanitaire des Produits de Santé (AFSSAPS), Saint Denis, France*
- 559/91P Practical application of an internal quality control for agar susceptibility testing using sirscan2000 automatic**  
 00:00 P. Honderlick<sup>1</sup>, S. Baheux<sup>1</sup>, D. Vignon<sup>1</sup>, J.C. Ghnassia<sup>2</sup>  
<sup>1</sup>*Microbiologie, Hôpital Foch, Suresnes* <sup>2</sup>*Microbiologie, Hôpital Mignot, Versailles, France*
- 560/91P Susceptibility to cefradine does not reliably exclude presence of extended-spectrum beta-lactamases.**  
 00:00 F. Mzali, B. Stoddart, T. Collyns, S. Butler, M. Denton, M. Wilcox  
*Microbiology, Leeds Teaching Hospitals Trust, Leeds, United Kingdom*
- 561/91P Quantitative real-time LightCycler PCR for investigation of legionella in 81 industrial cooling water systems**  
 00:00 M. Bernier, B. Baillet, S. Dupuy, R. Fabre  
*LABEGE INNOPOLE, HYGIDIAG, Laboratoire Biopole, Toulouse, France*
- 562/91P Real time PCR for detection of *Brucella* DNA in human serum samples.**  
 00:00 C. Debeaumont, I. Pelloux, M. Maurin  
*Service de bactériologie-virologie, CHU de Grenoble, Grenoble, France*
- 563/91P Contribution of a real-time PCR procedure in the diagnosis of Lyme disease**  
 00:00 N. Houary, J. Wawrzyniak, R. Schroder, P. Goffinet  
*Clinique du Sud Luxembourg, Arlon, Belgium*
- 564/91P A rapid and versatile method to quantify the expression level of *mexAB-oprM* and *mexXY-oprM* genes in *Pseudomonas aeruginosa***  
 00:00 N. Mesaros, N. Caceres, F. Van Bambecke, M.P. Mingeot Leclercq, P.M. Tulkens  
*Unité de pharmacologie cellulaire et moléculaire, Université catholique de Louvain, Bruxelles, France*
- 565/91P Evaluation of VRE carriage in hospital : use of a laboratory method combining enrichment and molecular diagnostic.**  
 00:00 V. Foissaud<sup>1</sup>, M. Fabre<sup>1</sup>, C. Soler<sup>1</sup>, V. Enouf<sup>2</sup>, C. MacNab<sup>1</sup>, E. MBongo-Kama<sup>1</sup>, V. Hervé<sup>1</sup>  
<sup>1</sup>*Biologie, HIA Percy, Clamart* <sup>2</sup>*Biologie, HIA du Val de Grâce, Paris, France*
- 566/91P Evaluation of the GenoType<sup>®</sup> Enterococcus assay for identification of enterococci at the species level and detection of *van* genes**  
 00:00 M.O. Dubos<sup>1</sup>, N. Bourgeois-nicolaos<sup>3</sup>, F. Depardieu<sup>2</sup>, P. Courvalin<sup>2</sup>, F. Doucet-populaire<sup>1-3</sup>  
<sup>1</sup>*Microbiologie, C.H. de versailles, Le Chesnay* <sup>2</sup>*Unité des Agents Antibactériens, Institut Pasteur* <sup>3</sup>*Microbiologie, UFR des Sciences Pharmaceutiques et Biologiques, Paris, France*
- 567/91P VCA3<sup>®</sup> agar (bioMérieux) for selective isolation of vancomycin-resistant enterococci (VRE) from fecal specimens**  
 00:00 J. Delmas, J.P. Romaszko, R. Baraduc, O. Lesens, H. Laurichesse, J. Sirot  
*University Hospital of Clermont-Ferrand, Clermont-Ferrand, France*
- 568/91P A new genetic test for the rapid identification of shiga-toxin producing (STEC) and enteropathogenic (EPEC) *E. coli* isolates from children .**  
 00:00 M.F. Prere, O. Fayet  
*Laboratoire de microbiologie CHU, Laboratoire de microbiologie et génétique moléculaires CNRS-Université Paul Sabatier, Toulouse, France*
- 569/91P Evaluation of the Bactec Mycobacterium Growth Indicator Tube 960 in studying the sensitivity of 91 stains of *Mycobacterium tuberculosis* to first-line drugs**  
 00:00 P. Gérôme<sup>2</sup>, M. Fabre<sup>1</sup>, V. Hervé<sup>1</sup>, C.P. Soler<sup>1</sup>  
<sup>1</sup>*Biologie, Hôpital Percy, Clamart* <sup>2</sup>*Biologie, Hôpital des Armées Desgenettes, Lyon, France*

570/91P	<b>New taxonomy and new identification tools for identification of <i>Nocardia</i> species: new surprising data - A revised epidemiology of nocardiosis in France (2000-2002)</b>
00:00	V. Rodriguez-nava <sup>1</sup> , A. Couble, F. Laurent, P. Boiron <sup>1</sup> UMR 5557 - Center for Microbial Ecology - Opportunistic Pathogens and Environment Research Group, Université Claude Bernard Lyon I - Faculté de Pharmacie, Lyon, France
571/91P	<b>Use of the INO-LiPA Rif.TB ®with regard to surveillance of resistance to rifampicin in <i>Mycobacteria tuberculosis</i></b>
00:00	M. Fabre <sup>2</sup> , C. Soler <sup>2</sup> , P. L'her <sup>2</sup> , J.L. Koeck <sup>5</sup> , P. Gérôme <sup>3</sup> , R. Vong <sup>2</sup> , J.J. De Pina <sup>4</sup> , F. Simon <sup>4</sup> , F. Gérard <sup>2</sup> , E. Garnotel <sup>4</sup> , M. Elouennass <sup>2</sup> , B. Chevalier <sup>6</sup> , G. Raphenon <sup>1</sup> , V. Hervé <sup>2</sup> <sup>1</sup> Biologie, CHA Bouffard, Djibouti, Djibouti <sup>2</sup> Biologie, HIA Percy, Clamart <sup>3</sup> Biologie, HIA Desgenettes, Lyon <sup>4</sup> Biologie, HIA Laveran, Marseille <sup>5</sup> Biologie, HIA du Val de Grâce, Paris, France <sup>6</sup> Biologie, Hôpital Principal de Dakar, Dakar, Senegal
572/91P	<b>Evaluation of the single-use immunoassay Immuno Card Toxins A &amp; B for the diagnosis of <i>Clostridium difficile</i> associated diarrhea.</b>
00:00	V. Lalande <sup>2</sup> , A. Chauvinet <sup>2</sup> , G. Guignedoux <sup>2</sup> , N. Borrelut <sup>2</sup> , C. Gourmet <sup>2</sup> , S. Courant <sup>2</sup> , S. Bonn <sup>1</sup> , M. Moulard <sup>1</sup> , F. Barbut <sup>2-3</sup> , J.C. Petit <sup>2</sup> <sup>1</sup> Meridian Bioscience Europe, Nice <sup>2</sup> Bactériologie <sup>3</sup> Unité d'Hygiène et de Lutte contre les Infections Nosocomiales, Hopital Saint-Antoine, Paris, France
573/91P	<b>Comparison of isolation rates for two culture methods in a well-controlled acute maxillary sinusitis (AMS) clinical study</b>
00:00	D. Shortridge, T. Busman, J. Valdes, C. Olson Anti-Infectives, GPRD, Abbott Laboratories, Abbott Park, IL, United States
574/91P	<b>Consideration of new methods of syphilis diagnosis.</b>
00:00	A. Kerléguer, C. Girard, M. Lenoble, M. Gourven, F. Tissèdre, M. Joussemet Laboratoire de Qualification Biologique du Don, Centre de Transfusion Sanguine des Armées, Clamart, France
575/91P	<b>Short time to positivity in blood cultures with clustered Gram-positive cocci on direct smear examination is highly predictive of <i>Staphylococcus aureus</i>.</b>
00:00	R. Ruimy, L. Armand-lefeuvre, A. Andremont Laboratoire de Bactériologie, Groupe Hospitalier Bichat - Claude-Bernard, Paris, France
576/91P	<b>Analysis of consecutive blood cultures performed in one year by an infectious team: Are three hemocultures still necessary?</b>
00:00	A. Ben Ali, S. Males, M.D. Kitzis, J.C. Nguyen Van, R. Sanz, J. Carlet, F.W. Goldstein Pôle Infectieux., Fondation-Hôpital Saint-Joseph., Paris, France
577/91P	<b>Antimicrobial and membrane permeabilizing activity of peptides derived from human cationic proteins as assessed by the official NCCLS test and by alternative assays</b>
00:00	S. Sánchez Gómez <sup>2</sup> , M. Lamata Subero <sup>2</sup> , G. Martínez De Tejada <sup>2</sup> , J. Leiva León <sup>2</sup> , S. Blondelle <sup>3</sup> , K. Lohner <sup>1</sup> , I. Moriyón <sup>2</sup> <sup>1</sup> Biophysics, Institute of Biophysics and X-Ray Structure Research, Graz, Austria <sup>2</sup> Microbiology, University of Navarra, Pamplona, Spain <sup>3</sup> Microbiology, Torrey PinesInstitute for molecular Studies, San Diego, United States

Friday vendredi	3	December décembre	00:00 00:00	ROOM Salle	POSTER Poster	92P
--------------------	---	----------------------	----------------	---------------	------------------	-----

## BACTERIOLOGICAL INVESTIGATIONS RECHERCHES EN BACTÉRIOLOGIE

578/92P	<b>Use of 16s rRNA gene sequencing for identification of "pseudomonas-like" bacilli isolated from sputum of patients with cystic fibrosis</b>
00:00	D. Moissenet <sup>1</sup> , G. Arlet <sup>2</sup> , H. Vu-Thien <sup>1</sup> <sup>1</sup> Microbiologie, Hôpital Armand-Trousseau <sup>2</sup> Microbiologie, Hôpital Tenon, Paris, France
579/92P	<b>Bacteremic cholangitis due to <i>Pseudomonas mendocina</i> identified by 16S rDNA sequencing and its unique marine smell</b>
00:00	V. Cattoir, O. Lemenand, J.L. Avril, O. Gaillot Bactériologie-Virologie, CHU Pontchaillou, Rennes, France
580/92P	<b>Chronology of the acquisition of mobile genetic elements among <i>Streptococcus agalactiae</i> species</b>
00:00	G. Hery-arnaud, G. Bruant, P. Lanotte, S. Brun, A. Rosenau, N. Van Der Mee-marquet, R. Quentin, L. Mereghetti EA 3250 "Bactéries et risque materno-foetal", Faculté de Médecine, Tours, France
581/92P	<b>Hsp65 gene for the identification of <i>Nocardia</i> : past, present and future</b>
00:00	V. Rodriguez-nava <sup>1</sup> , A. Couble <sup>1</sup> , G. Devulder <sup>2</sup> , J.P. Flandrois <sup>2</sup> , P. Boiron <sup>1</sup> , F. Laurent <sup>1</sup> <sup>1</sup> UMR CNRS 5557 - Center for Microbial Ecology - Opportunistic Pathogens and Environment Research Group - Observatoire Français des Nocardioses, Université Claude Bernard Lyon I, Faculté de Pharmacie, Lyon <sup>2</sup> UMR 5558 Laboratoire de Bactériologie, Université Claude Bernard Lyon I, Faculté de Médecine Lyon Sud, Pierre Bénite, France

- 582/92P** Investigation of co-amoxiclav reduced susceptibility in *Klebsiella pneumoniae* without ESBLs : genetic mechanisms and consequences  
 00:00 S. Corvec<sup>1</sup>, N. Caroff<sup>2</sup>, D. Cosano<sup>2</sup>, E. Espaze<sup>1</sup>, H. Drugeon<sup>1</sup>, A. Reynaud<sup>2</sup>  
<sup>1</sup>Laboratoire de Bactériologie-Virologie-Hygiène Hospitalière, CHU de Nantes <sup>2</sup>Laboratoire de Bactériologie-Virologie, UPRES-JE 2437 Génétique des interactions Hôte-microorganismes, Faculté de Pharmacie, Université de Nantes, Nantes, France
- 583/92P** Many virulence associated genes occur in most K1 and non K1 *E.coli* strains isolated in neonatal infections  
 00:00 M.F. Prère, J. Hoffman, O. Fayet  
*Laboratoire microbiologie et génétique moléculaires, Université Paul Sabatier-CNRS, Toulouse, France*
- 584/92P** Phenotypic and molecular characterisation of human *Streptococcus porcinus* isolates responsible for neonatal and genital tract infections.  
 00:00 C. Martin<sup>1</sup>, N. Lacaux<sup>1</sup>, D. Chainier<sup>1</sup>, C. Marois<sup>2</sup>  
<sup>1</sup>Laboratoire de Bactériologie Virologie Hygiène, CHU Dupuytren, Limoges <sup>2</sup>Unité de Mycoplasmologie, Bactériologie, AFSSA, Ploufragan, France
- 585/92P** Evaluation of two rapid molecular methods: mvla and rapd for cystic fibrosis *Pseudomonas aeruginosa* strains typing  
 00:00 M. Ollier, A. Dubouix, S. Dulon, P. Genon, N. Marty  
*actériologie-Hygiène, CHU RANGUEIL, Toulouse, France*
- 586/92P** Distribution of *papA* and *hlyA* genes in uropathogenic *Escherichia coli* isolated in Alexandria  
 00:00 B.Z. Massoud, S.M. Nafis, M.M. Elmofty, H.A. Hassan  
*Microbiology & Urosurgery, Faculty of medicine, Alexandria, Egypt*
- 587/92P** VacA alleles and CagA distribution of *H.pylori* strains colonized in gastric biopsy samples.  
 00:00 F. Koksal, M.S. Serin, S. Colakoglu, B. Kayar, M. Yetkin, T. Nagiyev, M. Urunsak  
*Dept. of Clin Microbiol, Dept. of Gastroenterol, Faculty of Medicine, Balcal Adana, Turkey*
- 588/92P** A new integron-mediated rifampin resistance in a clinical isolate of *Pseudomonas aeruginosa* , from a Portuguese hospital  
 00:00 A. Duarte<sup>1</sup>, A. Brizio<sup>1</sup>, T. Conceição<sup>1</sup>, T. Ferreira<sup>2</sup>  
<sup>1</sup>Microbiology, Faculty of Pharmacy<sup>2</sup>Microbiology, Hospital Santo Antonio Capuchos, Lisboa, Portugal
- 589/92P** Mechanisms of antibiotic resistance in *Streptococcus pyogenes* (GAS) in Barcelona (January 1999-June 2004).  
 00:00 M. Rebollo<sup>1</sup>, A. Rivera<sup>1</sup>, E. Miró<sup>1</sup>, F. Navarro<sup>1,2</sup>, B. Mirelis<sup>1,2</sup>, P. Coll<sup>1,2</sup>  
<sup>1</sup>Servei de Microbiologia, Hospital de la Santa Creu i Sant Pau<sup>2</sup>Departament de Genètica i Microbiologia, Universitat Autònoma de Barcelona, Barcelona, Spain
- 590/92P** In vitro transfer of erm resistance determinant between the human pathogen *Clostridium difficile* and the rumen anaerobe *Butyrivibrio fibrisolvens*.  
 00:00 P. Mastrantonio, F. Barbanti, P. Spigaglia  
*Department of Infectious, Parasitic and Immune-mediated Diseases ARTRADI Project: European contract QLK2-2002-00843, Istituto Superiore di Sanità, Rome, Italy*
- 591/92P** Plasmid elimination and antimotility studies in the presence of a trifluoroketone proton pump inhibitor on *Escherichia coli* and *Helicobacter pylori* strains  
 00:00 G. Spengler<sup>1</sup>, A. Molnár<sup>1</sup>, G. Klausz<sup>1</sup>, Y. Márdi<sup>1</sup>, M. Kawase<sup>2</sup>, L. Amaral<sup>3</sup>, J. Molnár<sup>1</sup>  
<sup>1</sup>Department of Medical Microbiology and Immunobiology, University of Szeged, Faculty of Medicine, Szeged, Hungary<sup>2</sup>Faculty of Pharmaceutical Sciences, Josai University, Sakado, Saitama, Japan<sup>3</sup>Unit of Mycobacteriology, Universidade Nova de Lisboa, Instituto de Higiene e Medicina Tropical, Lisbon, Portugal
- 592/92P** Characterization of a new integron containing VIM-1, metallo- beta-lactamase gene cassette, in a clinical isolate of *Enterobacter cloacae* and first identification of VIM-1 in *E. aerogenes* and *Citrobacter freundii*.  
 00:00 I. Galani, M. Souli, E. Koratzanis, Z. Chrysouli, H. Giannarellou  
*4th Department of Internal Medicine, Molecular Biology Section of Infectious Diseases Lab, Attikon University General Hospital, Chaidari, Greece*
- 593/92P** Relationships between integrons and antibiotic resistance in commensal *E.coli* isolated from the fecal flora of animals with various vicinity with humans.  
 00:00 D. Skurnik<sup>3</sup>, R. Ruimy<sup>3</sup>, B. Picard<sup>2</sup>, E. Denamur<sup>1</sup>, A. Andremont<sup>3</sup>  
<sup>1</sup>INSERM E03 39, Faculté de Médecine Xavier-Bichat<sup>2</sup>Laboratoire de Microbiologie, Hôpital Avicenne<sup>3</sup>Laboratoire de Bactériologie, Hôpital Bichat-Claude Bernard, Paris, France
- 594/92P** SodA gene sequence-based identification of human isolates of *Pasteurella* and related species  
 00:00 O. Gaillot<sup>3,2</sup>, A. Gautier<sup>3</sup>, D. Dubois<sup>3</sup>, F. Escande<sup>1</sup>, P. Trieu Cuot<sup>2</sup>, J.L. Avril<sup>3</sup>  
<sup>1</sup>Centre National des Pasteurelles<sup>2</sup>Unité de Biochimie Bactérienne, Institut Pasteur, Paris<sup>3</sup>Bactériologie-Virologie, Faculté de Médecine - Université Rennes I, Rennes, France
- 595/92P** Development of a real-time Fluorescence Resonance Energy Transfer (FRET) PCR to identify the main pathogenic *Campylobacter* species  
 00:00 A. Ménard<sup>2</sup>, F. Dachet<sup>2</sup>, V. Prouzet-mauléon<sup>1</sup>, M. Oleastro<sup>3</sup>, F. Mégraud<sup>2,1</sup>  
<sup>1</sup>Centre National de Référence des Campylobacters et Helicobacters, Laboratoire de Bactériologie, Hôpital Pellegrin<sup>2</sup>Laboratoire de Bactériologie, Université Victor Segalen Bordeaux 2, Bordeaux, France<sup>3</sup>Unidade Helicobacter/Campylobacter, INSA, Lisboa, Portugal

- 596/92P** **OmpX, a stress sensor of the enterobacterial outer membrane.**  
 00:00 M. Dupont, J. Chevalier, J.M. Pagès  
*EA 2197, Faculté de Médecine, Marseille, France*
- 597/92P** **Multiple norA promoter mutation leading to ciprofloxacin resistance in *S. aureus*.**  
 00:00 M.A. Gil Díez De Medina<sup>2-3</sup>, J.L. Muñoz Bellido<sup>1,3</sup>, T. Parras Padilla<sup>2-3</sup>, J.A. García Rodríguez<sup>2</sup>  
<sup>1</sup>Subdirección Médica, Servicio de Salud, Valdivia, Chile<sup>2</sup>Departamento de Microbiología, Hospital Universitario de Salamanca<sup>3</sup>Departamento de Medicina Preventiva, Salud Pública y Microbiología Médica, Universidad de Salamanca, Salamanca, Spain
- 598/92P** **Comparision of three extraction methods before real-time pcr amplification of *Streptococcus agalactiae* in gastric aspirates**  
 00:00 A. Jolivet-gougeon<sup>2</sup>, A. Le Meur<sup>2</sup>, M. Robert<sup>2</sup>, J.Y. Grall<sup>1</sup>, J. Minet<sup>2</sup>, M. Cormier<sup>2</sup>  
<sup>1</sup>Gynécologie Obstétrique, CHU Rennes <sup>2</sup>Microbiologie, Université de Rennes 1, Rennes, France
- 599/92P** **Molecular typing of coagulase-negative staphylococci (CNS) isolated from successive blood cultures of inpatients, and evaluating its correlation with infection**  
 00:00 S. Serin Senger, M. Erdenizmenli Saccozza, A. Yuce  
*Department of Infectious Diseases and Clinical Microbiology, Dokuz Eylul University, Izmir, Turkey*
- 600/92P** **In vitro synergy of linezolid (LNZ) in combination with ertapenem (ETP) against methicillin-resistant *Staphylococcus aureus* (MRSA)**  
 00:00 C. Jacqueline, J. Caillon, V. Le Mabecque, A.F. Miegeville, E. Batard, B. Helfer, D. Bugnon, G. Potel  
*UPRES EA 1156, Lab. Antibioologie, Nantes, France*
- 601/92P** **Susceptibility of isolated bacteria to antibiotics in hospitalized patients**  
 00:00 O. Katashinsky<sup>1</sup>, V. Kresiun<sup>3</sup>, P. Tchuev<sup>4</sup>, T. Opiatova<sup>2</sup>, V. Pushkina<sup>5</sup>, V. Lozitsky<sup>6</sup>  
<sup>1</sup>Anesthesiology and Resuscitation <sup>2</sup>Microbiology, State Clinical Hospital <sup>3</sup>Pharmacology <sup>4</sup>Resuscitation, State Medical University <sup>5</sup>Bacteriology <sup>6</sup>Chemotherapeutical and Immunobiological Preparations, Ukrainian Anti-Plague Institute, Odessa, Ukraine
- 602/92P** **Influence of alteplase on minimal inhibitory concentrations of vancomycin and amikacin**  
 00:00 V. Thonier<sup>1</sup>, M. Levast<sup>1</sup>, D. Champelovier<sup>1</sup>, C. Recule<sup>1</sup>, P. Pavese<sup>3</sup>, L. Foroni<sup>4</sup>, G. Pernod<sup>2</sup>, J. Croize<sup>1</sup>, M. Maurin<sup>1</sup>  
<sup>1</sup>Laboratoire bactériologie<sup>2</sup>Laboratoire hématologie<sup>3</sup>Médecine infectieuse<sup>4</sup>Pharmacie, CHU Grenoble, Grenoble, France
- 603/92P** **Synergistic action of phospholipase a<sub>2</sub> and betalactam antibiotics against *Pseudomonas aeruginosa* cystic fibrosis isolates**  
 00:00 A. Dubouix, C. Campanac, C. Roques, J.P. Salles, H. Chap, G. Chabanon, N. Marty  
*Bactériologie-Hygiène, CHU RANGUEIL, Toulouse, France*
- 604/92P** **Bactericidal activity of serum against *Salmonella* O48 serovars.**  
 00:00 G. Bugla<sup>2</sup>, A. Korzeniowska-Kowal<sup>1</sup>, A. Gamian<sup>1</sup>, W. Doroszkiewicz<sup>2</sup>  
<sup>1</sup>Ludwik Hirszfeld Institute of Immunology and Experimental Therapy,, Polish Academy of Sciences <sup>2</sup>Institute of Genetic and Microbiology, University of Wrocław, Wrocław, Poland
- 605/92P** ***Salmonella enterica* serovar Infantis harbouring a CTX-M-9 beta-lactamase.**  
 00:00 E.D. Valverde Romero<sup>1</sup>, M.I. Garcia Garcia<sup>1</sup>, T. Parras Padilla<sup>1</sup>, A. Herrero Hernández<sup>1</sup>, J.L. Muñoz Bellido<sup>1,2</sup>, J.A. García Rodríguez<sup>1-2</sup>  
<sup>1</sup>Departamento de Microbiología, Hospital Universitario de Salamanca<sup>2</sup>Departamento de Medicina Preventiva, Salud Pública y Microbiología Médica, Universidad de Salamanca, Salamanca, Spain
- 606/92P** **Antimicrobial activity of non-antibiotics and chances for eradication of infection diseases**  
 00:00 S. Tyski, H. Kruszewska, T. Zareba  
*Antibiotics and Microbiology, National Institute of Public Health, Warsaw, Poland*
- 607/92P** **Phage type, drug resistance and biofilm formation of human *Salmonella enterica* serovar Typhimurium strains isolated in Slovakia**  
 00:00 L. Majtanova, V. Majtan  
*Microbiology, Slovak Medical University, Bratislava, Slovakia*
- 608/92P** **Postantibiotic effects of fluoroquinolones on some Gram-negative bacterial pathogens.**  
 00:00 V. Majtan, L. Majtanova  
*Microbiology, Slovak Medical University, Bratislava, Slovakia*
- 609/92P** **Antimicrobial activity of volatile oils**  
 00:00 Z.S. Schelz<sup>1</sup>, J. Molnar<sup>1</sup>, J. Hohmann<sup>2</sup>  
<sup>1</sup>Department of Medical Microbiology and Immunobiology, University of Szeged, Faculty of Medicine <sup>2</sup>Department of Pharmacognosy, University of Szeged, Faculty of Pharmacy, Szeged, Hungary
- 610/92P** **Postantibiotic effect (PAE) of colisin on multidrug-resistant *Acinetobacter baumannii***  
 00:00 A. Antonopoulou, N. Ketebozidis, T. Tsaganos, F. Baziaka, H. Giannarellou, E.J. Giannarellou-Bourboulis  
*4th Department of Internal Medicine, Athens Medical School, Athens, Greece*
- 611/92P** **Phenotypic detection of metallo-beta-lactamase producing *Pseudomonas aeruginosa* imipenem resistant**  
 00:00 S. Hammami, R. Ghazzi, A. Ben Hassen, I. Boutiba, A. Kammoun, S. Ben Redjeb  
*Laboratoire "Résistance aux antibiotiques", Faculté de Médecine, Tunis, Tunisia*

- 612/92P** **Photodynamic therapy with a cationic phthalocyanine: a new antimicrobial approach to infectious diseases**  
 00:00 M. Soncin<sup>2</sup>, C. Fabris<sup>2</sup>, L. Fantetti<sup>1</sup>, D. Dei<sup>1</sup>, G. Roncucci<sup>1</sup>, G. Jori<sup>2</sup>  
<sup>1</sup>Molteni Farmaceutici, Florence<sup>2</sup>Department of Biology, University of Padova, Padova, Italy
- 613/92P** **Anti-microbial effects of nonantibiotics: Influence of phenothiazine -derivatives on bacterial invasion of epithelial cells**  
 00:00 O. Hendricks<sup>2-4</sup>, H. Sahly<sup>5</sup>, R. Podschun<sup>5</sup>, J.B. Christensen<sup>1</sup>, M. Skov<sup>2</sup>, U. Ullmann<sup>5</sup>, H.J. Kolmos<sup>2-4</sup>, J.E. Kristiansen<sup>2-3</sup>  
<sup>1</sup>Chemical Laboratory II, University of Copenhagen, Copenhagen<sup>2</sup>Department of Clinical Microbiology, University of Southern Denmark, Odense<sup>3</sup>Department of Clinical Microbiology, Sønderborg Hospital<sup>4</sup>Department of Clinical Research, University of Southern Denmark, Sønderborg, Denmark<sup>5</sup>Department of Medical Microbiology and Virology, University of Kiel, Kiel, Germany
- 614/92P** **Detection of a variant CTX-M3 extended spectrum beta-lactamase gene, in a community-acquired strain of *Escherichia coli***  
 00:00 S. Pournaras<sup>2</sup>, I. Kristo<sup>2</sup>, A. Tsakris<sup>1</sup>, A.N. Maniatis<sup>2</sup>  
<sup>1</sup>Dept. of Microbiology, Faculty of Nursing, Univ. of Athens, Athens<sup>2</sup>Dept. of Microbiology, Medical School, Univ. of Thessaly, Larissa, Greece
- 615/92P** **Descriptive study of β-lactamase with broad spectrum detected in enterobacteria isolated in Central African Republic (CAR)**  
 00:00 T. Frank<sup>1</sup>, G. Arlet<sup>2</sup>, R. Zenguela<sup>1</sup>, J.R. Mbecko<sup>1</sup>, P. Missatou<sup>1</sup>, A.R. Bercion<sup>1</sup>  
<sup>1</sup>Service de Bactériologie, Institut Pasteur de Bangui, Bangui, Central African Republic<sup>2</sup>Service de Bactériologie - Hygiène, Hôpital Tenon, Paris, France
- 616/92P** **Experimental prediction of the evolution of ceftazidime resistance in the CTX-M-9 extended-spectrum beta-lactamase**  
 00:00 J. Delmas, F. Robin, R. Bonnet, C. Chanal, D. Sirot, J. Sirot  
*Bactériologie, Faculté de Médecine, Clermont-Ferrand, France*
- 617/92P** **Bactericidal activity of 2000/125 mg sustained-release versus 875/125 mg amoxicillin/clavulanic acid against *S. pneumoniae*: an amoxicillin in vitro pharmacodynamic simulation.**  
 00:00 D. Sevillano, A. Calvo, L. Aguilar, L. Alou, M.J. Giménez, E. Valero, J. Prieto  
*Microbiology Department, School of Medicine. Universidad Complutense de Madrid, Madrid, Spain*
- 618/92P** **Inducement and reversal of tetracycline resistance in *Escherichia coli* K-12 through the expression of proton gradient dependent multidrug efflux pumps.**  
 00:00 L. Amaral<sup>2</sup>, M. Viveiros<sup>2</sup>, C. Leandro<sup>2</sup>, M. Martins<sup>2</sup>, D. Ordway<sup>2</sup>, A.N. Molnar<sup>1</sup>, J. Molnar<sup>1</sup>  
<sup>1</sup>Microbiology & Immunology, Institute of Medical Microbiology, Szeged, Hungary<sup>2</sup>Unit of Mycobacteriology, Centre for Parasitology & Medical Microbiology, Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa, Lisbon, Portugal
- 619/92P** **MedQual, a network for the good use of antibiotics in the Pays de la Loire's Region**  
 00:00 F.N. Ballereau<sup>1-5</sup>, F. Ollivier<sup>1</sup>, H.B. Drugeon<sup>3-5-1</sup>, P. Lombrail<sup>2-5-1</sup>, B. Chupin<sup>1</sup>, G. Potel<sup>4-5-1</sup>  
<sup>1</sup>MedQual<sup>2</sup>PIMESP<sup>3</sup>Service de Bactériologie et Hygiène<sup>4</sup>Service des Urgences, CHU de Nantes<sup>5</sup>UPRES EA 1156: thérapeutiques cliniques et expérimentales des infections, Université de Nantes, Nantes, France
- 620/92P** **Nosocomial legionella from a hot water supply**  
 00:00 N.H. O'Connell, J.K. Struthers, M.J. Weinbren  
*Microbiology, UHCW, Coventry, United Kingdom*
- 621/92P** **Evaluation of experimental mediastinitis model by using precolonized implants and bacterial suspension**  
 00:00 G. Ersoz<sup>2</sup>, B. Aytacoglu<sup>1</sup>, N. Sucu<sup>1</sup>, I. Bayindir<sup>2</sup>, A. Kayar<sup>1</sup>, M. Dikmengil<sup>1</sup>  
<sup>1</sup>department of cardiovascular surgery<sup>2</sup>department of clinical microbiology and infectious diseases, mersin university, school of medicine, Mersin, Turkey
- 622/92P** **An in-vitro comparison of the adherence ability of cell wall deficient *Staphylococcus aureus* versus cell wall competent *S. aureus*.**  
 00:00 J. Page<sup>2</sup>, T. Fawcett<sup>1</sup>, F. Natrass<sup>2</sup>, P. Cook<sup>2</sup>  
<sup>1</sup>Microbiology, University of Durham, Durham<sup>2</sup>Clinical Medical Sciences, University of Newcastle, Newcastle Upon Tyne, United Kingdom
- 623/92P** **Comparison of the efficacy of rifampicin and moxifloxacin in experimental brucellosis in a rat model**  
 00:00 N. Sezak, Z. Kuruuzum, N. Cakir, A. Yuce  
*Department of Infectious Diseases and Clinical Microbiology, Dokuz Eylul University School of Medicine, Izmir, Turkey*
- 624/92P** **In vitro activities of azithromycin, telithromycin and levofloxacin against *Chlamydophila pneumoniae* in an acute and in a continuous-infection model**  
 00:00 D. Caronzolo, V. Lucini, S. Grosso, M. Pannacci, F. Colleoni, F. Scaglione  
*Dept. Pharmacology, University of Milan, Milan, Italy*
- 625/92P** **Staphylococcal Panton-Valentine leucocidin as the single virulence factor associated to furuncles**  
 00:00 L. Baba Moussa<sup>1</sup>, G. Prévost<sup>4</sup>, M. Couturier<sup>4</sup>, B. Moreau<sup>2</sup>, R. Pradinaud<sup>3</sup>, H. Monteil<sup>4</sup>, P. Couppié<sup>3</sup>  
<sup>1</sup>FAST, Université d'Abomey-Calavi, Cotonou, Benin<sup>2</sup>Bactériologie<sup>3</sup>Dermatologie, CHG Cayenne, Cayenne<sup>4</sup>Bactériologie - EA-3432, CHRU - ULP, Strasbourg, France
- 626/92P** **EPs 7630 exhibits antibacterial activity by inhibiting adhesion of group A streptococci to HEp-2 cells**  
 00:00 A. Dorfmüller, I. Jung, C. Lallemand, I. Engels, F. Daschner, U. Frank  
*Institute of Environmental Health and Hospital Epidemiology, University Hospital Freiburg, Freiburg, Germany*

<b>627/92P</b>	<b>Are bacterial virulence factors involved in <i>E. coli</i> bacteraemia secondary to urinary tract infection?</b>
00:00	X. Bertrand, D. Mercier, D. Talon Hygiène Hospitalière, CHU, Besançon, France
<b>628/92P</b>	<b>Longitudinal survey of virulence factors: EXO U, EXO S and PLC produced by <i>Pseudomonas Aeruginosa</i> cystic fibrosis isolates</b>
00:00	A. Dubouix, M. Ollier, S. Dulon, N. Marty Bactériologie-Hygiène, CHU RANGUEIL, Toulouse, France
<b>629/92P</b>	<b>Putative role of antibodies against <i>Clostridium difficile</i> virulence factors in <i>Clostridium difficile</i> associated disease</b>
00:00	S. Pechine <sup>2</sup> , A. Gleizes <sup>2</sup> , C. Janoir - Jouveshomme <sup>2</sup> , M.C. Barc <sup>2</sup> , M. Delmee <sup>1</sup> , A. Collignon <sup>2</sup> <sup>1</sup> Microbiologie, Université catholique de Louvain, Faculté de Médecine, Bruxelles, Belgium <sup>2</sup> Microbiologie, Université Paris XI, Faculté de pharmacie, Chatenay-Malabry, France
<b>630/92P</b>	<b>Virulence factors associated with <i>Staphylococcus aureus</i> isolated from genitourinary tracts infections</b>
00:00	L. Baba-moussa <sup>2</sup> , L. Anani <sup>1</sup> , N. Haïkou <sup>2</sup> , F. Hounsoou <sup>1</sup> , M. Couturier <sup>3</sup> , A. Sanni <sup>2</sup> , H. Montell <sup>3</sup> , G. Prévost <sup>3</sup> <sup>1</sup> Laboratoire National de Santé Publique <sup>2</sup> F.A.S.T., Université d'Abomey-Calavi, Cotonou, Benin <sup>3</sup> Bactériologie - UPRES EA-3432, CHRU - ULP, Strasbourg, France
<b>631/92P</b>	<b>Sero-epidemiological study of rickettsioses in the 'Aures'. A preliminary inquiry's results</b>
00:00	S. Tebbal, A. Benyahia, R. Ait Hamouda, B. Amrani, H. Mahdjoub Maladies Infectieuses, Hôpital Batna, Batna, Algeria
<b>632/92P</b>	<b>Identification of a new restriction modification system in <i>Helicobacter pylori</i>.</b>
00:00	P. Lehours <sup>2-1</sup> , J. Chaineux <sup>2-1</sup> , S. Dupouy <sup>2-1</sup> , A. Ménard <sup>2-1</sup> , A. Morgner <sup>3</sup> , F. Mégraud <sup>2-1</sup> <sup>1</sup> Centre National de Référence des Campylobacter et Helicobacters, Laboratoire de Bactériologie, Hôpital Pellegrin <sup>2</sup> Laboratoire de Bactériologie, Université Victor Segalen Bordeaux 2, Bordeaux, France <sup>3</sup> Bereich Gastroenterologie, Medizinische Klinik und Poliklinik I, Dresden, Germany
<b>633/92P</b>	<b>Etiology and resistance in bacterial isolates from oncologic surgery in 2002 in comparison to 1999 after 4 years of increasing use of antibiotics.</b>
00:00	E. Kalavsky, M. Sasalova, J. Vasilova Department of Clinical farmacology, Faculty of Public Health, Trnava, Slovakia

Friday vendredi	<b>3</b>	December décembre	00:00 00:00	ROOM Salle	—	POSTER Poster	<b>93P</b>
--------------------	----------	----------------------	----------------	---------------	---	------------------	------------

## ANTIBIOTICS, ANTISEPTICS, HYGIENE ANTIBIOTIQUES, ANTISEPTIQUES, HYGIÈNE

<b>634/93P</b>	<b>Administration of one versus two doses of ticarcillin / clavulanic acid for chemoprophylaxis on large bowel surgery.</b>
00:00	P.N. P. Ntasiou <sup>1</sup> , K.K. K. Kanellakopoulou <sup>2</sup> , S.P. S. Pinis <sup>1</sup> , P.G. P. Giannakakis <sup>1</sup> , A. Dervisoglou <sup>1</sup> , H.G. H. Giamarellou <sup>2</sup> <sup>1</sup> 2nd Department of Surgery, General State Hospital of Piraeus <sup>2</sup> 4th Department of Internal Medicine, Athens University, Athens, Greece
<b>635/93P</b>	<b>Antibiotic prophylaxis and anterior cruciate ligament reconstruction</b>
00:00	N. Kordalis <sup>2</sup> , C.H. Papageorgiou <sup>2</sup> , H. Vasiliadis <sup>2</sup> , D. Pafilis <sup>2</sup> , M. Marangos <sup>3</sup> , D. Papamichail <sup>1</sup> , A. Beris <sup>2</sup> <sup>1</sup> Biopathology <sup>2</sup> Orthopaedic, University Hospital of Ioannina, Ioannina <sup>3</sup> Infectious Diseases, University Hospital of Patras, Patra, Greece
<b>636/93P</b>	<b>Antibiotic prophylaxis of postoperative infectious complications (POIC) in colorectal cancer (CRC) patients</b>
00:00	I.N. Petukhova NN Blokhin Cancer Res Ctr, Moscow, Russia
<b>637/93P</b>	<b>Antimicrobic linen in the control of hospital infection in neutropenic patients</b>
00:00	I. Kuznecovs, S. Kuznecovs, G. Kuznecova Microbiology Unit, Public Health Research Laboratory, Riga, Latvia
<b>638/93P</b>	<b>Antimicrobial surveillance in the Intensive Care Unit, using Serial Temporal Models and calculation of the Dispensed Daily Total Dose</b>
00:00	O. Lupi <sup>2-1</sup> , T. Campos <sup>1</sup> , E. Faria <sup>1</sup> , N. Percia <sup>1</sup> , L. Kalab <sup>1</sup> , B. Pereira <sup>3</sup> , P. Brasil <sup>2</sup> <sup>1</sup> ICT, Hospital Barra D'or <sup>2</sup> Medicina tropical, Instituto Oswaldo Cruz <sup>3</sup> NESC, Universidade Federal do Rio de Janeiro, Rio De Janeiro, Brazil
<b>639/93P</b>	<b>Imipenem-cilastatin in treatment of complicated urinary tract infections (UTIs)</b>
00:00	O. Loran, V. Beloborodov, L. Sinyakova, I. Kosova Urology, RMAPO, Moscow, Russia

<b>640/93P</b>	<b>Prospectives in multifunctional materials (MFM): bioabsorbable osteoconductive drug-releasing hard tissue fixation devices</b>
00:00	N. Ashammakh <sup>1,2</sup> , M. Veiranto <sup>4</sup> , P. Viitanen <sup>4</sup> , K. Knuutila <sup>4</sup> , E. Suokas <sup>3</sup> , J. Tiainen <sup>2</sup> , S. Leinonen <sup>2</sup> , S.M. Niemelä <sup>2</sup> , H. Syrijälä <sup>1</sup> , H. Aro <sup>5</sup> , T. Waris <sup>2</sup> , P. Törmälä <sup>4</sup>
	<sup>1</sup> Department of Infection control <sup>2</sup> Department of Surgery, Oulu University Hospital, Oulu <sup>3</sup> Linvatec Biomaterials Ltd. <sup>4</sup> Institute of Biomaterials, Tampere University of Technology, Tampere <sup>5</sup> Department of Surgery, University of Turku, Turku, Finland
<b>641/93P</b>	<b>Could short-acting alcohol-only gels facilitate cross-infection?</b>
00:00	R.L.R. Hill <i>HPA &amp; Infection, GKT School of Medicine, London, United Kingdom</i>
<b>642/93P</b>	<b>Compliance with hand hygiene recommendations in a Greek tertiary hospital</b>
00:00	S. Athanasia, A. Antoniadou, H. Giannarellou <i>4th Department of Internal Medicine, Athens Medical School, Athens, Greece</i>
<b>643/93P</b>	<b>Comparative eradication of transient carriage of multidrug-resistant species by two alcohol-base antiseptics: Hibitane vs Sterillium.</b>
00:00	S. Athanasia, R. Vorou, S. Trichias, S. Voulgaridis, X. Papathanakos, H. Giannarellou <i>4th Department of Internal Medicine, Athens Medical School, Athens, Greece</i>
<b>644/93P</b>	<b>Cephalosporins cycling in the cardio-surgery intensive care unit</b>
00:00	N.V. Beloborodova, T.Y.U. Vostrikova, D.A. Popov <i>Laboratory of Clinical Microbiology and Antimicrobial Therapy, Bakoulev Scientific Center for Cardiovascular Surgery, Moscow, Russia</i>

Friday vendredi	<b>3</b>	December décembre	00:00 00:00	ROOM Salle	POSTER Poster	<b>94P</b>
--------------------	----------	----------------------	----------------	---------------	------------------	------------

## OSTÉO-ARTICULAR INFECTIONS INFECTIONS OSTÉO-ARTICULAIRES

<b>645/94P</b>	<b>Coagulase negative <i>Staphylococci</i> isolated in septic orthopedic surgery: a four year prospective study using sodA sequencing genotypic identification.</b>
00:00	V. Sivadon-tardy <sup>3</sup> , M. Rottman <sup>3</sup> , S. Chaverot <sup>3</sup> , J.C. Quincampoix <sup>3</sup> , V. Avetand <sup>3</sup> , P. De Mazancourt <sup>2</sup> , L. Bernard <sup>5</sup> , P. Trieu-cuot <sup>6</sup> , J.M. Féron <sup>4</sup> , A. Lortat-jacob <sup>1</sup> , P. Piriou <sup>4</sup> , T. Judet <sup>4</sup> , J.L. Gaillard <sup>3</sup> <sup>1</sup> Service de Chirurgie Orthopédique et Traumatologique, Hôpital Ambroise Paré, AP-HP <sup>2</sup> Laboratoire de Biochimie <sup>3</sup> Laboratoire de Microbiologie <sup>4</sup> Service de Chirurgie Orthopédique et Traumatologique <sup>5</sup> Service de Maladies Infectieuses, Hôpital Raymond Poincaré. AP-HP, Garches <sup>6</sup> Laboratoire Mixte Pasteur-Necker de Recherche sur les Streptocoques et Streptococcies and Unite INSERM 570, Faculté de Médecine Necker-Enfants Malades, Paris, France
<b>646/94P</b>	<b><i>Streptococcus agalactiae</i>(group B) joint prosthesis infection: a retrospective study of 20 cases</b>
00:00	M. Lavigne <sup>2</sup> , V. Zeller <sup>1,2</sup> , L. Lhotellier <sup>1</sup> , W. Graff <sup>1</sup> , P. Leonard <sup>1</sup> , F. Ducroquet <sup>1</sup> , J.M. Ziza <sup>2</sup> , P. Mamoudy <sup>1</sup> , N. Desplaces <sup>1</sup> <sup>1</sup> Chirurgie Orthopédique, GH Diaconesses- Croix Saint Simon <sup>2</sup> Médecine Interne et Rhumatologie, GH Diaconesses -Croix Saint Simon, Paris, France
<b>647/94P</b>	<b>The role of fungi in the pathogenesis of chronic post-traumatic osteitis.</b>
00:00	B. Beovic <sup>2</sup> , N. Gunde Cimerman <sup>4</sup> , M. Cimerman <sup>3</sup> , P. Zalar <sup>4</sup> , M. Volavsek <sup>1</sup> , M. Groznik <sup>3</sup> <sup>1</sup> Institute of Pathology, Medical Faculty <sup>2</sup> Department of Infectious Diseases <sup>3</sup> Department of Traumatology, University Medical Centre <sup>4</sup> Faculty of Biology, University of Ljubljana, Ljubljana, Slovenia
<b>648/94P</b>	<b>Imipenem-cilastatin treatment of osteo-articular infections caused by Gram-negative rods resisting all β-lactams other than carbapenems.</b>
00:00	M. Rottman <sup>3</sup> , J.N. Martin <sup>2</sup> , P. Gaudin <sup>1</sup> , T. David <sup>1</sup> , E. Ronco <sup>3</sup> , T. Judet <sup>2</sup> , A. Lortat Jacob <sup>1</sup> , P. Piriou <sup>3</sup> , J.L. Gaillard <sup>3</sup> <sup>1</sup> Service de Chirurgie Orthopédique et Traumatologique, Hôpital Ambroise Paré. AP-HP, Boulogne Billancourt <sup>2</sup> Service de Chirurgie Orthopédique et Traumatologique <sup>3</sup> Service de Microbiologie, Hôpital Raymond Poincaré. AP-HP, Garches, France
<b>649/94P</b>	<b>Teicoplanin osteitis therapy in the elderly : is it secure enough?</b>
00:00	L. Bourguignon <sup>1</sup> , M.A. Confesson <sup>2</sup> , G. Carret <sup>1</sup> , P. Maire <sup>1</sup> <sup>1</sup> UMR CNRS 5558, Hospices Civils de Lyon, Francheville <sup>2</sup> Centre Hospitalier de Mâcon, Infection Control Unit, Mâcon, France
<b>650/94P</b>	<b>In vitro elution of fucidic acid from Plaster of Paris</b>
00:00	P. Panagopoulos, K. Kanellakopoulou, K. Athanasiou, I. Katsarolis, G. Poulakou, Z. Chrysouli, H. Giannarellou <i>4th Department of Internal Medicine, ATTIKON University General Hospital, Athens University Medical School, Athens, Greece</i>

**OUTBREAKS OF GRAM NEGATIVE BACILLI INFECTIONS**  
**EPIDÉMIES D'INFECTIONS À BACILLES GRAM NÉGATIF**

- 651/95P Use of pulsed field gel electrophoresis to investigate an outbreak of *Serratia marcescens* infection in a Tunisian intensive care unit**  
00:00 S. Ktari<sup>1</sup>, H. Kallel<sup>2</sup>, N. Hammami<sup>1</sup>, L. Hergaff<sup>2</sup>, F. Mahjoubi<sup>1</sup>, M. Bouaziz<sup>2</sup>, A. Hammami<sup>1</sup>  
<sup>1</sup>Laboratoire de Microbiologie<sup>2</sup>Service de Réanimation Médicale, CHU Habib Bourguiba, Sfax, Tunisia
- 652/95P Clinical and molecular epidemiology of *Citrobacter* spp. infections in Nîmes University Hospital.**  
00:00 J.P. Lavigne<sup>2,4</sup>, C. Defez<sup>1,3</sup>, N. Bouziges<sup>2,4</sup>, A. Sotto<sup>1,2</sup>  
<sup>1</sup>Laboratoire d'Epidémiologie, de Biostatistiques et de Recherche Clinique, EA 2415, Montpellier<sup>2</sup>Laboratoire Universitaire d'Antibiologie, Faculté de Médecine Montpellier Nîmes<sup>3</sup>Département d'Information Médicale<sup>4</sup>Laboratoire de Bactériologie Virologie, Groupe Hospitalo-Universitaire de Carémeau, Nîmes, France
- 653/95P Exploration of an outbreak of cefotixin-resistant *Klebsiella pneumoniae* in a neonatal intensive care unit**  
00:00 N. Ben Saida, N. Sfar, J. Boukadida  
Microbiologie - UR 16/02, CHU F HACHED, Sousse, Tunisia
- 654/95P Contribution of tap water to nosocomial transmission of *Pseudomonas aeruginosa* in intensive care unit**  
00:00 A.M. Rogues<sup>1</sup>, D. Gruson<sup>3</sup>, H. Boulestreau<sup>1</sup>, S. Boulon<sup>1</sup>, C. Merle<sup>1</sup>, A. Lasheras<sup>1</sup>, C.M. Bébérard<sup>2</sup>, J.P. Gachie<sup>1</sup>  
<sup>1</sup>Service d'Hygiène Hospitalière<sup>2</sup>Service de Bactériologie Groupe Hospitalier Pellegrin<sup>3</sup>Service de réanimation médicale, CHU de Bordeaux, Bordeaux, France
- 655/95P Nosocomial outbreak of *Burkholderia cepacia* in a French ICU: epidemiological investigations and control**  
00:00 C. Bouvet<sup>3</sup>, A. Menard<sup>4</sup>, R. Miollan<sup>3</sup>, S. Gaillard<sup>2</sup>, B. Cournoyer<sup>4</sup>, F. Laurent<sup>1,4</sup>, H. De Montclos<sup>1</sup>  
<sup>1</sup>Laboratoire de Microbiologie<sup>2</sup>Service de Réanimation<sup>3</sup>UDLIN de l'Ain, Centre Hospitalier Fleyriat, Bourg-En-Bresse<sup>4</sup>UMR CNRS 5557 - Center for Microbial Ecology - Opportunistic Pathogens and Environment Research Group, Université Claude Bernard Lyon I, Villeurbanne, France
- 656/95P Spread of non-metallo-beta-lactamase-producing highly meropenem resistant *Pseudomonas aeruginosa* in a region with bla<sub>VIM</sub> endemicity.**  
00:00 M. Maniatis<sup>3</sup>, S. Pournaras<sup>3</sup>, P.T. Tassios<sup>2</sup>, A. Tsakris<sup>1</sup>, N.J. Legakis<sup>2</sup>, A.N. Maniatis<sup>3</sup>  
<sup>1</sup>Department of Microbiology, Faculty of Nursing<sup>2</sup>Department of Microbiology, Medical School, University of Athens, Athens<sup>3</sup>Department of Medical Microbiology, Medical School, University of Thessaly, Larissa, Greece
- 657/95P Implication of multiresistant *Acinetobacter baumannii* in nosocomial outbreaks**  
00:00 D. Hédhli, R. Ghazzi, I. Boutiba, A. Kammoun, S. Ben Redjeb  
laboratoire "Résistance aux antibiotiques", Faculté de Médecine, Tunis, Tunisia
- 658/95P Nosocomial outbreak of *Salmonella* Livingstone in a newborn unit in Tunisia**  
00:00 N. Ben Saida, H. Ben Abdallah, N. Hannachi, J. Boukadida  
MICROBIOLOGY - UR 16/02, CHU F. HACHED, Sousse, Tunisia
- 659/95P Bacterial contamination associated with electronic and manual faucets**  
00:00 J. Merrer<sup>4</sup>, E. Girou<sup>2</sup>, D. Ducellier<sup>2</sup>, N. Clavreul<sup>4</sup>, F. Cizeau<sup>2</sup>, P. Legrand<sup>1</sup>, M. Leneveu<sup>3</sup>  
<sup>1</sup>Laboratoire de Bactériologie<sup>2</sup>Unité d'Hygiène, CHU Henri Mondor, Creteil<sup>3</sup>Laboratoire de Microbiologie<sup>4</sup>Unité d'Hygiène, CHI Poissy/St Germain-en-Laye, Poissy, France

**PHARMACOLOGY, SAFETY AND PHARMACOECONOMY OF ANTIINFECTIVE DRUGS**  
**PHARMACOLOGIE, TOLÉRANCE ET PHARMACOÉCONOMIE DES ANTIINFECTIEUX**

- 660/96P Continuous (CI) versus intermittent (BID) infusion of temocillin (TMO) in intensive care (IC) patients**  
00:00 V. Basma, R. De Jongh, F. Van Bambeke, M.P. Mingeot Leclercq, P.M. Tulkens  
Université catholique de Louvain, Bruxelles, Belgium
- 661/96P Concentrations in plasma and urinary excretion of Ciprofloxacin XR (1000 Milligrams) versus levofloxacin (500 Milligrams) in healthy volunteers receiving a single oral dose**  
00:00 F.M.E. Wagenlehner<sup>2</sup>, U. Tischmeyer<sup>2</sup>, M. Kinzig-schippers<sup>1</sup>, C. Wagenlehner<sup>2</sup>, F. Sörgel<sup>1</sup>, K.G. Naber<sup>2</sup>  
<sup>1</sup>Institute for Biomedical and Pharmaceutical Research, IBMP, Nürnberg-Heroldsberg<sup>2</sup>Urologic Clinic, Hospital St. Elisabeth, Straubing, Germany

<b>662/96P</b>	<b>Importance of monitoring antibiotic plasma levels in bone and joint infections</b>
00:00	V. Zeller <sup>1</sup> , M.D. Kitzis <sup>2</sup> , L. Lhotellier <sup>1</sup> , W. Graff <sup>1</sup> , P. Leonard <sup>1</sup> , P. Mamoudy <sup>1</sup> , N. Desplaces <sup>2</sup> <sup>1</sup> Chirurgie Orthopédique, GH Diaconesses-Croix Saint Simon <sup>2</sup> Service de Microbiologie Médicale, Hôpital Saint Joseph, Paris, France
<b>663/96P</b>	<b>Population pharmacokinetic of atazanavir in HIV -infected patients</b>
00:00	F. Lanet <sup>4</sup> , N. Simon <sup>4</sup> , C. Solas <sup>4</sup> , I. Ravaux <sup>1</sup> , MP. Drogoul <sup>3</sup> , A. Lafeuillade <sup>5</sup> , S. Mokhtari <sup>2</sup> , A. Durand <sup>4</sup> , B. Lacarelle <sup>4</sup> <sup>1</sup> Infectious Diseases, AP-HM Conception <sup>2</sup> Infectious Diseases, AP-HM Nord <sup>3</sup> Haematology, AP-HM Sainte-Marguerite <sup>4</sup> Pharmacokinetics, AP-HM Timone, Marseille <sup>5</sup> Infectious Diseases, Chalucet Hospital, Toulon, France
<b>664/96P</b>	<b>High lopinavir plasma concentrations are associated with changes in lipid levels at m6 in HIV-infected patients</b>
00:00	J.M. Besnier <sup>3</sup> , S. Veillon <sup>3</sup> , P. Arsac <sup>2</sup> , Y. Guimard <sup>1</sup> , H. Bourgois <sup>3</sup> , F. Bastides <sup>3</sup> , D. Garot <sup>3</sup> , E. Autret-leca <sup>3</sup> , P. Choulet <sup>3</sup> , C. Le Guellec <sup>3</sup> <sup>1</sup> Bourges <sup>2</sup> Hospital, Orleans <sup>3</sup> University Hospital, Tours, France
<b>665/96P</b>	<b>Pharmacokinetics of generic acyclovir tablets</b>
00:00	D. Razdvestvensky, N. Alexeey, G. Voronov Pharmacology, Republic Clinical Pharmacological Laboratory, Minsk, Belarus
<b>666/96P</b>	<b>Tolerability comparison of once -daily clarithromycin extended-release (CLA-ER) and twice-daily clarithromycin immediate-release (CLA-IR)</b>
00:00	K. Devcich, T. Busman, C. Olson, G. Notario Anti-Infectives, GPRD, Abbott Laboratories, Abbott Park, IL, United States
<b>667/96P</b>	<b>Tolerance of cutaneous antiseptics in 3526 patients in France</b>
00:00	E. Caumes <sup>4</sup> , M. Le Maitre <sup>1</sup> , J.M. Garnier <sup>2</sup> , F. Bricaire <sup>4</sup> , B. Crickx <sup>3</sup> <sup>1</sup> Société Française de Dermatologie, Caen <sup>2</sup> Pédiatrie, Hopital Nord, Marseille <sup>3</sup> Dermatologie, Hopital Bichat Claude Bernard <sup>4</sup> Maladies Infectieuses et Tropicales, Hopital Pitié salpêtrière, Paris, France
<b>668/96P</b>	<b>Panax Ginseng C.A. Mayer modulates TLRs expression in mice under physical stress.</b>
00:00	M. Pannacci, F. Colleoni, V. Lucini, S. Grossi, D. Caronzolo, F. Scaglione Dept. Pharmacology, University of Milan, Milan, Italy
<b>669/96P</b>	<b>Anti infective and chemotherapeutic micellar thiazine probes for biolipids</b>
00:00	V.C. Flores <sup>2</sup> , H. Keyzer <sup>2</sup> , J. Kristiansen <sup>1</sup> <sup>1</sup> Sønderborg Hospital, Sydvang, Sonderborg, Denmark <sup>2</sup> California State University, Los Angeles, Ca, United States
<b>670/96P</b>	<b>Comparative Stimulation of Innate Immunity by Susceptible and Multidrug-Resistant <i>Escherichia coli</i>.</b>
00:00	A. Antonopoulou, M. Bristianou, F. Baziaka, T. Tsaganos, T. Poukoulidou, E.J. Giamarellos-bourboulis, D. Plachouras 4th Department of Internal Medicine, Athens Medical School, Athens, Greece
<b>671/96P</b>	<b>Antibiotic management: an original experience of collaboration between the pharmacy and the laboratory.</b>
00:00	C. Baud <sup>1</sup> , C. Houdard - Gay-bellile <sup>2</sup> , Y. Boucaud-maitre <sup>1</sup> , M.O. Baume <sup>2</sup> <sup>1</sup> Bacteriology Laboratory <sup>2</sup> Pharmacy Unit, Saint Luc Saint Josrph, Lyon, France
<b>672/96P</b>	<b>Trends in aminopenicillins (ap) consumption in Russia</b>
00:00	L.P. Abramenco <sup>1</sup> , A.V. Bedenkov <sup>2</sup> , M.N. Denisova <sup>1</sup> , S.G. Gotovats <sup>1</sup> , A.A. Ishmukhametov <sup>1</sup> , L.S. Stratchounski <sup>2</sup> <sup>1</sup> The Remedium Group of Companies, Moscow <sup>2</sup> Institute of Antimicrobial Chemotherapy, Smolensk, Russia

Friday vendredi	<b>3</b>	December décembre	00:00 00:00	ROOM Salle	—	POSTER Poster	<b>97P</b>
--------------------	----------	----------------------	----------------	---------------	---	------------------	------------

## **ANTIBIOTIC USE, HYGIENE, PREVENTION AND INFECTIONS IN SURGERY WARD** *USAGE ANTIBIOTIQUE, HYGIÈNE, PROPHYLAXIE ET INFECTIONS EN CHIRURGIE*

<b>673/97P</b>	<b>Consumption of antibiotics and bacterial resistance</b>
00:00	A. Akpabie <sup>1</sup> , S. Nadal <sup>2</sup> <sup>1</sup> Microbiologie Hygiène, Limeil-Brévannes <sup>2</sup> Pharmacie, Hôpital Emile Roux, Limeil-Brévannes, France
<b>674/97P</b>	<b>Antimicrobial therapy within the preceding year: a characteristic strongly and independently associated with methicillin-resistant <i>Staphylococcus aureus</i> carriage in a long-term care facility.</b>
00:00	M. Eveillard <sup>2</sup> , P. Charru <sup>1</sup> , P. Rufat <sup>3</sup> , E. Lancien <sup>2</sup> , M.L. Joly-guillou <sup>2</sup> , C. Branger <sup>2</sup> <sup>1</sup> Gérontologie, CHU Louis Mourier (APHP) <sup>2</sup> Microbiologie-hygiène, CHU Louis Mourier (AP-HP), Colombes <sup>3</sup> Département d'information médicale, CHU Pitié Salpêtrière, Paris, France

<b>675/97P</b>	<b>One month survey of amoxicillin/clavulanic acid prescription in a 850-bed hospital.</b>
00:00	A. Scanvic <sup>1</sup> , F. Le Turdu <sup>1</sup> , J.L. Pons <sup>4</sup> , M. Abderhamane <sup>2</sup> , C. Allisy <sup>3</sup> , Y. Alaoui <sup>2</sup> , L. May <sup>1</sup> , F. Viguer <sup>4</sup> , E. Vigier <sup>1</sup> , F. Plassart <sup>4</sup> , J.M. Descoutures <sup>4</sup> , J.P. Sollet <sup>5</sup> <sup>1</sup> Biologie <sup>2</sup> Gériatrie <sup>3</sup> Néonatalogie <sup>4</sup> Pharmacie, France <sup>5</sup> Réanimation, Hôpital V. Dupouy, Argenteuil, Haiti
<b>676/97P</b>	<b>Appropriate use of fluoroquinolones : one-month survey in a French non teaching hospital.</b>
00:00	A. Scanvic <sup>1</sup> , J.L. Pons <sup>4</sup> , M. Abderhamane <sup>2</sup> , Y. Alaoui <sup>2</sup> , C. Allisy <sup>3</sup> , L. May <sup>1</sup> , J. Doisneau <sup>4</sup> , C. Gilles <sup>4</sup> , F. Plassart <sup>4</sup> , J.M. Descoutures <sup>4</sup> , F. Le Turdu <sup>1</sup> , J.P. Sollet <sup>5</sup> <sup>1</sup> Biologie <sup>2</sup> Gériatrie <sup>3</sup> Néonatalogie <sup>4</sup> Pharmacie <sup>5</sup> Réanimation, Hôpital V. dupouy, Argenteuil, France
<b>677/97P</b>	<b>Importance of audits: evaluation after modification of antibiotic prophylaxis protocol in surgery</b>
00:00	C. Barré-delhaye <sup>2</sup> , M. Andréoletti <sup>2</sup> , A. Descorps-declere <sup>1</sup> , M. Guibert <sup>3</sup> <sup>1</sup> CLIN <sup>2</sup> Département d'Anesthésie et de Réanimation <sup>3</sup> Hôpital A. Béclère, EOH, Clamart, France
<b>678/97P</b>	<b>Long-term evaluation of practices in surgical antibiotic prophylaxis at Saint Louis Hospital.</b>
00:00	A.M. Deguillaume <sup>3</sup> , O. Marie <sup>2</sup> , A. Carde <sup>3</sup> , F. Mourey <sup>1</sup> , M. Rouveau <sup>5</sup> , P. Faure <sup>3</sup> , B. Schlemmer <sup>1</sup> , S. Touratier <sup>3</sup> <sup>1</sup> Département d'anesthésie <sup>2</sup> Département d'anesthésie réanimation chirurgicale <sup>3</sup> Pharmacie <sup>4</sup> Réanimation médicale <sup>5</sup> Unité fonctionnelle de lutte contre les infections nosocomiales, Hôpital Saint Louis, Paris, France
<b>679/97P</b>	<b>Consideration of age at admission for selective screening to identify methicillin-resistant <i>Staphylococcus aureus</i> carriers to control dissemination in a medical ward.</b>
00:00	M. Eveillard <sup>2</sup> , E. Mortier <sup>1</sup> , E. Lancien <sup>2</sup> , G. Barnaud <sup>2</sup> , N. Lenfant <sup>1</sup> , P. Vinceneux <sup>1</sup> , M.L. Joly-guillou <sup>2</sup> <sup>1</sup> Médecine interne V <sup>2</sup> Microbiologie-hygiène, CHU Louis Mourier, Colombes, France
<b>680/97P</b>	<b>Hand hygiene adherence in a non teaching hospital</b>
00:00	L. May-michelangeli, Y. Roberto, B. Le Falher, L. Martin Equipe opérationnelle d'hygiène, Hopital Victor Dupouy, Argenteuil, France
<b>681/97P</b>	<b>Surgical site infection predictive model and impact of patient skin preparation after cardiac surgery</b>
00:00	D. Lepelletier <sup>2</sup> , S. Perron <sup>2</sup> , P. Bizouarn <sup>1</sup> , J. Caillon <sup>2</sup> , H. Drugeon <sup>2</sup> , J.L. Michaud <sup>3</sup> , D. Duveau <sup>3</sup> <sup>1</sup> Anesthésiologie <sup>2</sup> Bactériologie et Hygiène <sup>3</sup> Chirurgie Thoracique et Cardio-Vasculaire, Hôpital LAENNEC, Nantes, France
<b>682/97P</b>	<b>Surgical site infections after cesarean section : results of a five-year prospective surveillance.</b>
00:00	F. Barbut <sup>2</sup> , B. Carbonne <sup>1</sup> , F. Truchot <sup>2</sup> , C. Spielvogel <sup>1</sup> , D. Jannet <sup>1</sup> , V. Lejeune <sup>1</sup> , J. Milliez <sup>1</sup> <sup>1</sup> Gynécologie-Obstétrique <sup>2</sup> UHLIN, Hôpital Saint-Antoine, Paris, France
<b>683/97P</b>	<b>Bacteriology and impact of early adequate antibiotic treatment in severe post operative pneumonia after lung resection</b>
00:00	N. Béle <sup>3</sup> , A. Lefebvre <sup>3</sup> , A. Casetta <sup>2</sup> , C. Lorut <sup>3</sup> , J. Loubinoux <sup>2</sup> , J.F. Régard <sup>1</sup> , A. Rabbat <sup>3</sup> <sup>1</sup> Chirurgie thoracique <sup>2</sup> Microbiologie <sup>3</sup> Pneumologie et réanimation médicale, Hôtel-Dieu, Paris, France
<b>684/97P</b>	<b>Prevention of postoperative pneumonia (PP) in patients with esophageal cancer (EC).</b>
00:00	Z.V. Volkova NN Blokhin Cancer Res Ctr, Moscow, Russia

Friday vendredi	<b>3</b>	December décembre	00:00 00:00	ROOM Salle	POSTER Poster	<b>98P</b>
--------------------	----------	----------------------	----------------	---------------	------------------	------------

## SEVERE INFECTIONS INFECTIONS SÉVÈRES

<b>685/98P</b>	<b>Bloodstream infections in the Intensive Care Unit patients during 1996 and 2003</b>
00:00	I. Cirkovic <sup>2,2</sup> , M. Svabic-Vlahovic <sup>2,2</sup> , I. Dakic <sup>2,2</sup> , V. Kalezic <sup>1,1</sup> , S. Stepanovic <sup>2,2</sup> <sup>1</sup> Institute of Gastrointestinal Diseases, Clinical Center of Serbia <sup>2</sup> Institute of microbiology and Immunology, School of Medicine, Belgrade, Yugoslavia
<b>686/98P</b>	<b>Three-year prospective survey of community-acquired bacteraemic infections from a French hospital network: epidemiology and antimicrobial resistance.</b>
00:00	A. Scanvic, D. Barraud, M. Bingen-bidois, A. Boisivon, Y. Costa, M.C. Demachy, F. Faibis, B. Ferré, B. Hacquard, F. Richardin, E. Vallee, Y. Péan Groupe Ile de France des Microbiologistes, Hôpitaux Paris- Ile de France, Paris- Ile De France, France
<b>687/98P</b>	<b>Vital status during the seven days following diagnosis of bloodstream infection: Analysis of 1607 cases</b>
00:00	N.L. Van Der Mee-marquet <sup>1,2</sup> , N. Girard <sup>1</sup> , R. Quentin <sup>1,2</sup> , and the Bloodstream Infection Study Group Of The Relais D'hygiène Du Centre Service de Bactériologie et d'Hygiène, Centre Hospitalier Universitaire <sup>2</sup> Département de Microbiologie médicale et Moléculaire, EA 3250, UFR Médecine, F37034 Tours Cedex, France
<b>688/98P</b>	<b>Infectious diseases and pregnancy: A retrospective study of 58 cases during 27 years in intensive care unit (ICU).</b>
00:00	N. Memain, S. Georger, R. Chelha, A. Souhaid, J.L. Pallot

- réanimation polyvalente, CHI A. Grégoire, Montreuil, France**
- 689/98P Postoperative infectious complications in cardiac surgery: usefulness of procalcitonin monitoring**  
00:00 N.V. Beloborodova, D.A. Popov  
*Laboratory of Clinical Microbiology and Antimicrobial Therapy, Bakoulev Scientific Center for Cardiovascular Surgery, Moscow, Russia*
- 690/98P Iliopsoas abscess followed a chronic indwelling urinary catheter and urosepsis**  
00:00 E. Magira, T.H. Gounaris, T.H. Arsenoglou, O. Tsopra, P. Gounari, E. Sioula  
*1ST Department of internal medicine, Evangelismos Hospital, Athens, Greece*
- 691/98P Nosocomial urinary tract infections in urologic patients**  
00:00 M. Cek, Z. Yüzük, Ö. Güçtaş, F. Kurtulus, A. Fazlioglu  
*Urology Clinic, Taksim Teaching Hospital, Istanbul, Turkey*
- 692/98P Three prevalence surveys of urinary tract hospital-acquired infections in a Greek hospital**  
00:00 S. Kastanakis, S. Doukakis, P. Chatzilias, L. Tzimis, L. Kalogeraki, A. Tsafarakis, E. Papadomanolaki, G. Alevraki, I. Varthalitis  
*Infection Control Committee, "Saint George" Chania General Hospital, Chania, Greece*
- 693/98P Perioperative microbiologic monitoring in esophageal cancer (EC) patients.**  
00:00 Z.V. Volkova, E.V. Kulaga, I.I. Shilnikova, I.N. Petukhova, N.V. Dmitrieva  
*NN Blokhin Cancer Res Ctr, Moscow, Russia*
- 694/98P Postoperative anaerobic infections in patients with bone malignancies**  
00:00 I.I. Shilnikova, N.V. Dmitrieva  
*NN Blokhin Cancer Res Ctr, Moscow, Russia*
- 695/98P Risk factors for mechanical ventilator associated pneumonia in head trauma patients**  
00:00 F. Orion<sup>2,2</sup>, D. Lepelletier<sup>1</sup>, D. Demeure<sup>2</sup>, Y. Blanloeil<sup>2</sup>, M. Pinaud<sup>2</sup>  
<sup>1</sup>Bactériologie et Hygiène Hospitalière<sup>2</sup>Réanimation Chirurgicale, CHU Hôtel-Dieu, Nantes, France
- 696/98P Functional capacity and apoptotic index of blood monocytes of patients with nosocomial sepsis related to Ventilator-Associated Pneumonia (VAP).**  
00:00 D. Zervakis<sup>2</sup>, C.H. Vletsas<sup>2</sup>, S. Koliatis<sup>2</sup>, S. Raftopoulos<sup>2</sup>, E.J. Giamarellos-Bourboulis<sup>1</sup>, C.H. Routs<sup>2</sup>, H. Giamarelou<sup>1</sup>, C. Roussos<sup>2</sup>  
<sup>1</sup>4th Department of Internal Medicine<sup>2</sup>Department of Intensive Care Medicine, Athens Medical School, Athens, Greece
- 697/98P Lipid peroxidation in nosocomial sepsis related to Ventilator-Associated Pneumonia (VAP): Mechanism or epiphénoménon?**  
00:00 A. Koronaios<sup>2</sup>, P. Apostolopoulou<sup>2</sup>, M. Zervou<sup>2</sup>, I. Floros<sup>2</sup>, I. Andrianakis<sup>2</sup>, A. Kotanidou<sup>2</sup>, E.J. Giamarellos-Bourboulis<sup>1</sup>, S. Nanas<sup>2</sup>, C. Roussos<sup>2</sup>, H. Giamarelou<sup>1</sup>  
<sup>1</sup>4th Department of Internal Medicine<sup>2</sup>Department of Intensive Care Medicine, Athens Medical School, Athens, Greece
- 698/98P Pressure ulcers in an acute care hospital: prevalence, risk factors and microbiological results.**  
00:00 F. Barbut<sup>1</sup>, B. Parzybut<sup>1</sup>, R. Farid<sup>2</sup>, D. Neyme<sup>1</sup>, M.J. Kosmann<sup>1</sup>, L. Luquel<sup>2</sup>  
<sup>1</sup>Unité d'Hygiène et de Lutte contre les Infections Nosocomiales (UHLIN)<sup>2</sup>Unité Mobile de Gérontologie, Hôpital Saint-Antoine, Paris 12, France
- 699/98P Analysis and treatment of low-risk febrile neutropenia (LRFN) in cancer patients with solid tumours.**  
00:00 G.V. Varlan, N.A. Averina, I.N. Petukhova, N.V. Dmitrieva  
*NN Blokhin Cancer Res Ctr, Moscow, Russia*
- 700/98P Antibiotic associated colitis : value of colonic ultrasound in diagnosis and follow-up**  
00:00 L. Tarantino, A. Sullo, M.D. Ianuce, V. Pezzella, S. Quaranta, P. Rosario, R. Pempinello  
*V Division, D.Cotugno Hospital, Naples, Italy*
- 701/98P How can we simplify the bacteriological analysis of sputum collected from patients with cystic fibrosis (CF)?**  
00:00 C. Thomas<sup>1</sup>, P. Honderlinck<sup>3</sup>, L. Lemée<sup>2</sup>, C. Segonds<sup>4</sup>, F. Wallet<sup>1</sup>, M.O. Husson<sup>1</sup>  
<sup>1</sup>laboratoire de bactériologie, Hopital Calmette, Lille<sup>2</sup>CHU de Rouen, Rouen<sup>3</sup>Hôpital Foch, Suresnes<sup>4</sup>Hôpital Rangueil, Toulouse, France
- 702/98P Application of procalcitonin (PCT)-Q test for early detection of sepsis in Intensive Care Unit**  
00:00 R. Vatcheva-dobrevsky, K. Ramshev, J. Doncheva  
*Clinical Microbiology, ICU, Military Medical Academy, Sofia, Bulgaria*

**PEDIATRIC INFECTIONS**  
**INFECTIONS PÉDIATRIQUES**

- 703/99P Ascorbigen accelerates small intestine anti-infective barrier function in suckling mice**  
00:00 E. Pereverzeva, E. Mirchink, E. Isakova, M. Preobrazhenskaya, V. Bukhman  
*Gause Institute of New Antibiotics, Moscow, Russia*

- 704/99P A rabbit model of chronic infection for studying Group B streptococcus neonatal infection.**  
00:00 C. Nadeau, L. Mereghetti, N. Van Der Mee, P. Lanotte, A. Rosenau, R. Quentin  
*Dpt Microbiologie EA Bactéries et Risque materno-foetal, UFR Médecine, Tours, France*

- 705/99P Telephone consultations in pediatric infectious diseases: a prospective study in a tertiary care center**  
00:00 O. Stevert, C. Bergeron, M. Saint-Jean, D. Blais, M.H. Lebel  
*Division of Infectious diseases, Hôpital Sainte-Justine, Montreal, Canada*

- 706/99P Use of otitis clinical score index in acute otitis media clinical studies**  
00:00 M. Paris, T. Busman, K. Devcich  
*Anti-Infectives, GPRD, Abbott Laboratories, Abbott Park, IL, United States*

- 707/99P Comparison of symptomatology and treatment modalities of children with acute otitis media with and without associated conjunctivitis**  
00:00 F.A. Allaert<sup>1,2</sup>, M. Cozic<sup>3</sup>, D. Lemaybouzid<sup>3</sup>  
<sup>1</sup>Department of Epidemiology, McGill University, Montreal, Canada <sup>2</sup>CENBIOTECH, CHRU du Bocage, Dijon <sup>3</sup>Laboratoire Aventis, Paris, France

- 708/99P Cefdinir improves clinical outcome in children with acute otitis media (aom) previously vaccinated with Prevnar vaccine.**  
00:00 D. Kapral, T. Busman, M. Paris  
*Anti-Infectives, GPRD, Abbott Laboratories, Abbott Park, IL, United States*

- 709/99P Cefdinir twice -daily demonstrated similar efficacy, satisfaction, ease of use and compliance when compared with azithromycin once-daily in the treatment of acute otitis media (AOM)**  
00:00 S. Block<sup>2</sup>, T. Busman<sup>1</sup>, D. Kapral<sup>1</sup>, M. Cifaldi<sup>1</sup>, M. Paris<sup>1</sup>  
<sup>1</sup>Anti-Infectives, GPRD, Abbott Laboratories, Abbott Park, IL <sup>2</sup>Kentucky Pediatric/Adult Research, Bardstown, Ky, United States

- 710/99P Cefdinir demonstrated comparable efficacy to levofloxacin in the treatment of acute bacterial rhinosinusitis (ABRS)**  
00:00 D. Henry<sup>2</sup>, T. Busman<sup>1</sup>, D. Kapral<sup>1</sup>, M. Paris<sup>1</sup>  
<sup>1</sup>Anti-Infectives, GPRD, Abbott Laboratories, Abbott Park, IL <sup>2</sup>Foothill Family Clinic, Salt Lake City, Ut, United States

- 711/99P Early neonatal *E.coli* infection : what to do about detection of K1 capsule.**  
00:00 O. Baron, O. Fayet, M.F. Prère  
*Microbiologie, CHU et Université Paul Sabatier, CNRS, Toulouse, France*

- 712/99P Group B Streptococcus : Serotyping and macrolide resistance in GBS strains isolated from new-borns admitted in neonatology and infantile reanimation wards at the Hopital des Enfants de Toulouse in 2003.**  
00:00 O. Baron, C. Casper, M. Rolland, M.F. Prère  
*CHU, Toulouse, France*

- 713/99P Utility of the procalcitonin for detection of occult bacterial infection in children with fever without source**  
00:00 C. Delmas<sup>2</sup>, A. Espen<sup>1</sup>, V. Loubersac<sup>1</sup>, G. Picherot<sup>3</sup>, J.C. Roze<sup>2</sup>, C. Gras-le Guen<sup>3</sup>  
<sup>1</sup>Laboratoire de biochimie, CHU NANTES <sup>2</sup>Réanimation pédiatrique et néonatale <sup>3</sup>Urgences pédiatriques, Hopital Mère Enfant CHU NANTES, Nantes, France

- 714/99P Hematogenous osteomyelitis in children : differences between acute and subacute presentations.**  
00:00 M. Lorrot<sup>1</sup>, P. Wicart<sup>4</sup>, C. Chapalain<sup>1</sup>, P. Laudrin<sup>4</sup>, C. Adamsbaum<sup>5</sup>, J. Raymond<sup>3</sup>, L. Miladi<sup>4</sup>, C. Job - Deslandre<sup>6</sup>, F. Moulin<sup>2</sup>, R. Seringe<sup>4</sup>, D. Gendrel<sup>1</sup>  
<sup>1</sup>Department of Pediatrics <sup>2</sup>Emergency <sup>3</sup>Microbiology <sup>4</sup>Orthopaedic Surgery <sup>5</sup>Radiology <sup>6</sup>Rheumatology, Hôpital Universitaire Cochin - Saint Vincent de Paul, Paris, France

- 715/99P Incidence of salmonellosis in neonatology and resistance to antibiotics**  
00:00 C.H. Bentchouala, H. Alleg, K. Benlabeled, H. Laouar, A. Lettar, F. Smati  
*Laboratoire de Microbiologie, CHU Ben Badis, Constantine, Algeria*

- 716/99P A survey on the prevalence of beta hemolytic streptococci group A factor in the primary school students in Chaharmahal and Bakhtiari province**  
00:00 B.S. Hamid Reza  
*Heith Department, AZAD University, Shahrekord, Iran*

VIROLOGY  
VIROLOGIE**717/100P 2004: Confirmation of rare genotype II Hepatitis A Virus circulation in France**

00:00 V. Mackiewicz, A.M. Roque, E. Marchadier, F. Beaulieu, E. Dussaix

*Laboratoire de Virologie, Hôpital Paul Brousse, Assistance Publique Hôpitaux de Paris, Centre National de Référence du Virus de l'Hépatite A, Villejuif, France***718/100P Hepatitis B mutants : prevalence, clinical and diagnostic implications**00:00 A.M. Roque-afonso<sup>3</sup>, D. Belkhir<sup>3</sup>, M.P. Ferey<sup>3</sup>, T.D. Ly<sup>1</sup>, E. Schvoerer<sup>2</sup>, E. Dussaix<sup>3</sup>*<sup>1</sup>Laboratoire LCL, Ivry Sur seine <sup>2</sup>Virology, CHU, Strasbourg <sup>3</sup>Virologie, Hôpital Paul Brousse, Villejuif, France***719/100P Evaluation of performance of an 'in-house' sequencing assay for hepatitis B virus genotypes determination**00:00 A. Wagner<sup>2</sup>, G. Champier<sup>2</sup>, A. Monnet<sup>1</sup>, V. Thibault<sup>3</sup>, F. Denis<sup>2</sup>, S. Alain<sup>2</sup>*<sup>1</sup>Bayer Diagnostics, Cergy Pontoise <sup>2</sup>Department of Bacteriology Virology Hygiene, Teacher Hospital Dupuytren, Limoges <sup>3</sup>CERVI, Department of Virology, Teacher Hospital Pitie-Salpetriere, Paris, France***720/100P The importance of age, source of infection and duration of chronic Hepatitis C infection on efficacy of combined therapy**00:00 Z. Nesić<sup>3</sup>, D. Delić<sup>1</sup>, M. Prostran<sup>3</sup>, B. Obucina<sup>2</sup>, Z. Todorović<sup>3</sup>, S. Vučković<sup>3</sup>, R. Stojanović<sup>3</sup>*<sup>1</sup>Institute of Infectious and Tropical Disease, Clinical Center of Serbia <sup>2</sup>Panfarma <sup>3</sup>Department of Clinical Pharmacology, Pharmacology and Toxicology, School of Medicine Belgrade, Belgrade, Yugoslavia***721/100P Duplication of V3 domain in nonstructural 5A protein of Hepatitis C Virus genotype 1b**00:00 P. Veillon<sup>1</sup>, J. Redureau<sup>1</sup>, B. Coueffic<sup>3</sup>, J.F. Subra<sup>2</sup>, X. Causse<sup>4</sup>, C. Gaudy<sup>5</sup>, C. Payan<sup>1</sup>, F. Lunel-fabiani<sup>1</sup>*<sup>1</sup>Laboratoire de Virologie <sup>2</sup>Service de Néphrologie, CHU Angers <sup>3</sup>EFS Pays de la Loire, Angers <sup>4</sup>Service d'Hépatogastroentérologie, CHR La Source, Orléans <sup>5</sup>Laboratoire de Microbiologie Médicale et Moléculaire, EA 3250, Université François Rabelais, Tours, France***722/100P Hepatitis infections and alcohol intake in Italy**00:00 D. Rivanera<sup>2</sup>, D. Lilli<sup>2</sup>, M.L. Attilia<sup>1</sup>, I.G. Barbacini<sup>2</sup>, F. Attilia<sup>1</sup>, M. Ceccanti<sup>1</sup>*<sup>1</sup>Alcohol Liver Disease Unit <sup>2</sup>University La Sapienza, Department of Public Health Science, Rome, Italy***723/100P Gastrointestinal cytomegalovirus infection in patients with heart transplant. treatment experience**

00:00 M. Linares, M.F. Portero, T. Marco, A. Parra, S. Martin

*Servicio Microbiología, Hospital Universitario Puerta de Hierro, Madrid, Spain***724/100P Varicella and its complications in France**00:00 D. Floret<sup>2</sup>, C. Emery<sup>1</sup>, F. Fagnani<sup>1</sup>, F. Lancon<sup>3</sup>*<sup>1</sup>CEMKA-EVAL, Bourg La Reine <sup>2</sup>Hôpital E Herriot, Lyon <sup>3</sup>GSK, Marly Le Roi, France***725/100P Seroprevalence of varicella-zoster virus (VZV) in the French population**00:00 M. Debruyne<sup>4</sup>, D. Floret<sup>2</sup>, B. Khoshnood<sup>1</sup>, C. Emery<sup>1</sup>, F. Fagnani<sup>1</sup>, F. Lancon<sup>3</sup>*<sup>1</sup>CEMKA-EVAL, Bourg La Reine <sup>2</sup>Hôpital E Herriot, Lyon <sup>3</sup>GSK, Marly Le Roi <sup>4</sup>Pasteur Cerba, Paris, France***726/100P Evaluation of an herpes consensus generic amplification kit in BAL specimens**

00:00 P. Honderlick, D. Vignon

*Microbiologie, Hôpital Foch, Suresnes, France***727/100P Prevalence and characterization of enteric viruses in hospitalized children with acute gastroenteritis during a two year period.**00:00 M. Lorrot<sup>4</sup>, F. Bon<sup>1,2</sup>, M. Wolfer<sup>4</sup>, J. Kaplon<sup>1,2</sup>, H. Giraudon<sup>2,3</sup>, P. Lebon<sup>3</sup>, P. Pothier<sup>1,2</sup>, D. Gendel<sup>4</sup>*<sup>1</sup>CNR des Virus Entériques, Laboratoire de Virologie, CHU Dijon <sup>2</sup>Microbiologie Médicale et Moléculaire EA562, UFRs Médecine et Pharmacie, Dijon <sup>3</sup>Service de Pédiatrie, CH Saint Vincent de Paul <sup>4</sup>Laboratoire de Virologie, CH Saint Vincent de Paul, Paris, France***728/100P Patient with Kikuchi disease presented as mononucleosis**

00:00 L. Raptis, E. Tsiami, A. Gondoras, C. Gusis, K. Hristakis, K. Bugias, N. Akritidis, S. Stefanaki

*Internal Medicine Clinic, Department of Radiology, General Hospital G. Hatzi Costa, Ioannina, Greece***729/100P Quantification of HPV16 and 18 in saliva of HIV-infected patients by real time PCR.**00:00 V. Thonier<sup>3</sup>, E. Opoix<sup>1</sup>, M. Blanc<sup>1</sup>, A. Bosseray<sup>4</sup>, G. Bargues<sup>3</sup>, D. Seigneurin<sup>2</sup>, P. Leclercq<sup>1</sup>, J.M. Seigneurin<sup>3</sup>, P. Morand<sup>3</sup>*<sup>1</sup>CISIH <sup>2</sup>Laboratoire de cytologie <sup>3</sup>Laboratoire de virologie <sup>4</sup>Medecine interne, CHU Grenoble, Grenoble, France***730/100P HPV-DNA PCR and hybridization using INO-LIPA HPV genotyping v2**

00:00 P. Honderlick, M.L. Clement, R. Beddock, D. Vignon

*Microbiologie, Gynécologie, Hôpital Foch, Suresnes, France*

<b>731/100P</b>	<b>HYBRID CAPTURE 2</b>
00:00	<b>ASSAY<sup>0</sup> versus HPV CONSENSUS KIT<sup>0</sup>: comparison of 2 assays for human papillomavirus detection and typing.</b>
	<u>Σ. Ηαντζή</u> Σ. Αλατιν, X. Δεβροχκ, Σ. Ρογεζ, M. Βοριε, Φ. Δενισ <i>Department of Bacteriology- Virology- Hygiene, CHRU Dupuytren, Limoges, France</i>
	€
<b>732/100P</b>	<b>Crystals of a ribonucleoprotein complex of the Respiratory Syncytial Virus nucleoprotein N</b>
00:00	P.F. Varela <sup>1</sup> , S. Duquerroy <sup>1</sup> , J.F. Eleouet <sup>2</sup> , F.A. Rey <sup>1</sup> <sup>1</sup> Unité de Virologie Moléculaire - Structurale, CNRS, Gif-Sur-Yvette <sup>2</sup> Unité de Virologie et Immunologie Moléculaires, INRA, Jouy-En-Josas, France
<b>733/100P</b>	<b>In vitro and in vivo antiviral activity of bis-quaternary ammonium-bases</b>
00:00	T. Gridina <sup>1</sup> , V. Lozitsky <sup>1</sup> , Y. Boschenko <sup>1</sup> , A. Fedchuk <sup>1</sup> , V. Paliy <sup>2</sup> <sup>1</sup> Chemotherapeutic and Immunobiological Preparations, Ukrainian I.I. Mechnikov Research Anti-Plague Institute, Odessa <sup>2</sup> Microbiology, Vinnytsia National Pirogov Medical University, Vinnitsia, Ukraine
<b>734/100P</b>	<b>Evaluation of the « enterovirus consensus » kit (Argene Biosoft) on pericardial fluids and myocardial tissues</b>
00:00	N. Leveque, G. Bristow, F. Najjoullah, B. Lina, J.J. Chomel <i>Domaine Rockefeller, Centre National de Référence des Entérovirus, Lyon, France</i>
<b>735/100P</b>	<b>Clinical diagnosis of untypeable enteroviruses by RT-PCR</b>
00:00	N. Leveque, G. Bristow, F. Najjoullah, B. Lina, J.J. Chomel <i>Domaine Rockefeller, Centre National de Référence des Entérovirus, Lyon, France</i>

Friday vendredi	<b>3</b>	December décembre	00:00 00:00	ROOM Salle	—	POSTER Poster	<b>101P</b>
--------------------	----------	----------------------	----------------	---------------	---	------------------	-------------

## ANTIVIRAL THERAPEUTIC AND RESISTANCE THÉRAPEUTIQUE ANTIVIRALE ET RÉSISTANCE

<b>736/101P</b>	<b>Phenotypic characterization of Cytomegalovirus DNA polymerase: a tool to study Cytomegalovirus isolates resistant to foscarnet.</b>
00:00	A. Ducancelle <sup>2</sup> , J. Gravisse <sup>3</sup> , S. Alain <sup>1</sup> , A.M. Fillet <sup>4</sup> , F. Petit <sup>2</sup> , M.J. Sanson-le Pors <sup>2</sup> , M.C. Mazeron <sup>2</sup> <sup>1</sup> Bactériologie-Virologie, Hôpital Dupuytren, Limoges <sup>2</sup> Bactériologie-Virologie, Hôpital Lariboisière <sup>3</sup> Bactériologie-Virologie, Hôpital Saint-Louis <sup>4</sup> Virologie-CERVI, Hôpital Salpêtrière, Paris, France
<b>737/101P</b>	<b>Amino acid insertions in the flap of Human Immunodeficiency Virus</b>
00:00	Type 1-protease and resistance to protease inhibitors D. Affolabi <sup>1,2</sup> , M. Davi <sup>2</sup> , E. Gordien <sup>1</sup> , N. Dautin <sup>2</sup> , D. Hurez <sup>1</sup> , D. Ladant <sup>2</sup> , P. Deny <sup>1</sup> <sup>1</sup> Bactériologie, Virologie - Hygiène, Université Paris 13, Bobigny <sup>2</sup> Biochimie des des Interactions Macromoléculaires Département de Biologie Structurale et Chimie, Institut Pasteur, Paris, France
<b>738/101P</b>	<b>Inhibitor of Lassa virus infection.</b>
00:00	L. Rustamova, N. Bogdanova, A. Petkevich <i>Laboratory of Chemotherapy, Research Institute for Epidemiology &amp; Microbiology, Minsk, Belarus</i>
<b>739/101P</b>	<b>Development of a mouse encephalitis model to measles virus for in vivo evaluation of antiviral activity of ribavirin complexed with cyclodextrins</b>
00:00	N. Grancher <sup>1,2</sup> , V. Venard <sup>1</sup> , F. Kedzierewicz <sup>1</sup> , W. Ammerlaan <sup>2</sup> , C. Finance <sup>1</sup> , C.P. Muller <sup>2</sup> , A. Le Faou <sup>1</sup> <sup>1</sup> Groupe d'Etude des Vecteurs Supramoléculaires du Médicament, Unité Mixte de Recherche UHP-CNRS 7565, Vandoeuvre-Lès-Nancy, France <sup>2</sup> Département d'Immunobiologie, Laboratoire National de Santé, Luxembourg, Luxembourg
<b>740/101P</b>	<b>A novel generation of heparan sulfate mimetics for the treatment of prion diseases</b>
00:00	K.T. Adiou <sup>3,4</sup> , S. Simoneau <sup>3</sup> , N. Salès <sup>3</sup> , F. Lamoury <sup>3</sup> , D. Dormont <sup>4</sup> , D. Papy - Garcia <sup>2</sup> , D. Barritault <sup>1</sup> , J.P. Deslys <sup>3</sup> , C.I. Lasmézas <sup>3</sup> <sup>1</sup> Laboratoire CRET, CNRS FRE2412, Université Paris XII, Crétteil <sup>2</sup> OTR3 Sarl, Crétteil <sup>3</sup> CEA, DSV/DRM, Fontenay Aux Roses <sup>4</sup> Ecole Nationale Vétérinaire d'Alfort, Maisons -Alfort, France
<b>741/101P</b>	<b>Activity of antimicrobial textiles on enteric virus</b>
00:00	F. Morfin <sup>2</sup> , E. Bergeron <sup>2</sup> , J. Dore <sup>3</sup> , F.N.R. Renaud <sup>2,3</sup> , P.D. Samec <sup>1</sup> , J. Freney <sup>2,3</sup> <sup>1</sup> Abeil company, Aurillac <sup>2</sup> Laboratory of Microbiology, EA 3090, Faculty of Pharmacy <sup>3</sup> Nosoco.tech(R), Lyon, France

**HIV INFECTION**  
**INFECTION À VIH****742/102P HIV infection in Algeria**00:00  
**B. Ait Kaki, Z. Semra, E.H. Belabes**  
*Microbiologie CHU, Faculté de Médecine, Constantine, Algeria***743/102P Seroprevalence of HSV type 1 and type 2 in a French cohort of HIV-infected patients: relevance for the prevention of genital and neonatal herpes transmission**00:00  
**L. Andreoletti<sup>1</sup>, E. Pienoir<sup>2</sup>, V. Brodard<sup>1</sup>, I. Beguinot<sup>3</sup>, C. Rouger<sup>3</sup>, C. Strady<sup>3</sup>, J.L. Berger<sup>3</sup>, and the Champagne Ardenne Picardie Study Group**  
<sup>1</sup>*Department of Virology* <sup>2</sup>*Infection Control Department* <sup>3</sup>*Infectious Disease Unit, CHU Reims, Reims, France***744/102P Monitoring of HIV patients in Caen Hospital from 1998 to 2003: hospitalization and death causes?**00:00  
**C. Marchand<sup>1</sup>, V. Bige<sup>2</sup>, P. Goubin<sup>1</sup>, P. Feret<sup>1</sup>, J.C. Renet<sup>1</sup>, S. Dargere<sup>1</sup>, J.J. Parienti<sup>1</sup>, J.C. Bazin<sup>1</sup>, R. Verdon<sup>1</sup>**  
<sup>1</sup>*Maladies Infectieuses et Tropicales, Caen* <sup>2</sup>*Santé Publique, CHU, Reims, France***745/102P 5-Year follow-up of once-daily combination therapy with FTC, ddI and EFV in treatment of naïve HIV-infected adults (MONTANA ANRS 091 Trial).**00:00  
**A. Furco<sup>6</sup>, L. Lallemand<sup>1</sup>, P. Palmer<sup>4</sup>, P. Morlat<sup>1</sup>, D. Séreni<sup>5</sup>, T. May<sup>3</sup>, L. Cotte<sup>2</sup>, V. Journot<sup>1</sup>, G. Chene<sup>1</sup>, J.M. Molina<sup>3</sup>**  
<sup>1</sup>*INSERM U593, Bordeaux* <sup>2</sup>*Service de gastro-entérologie, Hôpitaux de Lyon, Lyon* <sup>3</sup>*Service des maladies infectieuses, Hôpitaux de Nancy, Nancy* <sup>4</sup>*Laboratoire de virologie* <sup>5</sup>*Service de médecine interne* <sup>6</sup>*Service des maladies infectieuses, Hôpital Saint-Louis, Paris, France***746/102P Effect of HAART immunorestoration on HBs/e Ag seroconversion in 85 HIV-HBV coinfected patients**00:00  
**P. Mialhes<sup>2</sup>, B. Lebouche<sup>2</sup>, M.A. Trabaud<sup>1</sup>, F. Bailly<sup>2</sup>, M. Maynard<sup>2</sup>, P. Pradat<sup>2</sup>, M. Chevallier<sup>3</sup>, P. Chevallier<sup>1</sup>, F. Zoulim<sup>2</sup>, C. Trepo<sup>2</sup>**  
<sup>1</sup>*Laboratoire de virologie, Faculté Rockefeller* <sup>2</sup>*Service d'Hépatogastroentérologie, Hôpital Dieu* <sup>3</sup>*Laboratoire Mérieux, Lyon, France***747/102P Characteristics of HIV-infected patients presenting adverse reactions induced by highly active antiretroviral therapy (HAART) and consequences to the continuation of this treatment: a survey over a 18-month period**00:00  
**A. Molia<sup>1</sup>, S. Havet<sup>1</sup>, C. Strady<sup>2</sup>, I. Beguinot<sup>2</sup>, C. Rouger<sup>2</sup>, J.L. Berger<sup>2</sup>, A. Waldner<sup>2</sup>, M.L. Germain<sup>1</sup>, T. Trenque<sup>1</sup>**  
<sup>1</sup>*Centre Régional de Pharmacovigilance* <sup>2</sup>*Service de Médecine interne et de Maladies infectieuses, CHU, Reims, France***748/102P Virological response to salvage saquinavir/ritonavir low dose containing regimen in DMI 2 French cohort: the IN VITO Cohort**00:00  
**A. Simon<sup>6</sup>, D. Zucman<sup>4</sup>, V. Calvez<sup>6</sup>, V. Le Moal<sup>2</sup>, S. Dantin<sup>7</sup>, L. Bergougnoux<sup>7</sup>, J.F. Delfraissy<sup>5</sup>, G. Peytavin<sup>3</sup>, F.A. Allaert<sup>1</sup>, D. Costagliola<sup>8</sup>**  
<sup>1</sup>*Cenbiotech, Dijon* <sup>2</sup>*Centre de Chauliac Hospital, Montpellier* <sup>3</sup>*CHU Bichat Claude Bernard* <sup>4</sup>*Foch Hospital* <sup>5</sup>*Kremlin-Bicêtre Hospital* <sup>6</sup>*Pitié-Salpêtrière Hospital* <sup>7</sup>*Roche Pharma France* <sup>8</sup>*Unité INSERM EMI 0214, Paris, France***749/102P Body composition analysis by DEXA in HIV+ patients: comparison between the years 1994 and 2004**00:00  
**G. Tsekes<sup>1</sup>, N. Mangafas<sup>1</sup>, M. Chini<sup>1</sup>, A. Mingas<sup>1</sup>, N. Tsogas<sup>1</sup>, A. Feretis<sup>2</sup>, V. Georgiou<sup>3</sup>, M.C. Lazanas<sup>1</sup>**  
<sup>1</sup>*3rd Dept. of Internal Medicine & Infectious Diseases Unit* <sup>2</sup>*Dept. of Radiology, Red Cross Hospital* <sup>3</sup>*Dept. of Medical Physics, Medical School, University of Athens, Athens, Greece***750/102P Body composition changes one year after switching to a tenofovir-containing antiretroviral regimen**00:00  
**G. Tsekes<sup>1</sup>, N. Mangafas<sup>1</sup>, N. Tsogas<sup>1</sup>, M. Chini<sup>1</sup>, J. Salpigitis<sup>1</sup>, M. Nikolakopoulou<sup>1</sup>, N. Flessas<sup>1</sup>, N. Batakis<sup>2</sup>, M.C. Lazanas<sup>1</sup>**  
<sup>1</sup>*3rd Dept. of Internal Medicine & Infectious Diseases Unit* <sup>2</sup>*Dept. of Radiology, Red Cross Hospital, Athens, Greece***751/102P Prevalence and characteristics of hepatitis C virus coinfection in a human immunodeficiency virus French clinical cohort.**00:00  
**C. Merle De Boever<sup>2</sup>, V. Le Moing<sup>2</sup>, M. Vidal<sup>2</sup>, J. Ducos<sup>1</sup>, J. Reynes<sup>2</sup>**  
<sup>1</sup>*Laboratoire de Virologie* <sup>2</sup>*Maladies Infectieuses et Tropicales, CHU Montpellier, Montpellier, France***752/102P Severe HIV-related laryngeal aphthous ulcer treated with thalidomide**00:00  
**C. Rapp, G. Defuente, S. Herve, P. Imbert, M. Jagou, J.L. Poncet, T. Debord**  
*Maladies infectieuses et tropicales, Hôpital militaire Bégin, Saint-Mandé, France***753/102P Rhodococcus equi pulmonary infection: efficacy of MAC therapy in an AIDS patient.**00:00  
**J.C. Quincampoix<sup>1</sup>, E. Ronco<sup>1</sup>, J. Clarisso<sup>2</sup>, T. Galperine<sup>2</sup>, M. Rottman<sup>1</sup>, L. Bernard<sup>2</sup>, J.L. Gaillard<sup>1</sup>**  
<sup>1</sup>*Laboratoire de Microbiologie* <sup>2</sup>*Service des maladies infectieuses et tropicales, Hôpital Raymond Poincaré, Garches, France***754/102P Nocardia cyriacigeorgica isolated from brain abscess of a patient with Human Immunodeficiency Virus infection**00:00  
**G. Barnaud<sup>3</sup>, C. Deschamps<sup>3</sup>, V. Manseron<sup>2</sup>, E. Mortier<sup>2</sup>, F. Bert<sup>1</sup>, P. Vinceneux<sup>2</sup>, C. Branger<sup>3</sup>**  
<sup>1</sup>*Service de Bactériologie, Hôpital Beaujon, Clichy* <sup>2</sup>*Service de Médecine Interne* <sup>3</sup>*Service de Microbiologie, Hôpital Louis Mourier, Colombes, France***755/102P Rectal Lymphogranuloma venereum**00:00  
**J. Gravis<sup>3</sup>, M. Allez<sup>4</sup>, M. Lemann<sup>4</sup>, M. Nachury<sup>4</sup>, M. Janier<sup>2</sup>, J. Timsit<sup>2</sup>, F. Agbalika<sup>3</sup>, B. De Barbeyrac<sup>1</sup>, C. Scieux<sup>3</sup>**  
<sup>1</sup>*Laboratoire de Bactériologie, GHR-Groupe Hospitalier Pellegrin, Bordeaux* <sup>2</sup>*Centre Clinique et Biologique des MST* <sup>3</sup>*Laboratoire de Bactériovirologie* <sup>4</sup>*Service d'Hépatogastro-entérologie, Hôpital Saint-Louis, Paris, France*

00:00

E. Chenot<sup>2</sup>, A. Marteau<sup>2</sup>, O. Menard<sup>4</sup>, B. Toussaint<sup>3</sup>, R. Snoeck<sup>1</sup>, T.H. May<sup>2</sup>, C.H. Rabaud<sup>2</sup><sup>1</sup>Rega Institute for Medical Research,, Katholieke Universiteit, Leuven, Belgium <sup>2</sup>Maladies Infectieuses <sup>3</sup>ORL <sup>4</sup>Pneumologie, CHU, Nancy, FranceFriday  
vendredi 3 December  
décembre00:00  
00:00ROOM  
SallePOSTER  
Poster

103P

### GENITO URINARY TRACT INFECTIONS - SEXUALLY TRANSMITTED INFECTIONS INFECTIONS GÉNITO-URINAIRES - INFECTIONS SEXUELLEMENT TRANSMISSIBLES

## 757/103P Syphilis serology: evaluation in routine of a new confirmatory assay

00:00

L. Deforges<sup>1</sup>, V. Ridony<sup>1</sup>, F. Thépault<sup>1</sup>, D. Simon<sup>1</sup>, R. Vergne<sup>1</sup>, C. Saguez<sup>2</sup>, C. Austruy<sup>2</sup>, C.J. Soussy<sup>1</sup><sup>1</sup>Laboratoire de Bactériologie-Virologie-Hygiène, Hôpital Henri Mondor, Créteil <sup>2</sup>Laboratoires InGen, Rungis, France758/103P Sharp increase of *Nesseiria gonorrhoea* ciprofloxacin resistant strains in France in 2001-2003

00:00

P. Sednaoui<sup>1</sup>, I. Martin<sup>3</sup>, V. Goulet<sup>2</sup>, M. Herida<sup>2</sup><sup>1</sup>Institut Alfred Fournier, Paris <sup>2</sup>Institut de Veille Sanitaire, Saint-Maurice, France <sup>3</sup>Health Protection Agency, London, United Kingdom

## 759/103P Seroprevalence of HSV 2 infection in women from Bucharest

00:00

V. Arama<sup>2</sup>, A. Streinu Cercel<sup>2</sup>, O. Benea<sup>2</sup>, V. Molagic<sup>2</sup>, R. Vladareanu<sup>1</sup>, A. Hristea<sup>2</sup>, C. Moga<sup>2</sup>, A. Negoita<sup>2</sup><sup>1</sup>Obstetrics - Gynecology, Elias University Clinic Hospital <sup>2</sup>Prof. Dr. Matei Bals, Infectious Diseases Institute, Bucharest, Romania

## 760/103P Group B streptococci susceptibility to telithromycin collected in genital specimens of pregnant women

00:00

J. Loulergue<sup>3</sup>, S. Riollet<sup>3</sup>, C. Grasmick<sup>2</sup>, P. Laudat<sup>1</sup>, R. Quentin<sup>4</sup><sup>1</sup>Réseau des Centres hospitaliers universitaires <sup>2</sup>Réseau des laboratoires privés (RBML et Epiville) <sup>3</sup>Réseau du Collège de bactériologie virologie hygiène des hôpitaux <sup>4</sup>CHU Trousseau, Laboratoire associé au Centre national de référence des streptocoques, CHU Trousseau, Tours, France761/103P Cytokine production induced by *Streptococcus agalactiae* strains from different phylogenetic groups

00:00

P. Lanotte, L. Mereghetti, N. Van Der Mee, R. Levillain, A. Rosenau, R. Quentin

Département de Microbiologie, Faculté de Médecine, Tours, France

## 762/103P Comparative study of antibiotic susceptibility of uropathogens at the university hospital centre of Nancy in 1997-1998 and 2002-2003.

00:00

C. Laurain, M. Dailloux, M. Albert, M. Weber, A. Lozniewski

Laboratoire de bactériologie, CHU, Nancy, France

## 763/103P Antimicrobial susceptibility of enterococci from urinary tract infectious

00:00

J. Markov, B. Nikolovski, E. Shopovski

Microbiology, Military Hospital, Skopje, Macedonia

## 764/103P Advantages of a continuous or intermittent levofloxacin (levofloxacin iv., tabl.500 mg) treatment in case of urinary obstruction caused by a complicated urinary tract infection after temporary insertion of a foreign body (double J ureteral stent, percutan nephrostomy).

00:00

P. Tenke, D. Ashaber, R. Benko, M. Jäcker

Urology, Jahn Ferenc South-Pest Teching Hospital, Budapest, Hungary